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Uric acid, the end product of purine catabolism in humans, is a biologically active 
molecule that plays a role in oxidative stress, inflammation, and the regulation of blood 
pressure. Excessively high serum urate levels (hyperuricaemia) are associated with 
a wide range of diseases. With the exception of gout, where monosodium urate 
crystals are known to trigger a painful inflammatory response, both the causality and 
the underlying mechanisms linking hyperuricaemia and disease are unclear. 
To better understand the link between uric acid and cardiometabolic disease, I have 
investigated the correlation between serum urate and 266 Olink protein biomarkers 
associated with cardiovascular disease and inflammation and 191 lipid species. Using 
partial correlation and lasso regression, I have identified and replicated 11 protein 
biomarkers whose serum levels covary with urate independently of the other 
biomarkers. The associated proteins are involved in diverse processes including 
phosphate metabolism and bone development, glucose metabolism, adipocyte 
function and blood pressure regulation. I have additionally identified 15 lipids, some 
of which have a potential link with cognitive function.  
To approach the question of uric acid from a regulation perspective, I have run 
genome-wide association scans, first in our own cohorts, with a sample exceeding 
10,000 individuals imputed to the Haplotype Reference Consortium reference panel, 
the first GWAS of serum urate levels to be run on this panel. Then, as part of the 
CKDGen consortium, I co-lead a transethnic meta-analysis of over 450,000 
individuals, the largest GWAS of serum urate to date. Our work identified 183 urate-
associated loci, of which 147 were novel.  These loci can be used to create a genetic 
risk score for urate that has considerable predictive potential for gout, assessed in the 
UK Biobank.  
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II. Lay Summary 
DNA is composed of two kinds of molecules, purines (As and Gs) and pyrimidines 
(Cs and Ts). When DNA is broken down into its component parts, surplus purines are 
disposed of in a complex series of carefully controlled biochemical reactions, the end 
result of which is a small molecule called uric acid.  
Uric acid is much more than just a waste product. It can soak up dangerous free 
radicals, highly reactive rogue molecules occurring naturally in our bodies which can 
cause damage if left unchecked. It is also involved in regulating blood pressure and 
promoting response to damage and infection.  
However, the amount you have in your blood needs to be very precisely controlled. 
Most mammals turn uric acid into another chemical which is easily passed out in urine. 
Humans have lost the ability to do this, so we have a lot more uric acid in our blood, 
and if levels get too high, crystals of uric acid can grow. These crystals can cause 
swelling and intense pain – the disease we know as gout. Gout is becoming 
increasingly common in developed countries, because we also get too many purines 
from our diet, particularly red meat, oily fish and alcohol. High uric acid levels are also 
linked to high blood pressure, heart disease, diabetes, liver disease, kidney disease 
and obesity. With the exception of gout, we don’t yet know whether uric acid is a cause 
or a consequence of these conditions. 
My project aims to help understand how uric acid can lead to disease, and how your 
genes can affect the amount of uric acid in your blood.  
To investigate the first point, I have been looking at several hundred molecules that 
have functions related to heart disease. I have identified eleven which seem to be 
closely linked to uric acid levels. With further study, these may help to understand 
mechanisms connecting uric acid to heart disease.  
To address the second question, I have joined an international collaboration looking 
at small changes in DNA between hundreds of thousands of people. I have helped to 
identify 183 changes which seem to cause differences in uric acid level. By looking at 
these changes, we can try to understand what their function is, which may help to 
understand how uric acid levels are controlled. If we can do this, we can predict 
people’s disease risk from their DNA. It might also be possible to design drugs based 
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1.1 Uric acid 
 What is uric acid? 
Uric acid is a weak organic acid composed of carbon, hydrogen, oxygen and nitrogen 
(Figure 1). Clinical reference ranges vary between health providers, but ‘normal’ adult 
concentrations in serum generally range between 2.6 and 6.0 mg/dL in 
premenopausal women and 3.5 and 7.2 mg/dL in men and postmenopausal women. 
The discrepancy in serum urate levels between males and females begins at puberty 
and ends at menopause1. At physiological pH values, it is present in serum primarily 
in the form of urate ions. The solubility of uric acid in water is low, and in human serum 
the solubility limit is just 6.8 mg/dL. Above this, uric acid can precipitate out of solution 
as crystals of monosodium urate (MSU). 
 
Uric acid is the end product of purine catabolism in humans, but far from being a 
simple waste product, its chemical properties suggest that it plays a complex and 
only partially understood role in a wide range of biological processes. Abnormally 
high or low levels of circulating uric acid (hyper- and hypo-uricemia) are both 
associated with a broad range of diseases. Most notably, hyperuricemia is linked to 
gout, a painful inflammatory arthritis triggered by monosodium urate crystals, as well 
as various cardiometabolic diseases, while hypouricaemia is associated with 
neurodegenerative disease. The importance of uric acid has been realised for 
 
Figure 1 - Chemical structure of uric acid. 
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centuries, but the mechanisms linking it to human health and disease are still fields 
of active study. 
The early history of uric acid is very much the history of gout, a disease known long 
before its primary cause. Descriptions of gout have been found as far back as ancient 
Egypt in 2640 BCE. Hippocrates’ own aphorisms include such observations as 
“Eunuchs do not take the gout”, “A woman does not take the gout, unless her menses 
be stopped” and “In gouty affections, inflammation subsides within 40 days”2. These 
early and remarkably accurate clinical observations reflect characteristics of gout still 
observed today. Gout has long been known as “the disease of kings” due it’s 
occurrence mainly in those who could afford a decadent and luxurious lifestyle, to the 
extent that it has even been considered something of a status symbol in various 
periods of western history2. Gout is driven in large part by diet, and for much of history 
only the very wealthy could afford the purine-rich foods – meat, alcohol and seafood 
– that lead to hyperuricaemia. There were also observations that gout tended to run 
in families, the first recognition that gout – and urate homeostasis – could have a 
significant heritable component. There is even evidence that as early as the 6th 
Century CE colchicine was used as a treatment for gout3 – a drug that is still used 
today as an anti-inflammatory agent for patients who cannot  tolerate non-steroidal 
anti-inflammatory drugs (NSAIDs) 
Though gout has been known for thousands of years, uric acid and the link between 
it and gout are comparatively recent discoveries. Uric acid was discovered in 1776 by 
Carl Wilhelm Scheele4, a pharmaceutical chemist from Swedish Pomerania (modern 
day Germany) who was studying kidney stones (as well as discovering a number of 
organic acids, Scheele is noteworthy for being the first to make a number of chemical 
discoveries, including oxygen, hydrogen and chlorine, but being consistently beaten 
to publication, a misfortune that will still resonate with many modern scientists). 
Shortly after its discovery, an English chemist named Woolaston identified that urate 
was present within a tophus (a nodular growth characteristic of advanced gout) on his 
own ear2. By the end of the 19th Century, it was known that urate crystals injected into 
a joint could cause the formation of tophi, but conclusive scientific proof that the 
crystals seen in gout were monosodium urate did not come until the mid-20th century5.  
In the era of modern medicine, hyperuricaemia has been linked not only to gout, but 
to a wide range of diseases including type 2 diabetes6, cardiovascular disease 
(CVD)7, chronic kidney disease (CKD) and components of metabolic syndrome8. 
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Hypouricaemia is associated with neurodegenerative diseases9–12. However, with the 
exception of gout, the mechanistic links behind these associations and the question 
of whether uric acid level has a causal role remain largely unresolved. The role of uric 
acid in disease thus remains an active and important area of medical research. 
 Urate production 
Uric acid is the final oxidation product of purine metabolism in apes, including humans. 
Purines are heterocyclic aromatic organic molecules consisting of a pyrimidine ring 
and an imidazole ring – informally, they have a 6- and 5-sided double-ring structure 
containing nitrogen, as seen in the structure of uric acid itself in Figure 1. The group 
includes a wide range of molecules, including caffeine, but perhaps the most 
biologically significant are adenosine and guanine and their derivatives, together 
comprising one of the two groups of nucleotide bases.  
Purines are metabolised primarily in the liver in a complex network of pathways 
summarised in Figure 2. In addition to exogenous purines obtained primarily through 
the diet, de novo synthesis of purines begins with the production of 
phosphoribosylpyrophosphate  (PRPP) from adenosine triphosphate (ATP) and 
ribose 5′-phosphate, catalysed by PRPP synthetase – overactivity of this enzyme 
leads to overproduction of uric acid and gout13. PRPP is converted to inosine 
monophosphate (IMP), which can be converted to adenosine monophosphate (AMP) 
or guanine monophosphate (GMP). 
AMP and GMP are removed by conversion back to IMP, which is dephosphorylated 
to inosine and converted to hypoxanthine. Xanthine oxidase (XO) catalyses the 
oxidation of hypoxanthine to xanthine, and xanthine to urate. Adenosine can also be 
deaminated directly to inosine, and guanine converted to xanthine. 
As Figure 2 shows, urate production is coupled to multiple different pathways 
including glucose and fructose metabolism, and any process consuming or producing 
ATP will alter these pathways - urate production rate is actually in index for ATP-
synthesis in hepatocytes14. This diagram is by no means exhaustive, but it is already 
clear from this limited view how increased alcohol consumption, diabetes, high 




Figure 2 - Uric acid pathways.  
Figure modified from Kushiyama et al. (2016)15. Abbreviations: (A/G)(TP/DP/MP) – adenosine/guanine tri/di/monophosphate. IMP – inosine 
monophosphate. TG – triglyceride. PRPP – phosphoribosylpyrophosphate. 
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1.1.2.1 The loss of uricase in humans 
In all mammals, including humans, uric acid is produced from xanthine, catalysed by 
the xanthine oxidase enzyme. In most mammals, uricase (also called urate oxidase) 
further oxidises urate to 5-hydroxyisourate, which is converted by two further enzymes 
into allantoin, a highly-soluble waste product that is easily excreted in urine16 (this is 
simplified into a single step in Figure 2). However, the apes, the group which includes 
humans, have lost uricase activity, breaking the pathway and leaving urate as the final 
end product of purine oxidation. Consequently, physiological levels of urate in serum 
are an order of magnitude higher in humans than most mammals (0.5 - 0.8 mg/dL in 
mice), and they vary over a much wider range.   
An interesting exception is seen in Dalmatian dogs, which have uric acid levels as 
much as ten times higher than mongrel dogs17,18, giving them a predisposition to 
urinary calculi formed from urate. This is not caused by mutations in uricase19, instead 
appearing to be due to a defect in the SLC2A9 gene, which encodes a urate 
transporter. This leads to reduced urate transport into the liver, the site of uricase 
activity, and reduced excretion in the kidney20. This mutation was likely fixed in the 
breed by artificial selection for their distinctive spotted appearance.  
By contrast, the loss of uricase activity in humans may in fact have had a selective 
advantage. Loss of function appears to have been gradual, caused by the 
accumulation of several mutations over millions of years21,22, and has occurred 
independently in several different lineages of higher primates. This suggests that 
increased concentrations of uric acid in the blood were beneficial. Various possible 
reasons for this have been suggested. The loss of uricase may have compensated 
for the earlier loss of ascorbic acid production in humans, as uric acid can also act as 
an antioxidant, and accounts for roughly half the antioxidant capacity of plasma23. It 
has also been suggested to be useful in times of starvation, as uric acid has been 
linked to the regulation of hepatic glucose production and the timing of the loss of 
uricase activity appears to coincide with a period of climatic change24. Kratzer et al. 
suggest that the progressive loss of uricase may have allowed the accumulation of 
fat via fructose metabolism, a potential advantage when climate shifts at the end of 
the Oligocene lead to the replacement of rainforests in Europe and Asia with less 
energy-dense temperate forest25. Regardless of the selective driver behind the loss 
of function, the accumulation of uric acid has a wide range of physiological and 
ultimately clinical consequences. 
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 Properties of uric acid 
Uric acid is a molecule with a complex range of biologically relevant and sometimes 
seemingly contradictory properties that make it a particularly interesting molecule to 
study. It is perhaps most famously known as an antioxidant, and indeed in vitro 
experiments in the 1980s showed that it is a powerful scavenger of damaging oxygen, 
peroxyl and hydroxy radicals, forming the basis of the theory that uricase activity was 
lost to compensate for the loss of ascorbate metabolism23. The antioxidant properties 
of uric acid have been proposed as the reason why gout appears to be protective 
against neurodegenerative diseases caused by radical damage26–28. Urate is a potent 
scavenger of peroxynitrite (ONOO-), a highly reactive oxidant and nitrating agent 
which can induce protein nitrosation and lipid and protein oxidation, as well as causing 
apoptosis through general oxidative damage to DNA and cellular components (Figure 
3a). Uric acid neutralises peroxynitrite many times faster than abscorbate29. In mice 
with experimental autoimmune encephalomyelitis (an animal model of demyelinating 
brain disease), uric acid was shown to have strong dose-dependent therapeutic 
effects, including blocking the peroxynitrate-mediated nitrosation of neuronal 
proteins28.  
However, it has since been observed that urate cannot scavenge all radicals, and 
does not consistently act as an antioxidant, requiring specific conditions to do so. 
While urate can inhibit Cu2+-induced oxidation of low-density lipoprotein (LDL) 
cholesterol (Figure 3b), in the presence of transition metals it can increase the 
oxidation of oxidised LDLs. In plasma, urate acts as an anti-oxidant, but in intracellular 
conditions, it can be a prooxidant. Urate can form radicals when reacting with other 
oxidants, particularly lipids. Additionally, the hydrophobic environment created by 
lipids limits the antioxidant capacity of uric acid, which has been proposed as an 
additional complication of the elevated serum urate levels seen in obesity30. In vitro 
experiments in rats have identified a role for uric acid in increasing monocyte 
chemoattractant protein-1 (MCP-1, also known as CCL2) production, a protein 
involved in vascular inflammation, via a mechanism that is driven by oxidative 
activity31 (Figure 3c). 
Uric acid also interacts with nitric oxide (NO), a gas originally identified as an 
endothelial cell-derived relaxing factor, but which has emerged to be an important 
regulator of cardiovascular function linked to hypertension, cardiovascular disease 
and metabolic syndrome. NO is a vasodilator, and reduced levels can lead to 
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endothelial dysfunction, a pathogenic event in which excess constriction of the blood 
vessels leads to inflammation, platelet activation and increased permeability to 
lipoproteins and other toxins. Endothelial dysfunction often precedes more advanced 
cardiometabolic disease. Oxidative stress is a primary driver of endothelial 
dysfunction, which  would suggest a protective role for uric acid, but hyperuricaemia 
was paradoxically found to induce it32. This effect was found to be driven by urate 
directly interacting with NO to form 6-aminouracil, which depletes NO, a reaction 
which could be blocked by another antioxidant, glutathione. When urate levels exceed 
the capacity of glutathione to supress this depletion, as in hyperuricaemia, endothelial 
dysfunction ensues33 (Figure 3c).  
To further complicate the paradoxical role of uric acid, the xanthine oxidase pathway, 
which produces uric acid, is actually one of the two major systems driving vascular 
oxidative stress. The process of converting xanthine to uric acid releases reactive 
oxygen species (ROS), highly oxidative molecules which cause endothelial 
dysfunction. For this reason, the XO inhibitor allopurinol, usually prescribed to treat 
gout, has been proposed as a treatment for hypertension. The other major process 
driving oxidative stress is NADPH oxidation, which uric acid can stimulate in 
adipocytes34, Figure 3c. 
The crystallised form of uric acid also plays a role as a danger signal. MSU crystals  
have been shown to trigger immune and inflammatory responses in various ways 
depending on the microenvironment in which the crystallisation occurs35.  Uric acid 
has also been identified as a damage-associated molecular patterns (DAMPs) 
component, being released from damaged cells, particularly after necrotic cell death, 
acting as an attractant for leukocytes and mesenchymal stromal cells, promoting 





Figure 3 - Antioxidant and prooxidant effects of uric acid.  
Figure adapted from So and Thorens (2010)37. a Peroxynitrite, produced by nitric oxide 
(NO●) radicals reacting with superoxide (O2-), can cause damage by nitrosating proteins, 
oxidising proteins and lipids. It also blocks tetrahydrobiopterin (HB4), an important 
cofactor necessary for nitric oxide synthase (NOS), which leads to production of reactive 
oxygen species (ROS). Uric acid (UA) can inactivate ONOO-, producing uric acid radicals 
(UA●) which are in turn neutralised by ascorbic acid. b UA can prevent copper ion (Cu2+) 
mediated oxidation of LDL. c In vascular smooth muscle cells, UA activates the NF-κB 
and MAPK pathways, increasing cyclooxygenase and MCP-1 production. In adipocytes, 
UA uptake activates NADPH oxidase, leading to ROS production. UA enhances arginase 
activity, which reduces NO levels by diverting L-arginine, necessary for NO production, 
into urea production. UA can react with NO to produce nitrosated UA, which can transfer 
its nitroso group to glutathione (GSH). In the presence of oxygen, this reaction produces 
stable 6-aminouracil, depleting NO.  
31 
 Uric acid transport  
Serum urate levels are the result of a balance between its production, primarily in the 
liver, and its excretion in the kidney and the gut. Transport proteins play a key role in 
regulating this balance, and consequently many have been identified as modulating 
serum urate levels and gout, both through genome-wide association studies (GWAS) 
and functional work.  
The kidney is a key organ in urate homeostasis, accounting for an estimated 70% of 
urate excretion37. Urate is filtered in the glomerulus and a combination of reabsorption 
and secretion is orchestrated in the proximal convoluted tubule by various 
transporters, summarised in Figure 4. A net reabsorption occurs such that the 
fractional excretion of urate (the fraction of the total filtrate which is ultimately 
excreted) is normally ~6-8%. 
Among the transporters are several proteins from the organic anion transporter-like 
(OAT) family, encoded for by genes in the SLC22A family. URAT1 (encoded by 
SLC22A12) is located on the apical membrane of proximal tubule epithelial cells, and 
transports urate into the cell in exchange for chlorine ions or organic anions38. 
Antiuricosuric agents (uricosuria is the condition of having uric acid in the urine, thus 
antiuricosuric drugs promote reuptake of urate) such as lactate, pyrazinoate and 
nicotinate can serve as substrates for URAT1 and thus increase urate uptake, while 
benzbromarone, probenecid and losartan, all used to treat gout, inhibit it and increase 
renal uric acid clearance38. Inactivating mutations in this protein have been found to 
cause idiopathic renal hypouricaemia38. 
OAT4 (SLC22A11) and OAT10 (SLC22A13) are also expressed at the apical 
membrane and thought to similarly reabsorb urate from the tubule lumen39–41. OAT4 
can transport urate into cells in exchange for dicarboxylates39. OAT10 is a high-affinity 
nicotinate transporter41. OAT1 (SLC22A6) and OAT3 (SLC22A8) also function as 
anion/dicarboxylate exchangers and can transport urate into cells but are expressed 
at the basolateral membrane.  They have been suggested to play a role in urate 
secretion, rather than uptake, based on the predicted gradient of dicarboxylate across 
cell membranes42–45. 
MRP4 (ABCC4) and ABCG2 (ABCG2) are both expressed on the apical membrane, 
but export urate out into the lumen in an ATP-dependent manner, therefore driving 
urate secretion46–48.ABCG2 is the major urate transporter in the gut49, and has been 
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suggested to play a compensatory role in individuals with CKD where renal urate 
excretion is impaired50. A Q141K mutation in this gene (rs2231142) confers a  
greatly increased risk of gout51.  
Sodium phosphate transporter 4 (NPT4, SLC17A3) is a voltage-driven transporter 
expressed on the apical membrane that secretes urate52.  NPT1 (SLC17A1) is 
similarly expressed on the apical membrane and a hypermorphic mutation in the 
protein has been linked to reduced risk of renal underexcretion gout53.  
Currently, only one transporter is known that transports reabsorbed urate into the 
interstitium for circulatory system uptake – GLUT9, encoded by SLC2A9. This protein 
is unusual in that its primary function was discovered following GWAS – prior to this 
it was known as a glucose/fructose transporter of very low activity54. Early GWAS of 
serum urate levels identified a strong association signal in SLC2A9 explaining around 
3.5% percent of variance in serum urate levels, with various experimental methods 
confirming its role as a urate transporter with low affinity but high capacity55–57. Two 
alternatively-spliced variants exist, GLUT9a and GLUT9b. In humans, GLUT9b is only 
expressed in the kidney and placenta, while GLUT9a is more broadly expressed in 
kidney, liver, intestine, leukocytes and chondrocytes58. The longer isoform GLUT9a 
traffics to the basolateral membrane of the kidney proximal tubule cells and plays a 
major role in urate reuptake, GLUT9b locates to the apical membrane. Its transport 
functions are dependent on membrane potential, but are not sensitive to Na+ or Cl- 
concentrations59. Loss of function mutations in GLUT9 cause monogenic 




Figure 4 - Uric acid transporters in renal proximal epithelial cells. 
Figure adapted from So and Thorens (2010)37.  
 Effect of sex hormones 
As mentioned above, serum urate levels are significantly higher in men than in 
women, and postmenopausal women have higher levels than premenopausal. It has 
been proposed that hormonal changes explain some of these differences – oestrogen 
appears to increase renal clearance of uric acid61–63, even when administered to 
males62, but the mechanism remains unknown. 
Male-to-female transsexuals showed reduced uric acid after hormone therapy, but 
while female-to-males showed increased uric acid, it remains unclear whether 
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testosterone also plays a role64. A recent study of postmenopausal women found that 
uric acid was lowered in a group receiving combined oestrogen and progesterone 
therapy, but no significant difference in a group receiving only oestrogen. This could 
suggest the regulatory system is more complex, but could also reflect the smaller 
sample size in the oestrogen-only group65.  
 Genome-wide association studies of serum urate 
GWAS have had a major impact on medical research over the last decade, and uric 
acid is no exception. The principles behind GWAS will be explored in more detail in 
Chapter 3, but to briefly summarise, the aim of a genome wide association scan is to 
identify genetic variants which are associated with a trait of interest – whether a 
disease or a quantitative trait, such as serum urate levels. Advances in computational 
power, recruitment of increasingly large research cohorts and development of 
sophisticated statistical techniques to maximise power have led to a steady increase 
in the number of regions of the genome known to have a link with serum urate levels, 
even though the mechanism behind the association is not always clear. 
1.1.6.1 SLC2A9/GLUT9 
The earliest GWAS of serum urate identified SLC2A9 as being significantly 
associated with serum urate55–57,66. The association between variants in this gene and 
levels of serum urate is so strong that it was detectable in fewer than 1,000 individuals. 
Prior to these associations,  the encoded protein GLUT9 was suspected by structural 
homology to be a glucose or fructose transporter, and while it does show transport 
ability for these molecules, functional experiments in Xenopus oocytes demonstrated 
that it  had a much greater urate transporting capacity55. As previously mentioned, 
this was a remarkable example of GWAS leading directly to a novel functional insight 
– most GWAS variants identify regulatory regions of the genome that are not so 
immediately interpretable.  
Strong sex-specific effects were also remarkable at this locus, with the same variant 
explaining 1.2% of the variation in serum urate levels in men, but 6% in women55,56. 
An early study of four directly-genotyped polymorphisms within the SLC2A9 locus 
within two cohorts, one a population sample of 800 and the other a case-control  
sample with 1,038 severely obese (body mass index (BMI) between 33 and 92 kg/m2) 
and 831 controls (BMI < 33kg/m2), suggested that obesity (body mass index (BMI) > 
40kg/m2) increased effects of these variants, with a stronger modulating effect in men 
35 
than women67. A later study in a predominantly female sample, with 520 obese (BMI 
> 35kg/m2), and 540 controls (BMI < 25kg/m2), reported the opposite, stronger 
associations in lean than obese68, but the sex differences and different criteria for 
controls make it difficult to draw direct comparisons. 
 A more recent GWAS with a somewhat larger sample size stratified into lean, 
overweight and obese individuals did not identify statistically significant differences 
between BMI strata at this locus69. 
1.1.6.2 Early meta-analysis of serum urate 
As the GWAS field matured, meta-analysis of multiple cohorts allowed increased 
statistical power. Power to detect variants increases with sample size, effect size and 
minor allele frequency, so larger sample sizes were necessary to detect the effects of 
rarer variants of similar effect size to those discovered in early studies, or variants 
with smaller effects. 
An early meta-analysis by Dehghan et al. (2008) identified variants in the ABCG2 and 
SLC17A4-SLC17A1-SLC17A3 loci51. The Q141K variant referred to above was 
identified in this analysis, which later analyses confirmed to be a strong risk variant 
for gout commonly segregatng in populations of European ancestry. Sex-specific 
effects were also identified in ABCG2, with stronger effect in men. Prior to this, 
ABCG2 was known as an efflux  transporter for  multiple drugs, but also purine 
nucleoside analogues, making it a promising candidate for urate transport. Follow up 
experiments confirmed its urate transporting activity70. SLC17A1 and SLC17A3 
encode the urate transporters NPT1 and NPT4 respectively, though at the time only 
NPT1 had been demonstrated to have a urate transporting effect in model systems71. 
Dehghan et al. also constructed a genetic risk score using variants in these two genes 
and SLC2A9 to test for association with gout, remarkably identifying a 41-fold 
difference in risk between the lowest and highest risk groups. 
Larger meta-analyses identified more signals. Kolz et al. (2009) meta-analysed data 
from 14 studies comprising over 28,000 individuals. They identified six additional loci, 
including two close the SLC22A11 and SLC22A12 genes. SLC22A12 encodes 
URAT1, the very first (and thoroughly) characterised urate transporter, identified 
before the GWAS era by sequence homology with known OAT proteins38, while 
SLC22A11 encodes OAT4. The study also identified monocarboxylic acid transporter 
9 (MCT9, SLC16A9), glucokinase regulatory protein (GCKR), Carmil (LRRC16A), and 
near PDZ domain-containing 1 (PDZK1).  
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OAT4 is a urate transporter active in the kidney, as described above.  
MCT9 transports monocarboxylic acid across cell membranes and is expressed in the 
kidney. Its role in urate homeostasis remains unknown, but later work identified a 
K258T mutation that is associated with renal overload gout (gout driven by 
overproduction of urate, rather than underexcretion)72 and Kolz et al noted that 
variants associated with urate levels at this locus also influenced carnitine levels 
suggesting a link to energy production and  fatty acid metabolism.  
Carmil is a regulator of actin polymerisation, and an abundant protein in the kidney 
and epithelia. 
GKCR encodes glucokinase regulatory protein, a regulator of glucokinase, the 
enzyme which phosphorylates glucose, a key first step in de novo synthesis of uric 
acid (see Figure 2). The identified variant is also associated with a range of 
metabolism- and diabetes-related traits. 
PDZK1 encodes a scaffolding protein thought to interact with and regulate OAT4, 
URAT1 and NTP1 (SLC17A1)  via N-terminal PDZ motifs, and has been proposed to 
link URAT1 and NPT1 into a functional complex that both secretes and reabsorbs 
urate, allowing precise regulation73. 
1.1.6.3 Global Urate Genetics Consortium 
The largest published GWAS of serum urate to date was run by the Global Urate 
Genetics Consortium (GUGC) and published in Köttgen et al. (2013)74. This GWAS 
identified 18 new signals, from a total of 28, with novel loci reported at TRIM46, 
INHBB, SFMBT1, TMEM171, VEGFA, BAZ1B, PRKAG2, STC1, HNF4G, A1CF, 
ATXN2, UBE2Q2, IGF1R, NFAT5, MAF, HLF, ACVR1B-ACVRL1 and B3GNT4. This 
analysis reported 7.0% of variance in serum urate levels was explained by these 28 
single nucleotide polymorphisms (SNPs) (5.2% by the previously known loci and 3.4% 
by SLC2A9 and ABCG2 alone). Heritability of serum urate concentration is estimated 
at 40-70%, suggesting that there are more genetic variants to be found. 
The novel regions identified in this meta-analysis were within or close to genes 
without an obvious role in urate transport. Expression quantitative trait locus (eQTL) 
and network analysis suggested that the implicated genes in the novel loci play roles 
in glucose and lipid metabolism. Inhibins-activins signalling pathways were 
suggested by protein-protein interaction networks, but it remains unclear which 
biological functions these contribute to. 
37 
 
1.1.6.4 BioBank Japan 
The latest development in the GWAS field is the rise of the ‘supercohort’, single 
cohorts of very large size – in excess of a hundred thousand individuals, with some 
projects aiming for a million. These are often national prestige projects, such as the 
UK Biobank75,76, a project notable for making its data available to any researcher 
subject to project approval. UK Biobank has not yet released biochemistry data (this 
is discussed in more detail in Sections 4.4.8 and 5.1.1), but the BioBank Japan project 
has recently published GWAS results for 58 quantitative traits, including uric acid77. 
Though the sample size of the analysis is slightly smaller than the GUGC meta-
analysis (>109,000), ten of the twenty-seven loci they reported were novel. This will 
be in part due to the different ancestry of the cohort – most GWAS research has been 
on European-ancestry populations – but will also reflect improvements in genotype 
imputation, as denser and more accurate reference panels have been released since 
the GUGC analysis (see Chapter 3). Novel loci were identified at USP34, 
PRDM8/FGF5, UNCX/MICALL2, TP53INP1/NDUFAF6, BICC1, FAM35A, 
EMX2/RAB11FIP2, SBF2, MPPED2/DCDC5 and LOC101927932. Little 
interpretation of these loci was made in the paper, which is an emerging characteristic 
of ‘supercohort’ publications: associations with dozens of phenotypes are published 
but it is left to the reader to interpret their relevance. In part this is an inevitable 
consequence of publishing such broad research, but it is also symptomatic of the 
increasingly complex associations revealed by GWAS analysis. Interpreting individual 
results is difficult, and network- and pathway-based approaches with functional 
validation will become indispensable in the future. 
1.2 Clinical and epidemiological relevance  
The ancestral loss of uricase may have conferred a selective advantage, but it has 
come at a cost to the health of modern humans. While mechanisms to regulate serum 
urate levels are sophisticated, modern western diets are purine-rich, containing large 
amounts of alcohol, red meat and seafood. This increases the pool of exogenous 
purines and consequently leads to elevated serum urate levels.  
Cross-sectional studies have found variation of serum uric acid level with age is 
complex and varies between sexes, but are inconsistent in their conclusions, likely 
because they provide a snapshot of the population rather than following the same 
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individuals over time78–80. In a longitudinal study of 80,506 Japanese office workers, 
serum urate levels were found to increase with age independently of changes in BMI 
and alcohol consumption81. This was particularly strong in women between 40 and 
70, corresponding to the menopause.  
Although uric acid has been associated with a wide range of diseases, evidence that 
it is a risk factor rather than a consequence is rarely consistent, except in the case of 
gout. A recent comprehensive umbrella review compared evidence from 101 
publications, encompassing systematic reviews, meta-analyses of observational 
studies, meta-analyses of randomised controlled trials and 107 Mendelian 
randomisation (MR) studies, exploring a total of 136 unique health outcomes82. 
Evidence was classified as ‘convincing’, ‘strongly suggestive’, ‘suggestive’ or ‘weak’ 
depending on criteria including P-values, sample size and heterogeneity. No 
observational studies were found to have ‘convincing’ evidence, but ‘strongly 
suggestive’ evidence was found for associations between serum urate and risk of 
heart failure, hypertension, impaired fasting glucose or diabetes, CKD and coronary 
heart disease (CHD) mortality. Four outcomes had significant P-values for MR studies 
– diabetic macrovascular disease, arterial stiffness, renal events and gout, but, of 
these, only gout had convincing evidence. Recurrence of nephrolithiasis (kidney 
stones) showed some evidence of association in randomised controlled trials, but not 
in observational studies or MR.  
However, this review is not without limitations. As Borghi points out in his response to 
the article83, serum uric acid levels may not be a good discriminatory tool, as the same 
level can arise through different mechanisms – overproduction or underexcretion, 
through a variety of pathways – and thus may not be expected to associated similarly 
with disease. Additionally, he suggests that the role of xanthine oxidase and oxidative 
stress cannot be dismissed, and that the considerable heterogeneity in thresholds 
used for hyperuricaemia between studies causes difficulties in interpretation. This 
review is cited here not as proof that abnormal serum urate levels are or are not causal 
for a given disease, but rather as a demonstration of how complex the question 
remains despite so many attempts to address it. 
 Gout 
The dominant cause of hyperuricaemia in individuals with gout appears to be 
underexcretion of urate, rather than overproduction – when compared to healthy 
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controls, gout patients showed lower uric acid clearance (filtration from serum), 
fractional excretion of uric acid (percentage of uric acid filtered  by the kidney that is 
then excreted in the urine) and urinary uric acid to creatinine ratio than controls84. 
While allantoin is highly soluble in water under physiological conditions, allowing it to 
be easily eliminated in urine, uric acid is considerably less so. The solubility limit of 
6.8mg/dL is within the normal range of serum urate concentrations in humans, and as 
a result, spontaneous formation of MSU crystals can occur. These can grow into 
nodular masses called tophi in advanced gout, usually around ten years after the initial 
flares. This most often occurs in the synovial fluid of the joints, but tophi can be found 
on the elbows, upper ear cartilage and joint surfaces. However, not all hyperuricaemic 
individuals exhibit MSU crystals. The factors controlling crystal formation remain 
poorly understood, but factors affecting the solubility of urate such as temperature 
and pH may contribute.  
Gout is characterised by painful ‘attacks’ or ‘flares’, periods of intense but self-limiting 
pain. These are triggered by macrophages interacting with MSU crystals and 
activating the NLRP3 inflammasome85, releasing interleukin 1β and activating 
neutrophils and mast cells, which release a host of pro-inflammatory cytokines, 
chemokines and ROS, amplifying the response86. However, only around 20%of 
hyperuricaemic individuals experience gout attacks87. The reasons for this are 
unclear, though perhaps related to variation in the concentration at which 
crystallisation occurs. It remains an area of active research which may lead to new 
therapeutic options for gout sufferers.  
The prevalence of gout is increasing worldwide, but it is asymmetrically distributed, 
being higher in developed countries and particularly high in Pacific island 
populations88. In a study in the US, prevalence increased by two cases per 1,000 over 
ten years, but in over 75s the rate doubled from 21 per 1,000 in 1990 to 41 per 1,000 
in 199989. Prevalence was estimated at around 4% in the US in 200890. Gout is also 
on the rise in the UK, from 1.42% in 1997 to 2.49% in 201291. Prevalence is much 
higher among men (3-6%) than women (1-2%), and but increases in women after 
menopause88, reflecting similar patterns in serum urate levels. 
 Cardiometabolic disease 
Hyperuricaemia frequently occurs in patients with metabolic syndrome – a collective 
term for a cluster of associated symptoms that put patients at increased risk of CHD, 
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stroke and diabetes. Its definition has varied over time – hyperuricaemia has 
previously been one of the defining components – but it broadly reflects central 
obesity, hypertension, hyperglycaemia, and dyslipidaemia. Obesity – visceral 
adiposity in particular – is closely correlated to hyperuricaemia92.  
Metabolic syndrome is driven by a complex and highly interconnected set of pathways 
(Figure 5). It is characterised by insulin resistance and high levels of free fatty acids, 
which can be due to a combination of genetics and lifestyle and are often associated 
with obesity. Adipose tissue releases inflammatory factors, angiotensin and 
adipokines, which suppress insulin signalling93,94. Angiotensin release leads to 
hypertension, exacerbated by increased sodium retention in the kidney driven by high 
levels of insulin, a consequence of insulin resistance. In the liver, free fatty acids 
accumulate from insulin-resistant adipose tissue, altering the balance of LDL and 
high-density lipoprotein (HDL) cholesterol and increasing glucose production. 
Combined with reduced glucose uptake by muscle and adipose tissue, this leads to 
hyperglycaemia95.  
Insulin drives increased reuptake of urate in the kidney – in vitro experiments have 
shown that insulin significantly increases endogenous levels of  URAT196. This is one 
pathway by which metabolic syndrome is connected to hyperuricaemia. Altered 
glucose metabolism also increases uric acid production, through ATP depletion and 
reduced phosphate levels. Inflammation and oxidative stress increase and are 
increased by elevated uric acid levels, leading to reduced bioavailability of NO and 





Figure 5 – Mechanisms of metabolic syndrome. 
Figure adapted from Battelli et al. (2018)95. NO: nitric oxide. VLDL: Very low-density 
lipoprotein. HDL: high-density lipoprotein. Na+: sodium ions. 
 
Hyperuricaemia is commonly found in CVD patients, but whether it is a risk factor or 
a consequence remains unclear. Mendelian randomisation analyses have found 
evidence both for and against causality82. Early work in the Framingham Heart Study 
concluded that hyperuricaemia was a consequence of known cardiovascular risk 
factors78 but several studies have suggested that uric acid plays a direct role in 
endothelial dysfunction97,98, which can lead to CVD. There is evidence that urate can 
increase the oxidation of already oxidised LDL cholesterol, leading to increased risk 
of thrombosis and atherosclerosis. The production of ROS involved in urate synthesis 
and the inflammatory response it triggers can also lead to endothelial damage (for 
details see Section 1.1.3). The direct effect of uric acid on endothelial function in vivo 
has been difficult to investigate due to confounding by comorbidities, reverse 
causations and canalization. In non-hypertensive hyperuricemic adult individuals, the 
XO inhibitor allopurinol, which lowers serum urate by preventing xanthine oxidation, 
and the linked ROS production, was shown not to affect endothelial function99. This 
suggested that serum urate level per se may not be directly implicated in regulating 
endothelial dysfunction.  
Hypertension has been suggested to passively increase serum urate levels, as early 
hypertension leads to decreased renal blood flow, which could alter the rate of urate 
secretion100. However, there is evidence that hyperuricaemia may play a direct role in 
hypertension through its activation of the renin-angiotensin system and its direct 
effects on NO (see Section 1.1.3) and trials have shown that allopurinol can reduce 
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blood pressure in adolescents101. There is also evidence that in children 
hyperuricaemia is associated with primary hypertension, but not secondary, 
suggesting it plays a causal role102. Mendelian randomisation studies remain 
inconclusive82, perhaps limited by current knowledge of genetic associations, and the 
pleiotropic effects of the different associated variants. 
A post-hoc analysis of the EURIKA study 103, a cross-sectional study of patients with 
no clinical disease but at least one risk factor for cardiovascular disease, identified an 
increased risk of death in patients with higher serum urate levels. This effect remains 
significant after accounting for diuretic use or impaired renal clearance. As observed 
by Carluccio et al. 104, this suggests that the risk is associated with increased urate 
production by XO, rather than accumulation of serum urate per se , which could also 
occur due to reduced excretion. 
The ready availability of urate-lowering drugs means that a better understanding of 
the relationship between cardiovascular disease and uric acid could lead to new 
therapeutic options without new drug development, if the relationship could be 
understood.  
Hyperuricaemia frequently co-occurs with type 2 diabetes, but again, the causality is 
unclear. Fructose, a major dietary cause of diabetes, is rapidly converted to fructose-
1-phosphate, which results in a fall of intracellular phosphate and ATP, stimulating  
the direct generation of uric acid though nucleotide turnover6. Uric acid clearance is 
inversely correlated with insulin resistance (IR).  
 Renal disease 
Serum uric acid levels are inversely correlated with measures of glomerular filtration 
rate (a measure of kidney function) and approximately 20 to 60% of gout patients also 
have some renal dysfunction105. Kidney disease will inevitably lead to abnormal 
concentrations of many substances in the blood, but there it has been suggested for 
decades that hyperuricaemia is more than just a symptom. A study published in 1978 
of patients with normal kidney function comparing hyperuricaemic (>8.0 mg/dL) to 
normal (<5.0 mg/dL) patients found nearly a threefold increase in risk of developing 
renal deficiency within two years for men, and a tenfold risk for women106. More 
recently, studies in rat models have found that hyperuricaemia-induced kidney 
damage can be reversed with urate-lowering agents107. A recent meta-analysis found 
elevated uric acid levels to be predictive of new-onset CKD108, and another cautiously 
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suggested that urate-lowering medication may slow the progression of CKD, but 
larger studies were required to test this assumption109.  
It has been suggested that activation of the renin-angiotensin system by uric acid is 
one mechanism by which uric acid could lead to kidney disease, as this raises 
systemic and glomerular pressure, which can cause fibrosis of renal cells110.  
 Neurodegenerative disease 
Low serum uric acid levels are also associated with neurogenerative  disease – 
associations have also been found between lower levels of uric acid and multiple 
sclerosis9, Parkinson's disease10, Huntington’s disease111, Alzheimer's disease112, 
and optic neuritis113, though these are all small studies. 
These associations may be consequences of diseases, but could also be due to uric 
acid’s role as an antioxidant, with its ONOO-  scavenging capacity suggested as a 
particularly important mechanism100. ONOO- and similar radicals are thought to be 
involved in the inflammation, demyelination and oxidative stress involved in various 
forms of neurodegenerative disease. 
1.3 Project Aims 
It is increasingly apparent that, far from the inert waste product it was once assumed 
to be, uric acid is a biologically active molecule that plays a range of roles in 
inflammation, signalling and protection against oxidative stress. As both 
hyperuricaemia and hypouricaemia are associated with disease, with some 
biologically plausible mechanisms for their pathogenicity, a better understanding of 
the pathways regulating uric acid levels could provide novel insights into these 
associated diseases. In addition to providing biological insight, this greater knowledge 
will be essential for guiding the assessment of the therapeutic potential of urate-
altering drugs.  
This project aims to further investigate serum urate associations and regulation, with 
a particular emphasis on exploring their genetic underpinning. It is hoped that this will 
help define specific pathways altering serum urate levels and lead to better 
understanding of the associated diseases and conditions.  
This will take two primary approaches. First, high-dimensional molecular phenotyping 
data, I aim to identify proteins and lipids which are associated with serum urate levels. 
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The significantly associated traits and the look up for shared genetic factors which 
could help interpret associations are detailed in Chapter 2. 
Second, I will use genetic association methods to identify new regions of the genome 
influencing serum urate levels, first using data from our own cohorts, detailed in 
Chapter 3 and then as part of a large GWAS consortium, CKDGen, detailed in 
Chapter 4.  
Finally, in Chapter 5, I will detail the current status of a work-in-progress collaboration 
with Professor Tony Merriman (University of Otago) to identify genetic variants which 
are protective against gout. 
Taken together, the work in this thesis represents a body of new knowledge on the 




 Phenotype Correlations 
2.1 Background 
Uric acid synthesis is tightly linked to ATP homeostasis and metabolic pathways, and 
accordingly serum urate levels are correlated with a variety of phenotypes. Some 
have been known for many years, such as BMI, HDL cholesterol levels or alcohol 
consumption114. While the associations often seem intuitive, the underlying 
mechanisms are partly or wholly unclear, as these complex phenotypes are the 
compound result of multiple different physiological pathways, governed by the 
complex interplay of both genetic and environmental factors.  
Less complex endophenotypes are an attractive way to attempt to untangle the 
relationships between uric acid and high-level phenotypes. As they are closer to the 
gene level, the relationship between genotype and phenotype is generally less 
polygenic and the underlying mechanism can be easier to interpret. This has become 
a particularly viable method with the advent of relatively cheap, high-throughput omic 
phenotyping platforms.  
‘Omics’ is a somewhat loosely defined collective term for fields that focus on the 
characterisation and quantification of a large number of related biological 
measurements – strictly speaking, the word encompasses all fields in biology ending 
in ‘omics’. Generally, though not exclusively, these are concentrations of biological 
molecules such as proteins (proteomics), lipids (lipidomics) or metabolites 
(metabolomics).  
A variety of technological and computational advances in recent years have led to 
large datasets of molecular omic data becoming available, and these are increasingly 
being used to investigate complex physiological changes or disease states. The 
combination of genomics and other omic phenotypes has proven effective for 
distinguishing between causal and non-causal biomarkers of disease. For example, 
in the field of proteomics, the OLINK-IMPROVE study (www.olink-improve.com) 
identified genetic variants regulating plasma protein biomarkers selected based on 
previous associations with CVD, and identified multiple new causal associations115. 
Recently, an analysis in the Framingham Heart Study, replicated in the INTERVAL 
and KORA cohorts, performed a similar analysis using 71 proteins previously 
associated with CVD, finding 69 novel loci, and using Mendelian Randomisation to 
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identify six proteins which were causal for CHD, two of which were associated with 
new-onset CHD or CVD events116. Proteomic measurements before and after weight 
loss have been used to identify differential genetic regulation of BMI-associated 
proteins, which led to the discovery of a new regulator of the satiation hormone 
leptin117. A large-scale lipidomic GWAS identified lipid-associated SNPs which 
conferred increased risk of coronary artery disease and type-2 diabetes118, while a 
similar study using metabolomic measurements found variants linked to a host of 
diseases including Crohn’s disease and CKD119. 
In the case of uric acid, progress has been made in the field of metabolomics by 
Albrecht et al., who investigated 355 metabolites on the Metabolon platform 
(www.metabolon.com) by constructing a Gaussian graphical model of significant 
partial correlations with uric acid in the 1,764 individuals from the KORA cohort120. 
They identified a network of 38 metabolites linked to serum urate level, including 
nucleotides such as xanthine, a known precursor to uric acid in the purine catabolism 
pathway, and aspartame, used as a low-calorie sweetener, essential amino acids 
histidine and methionine and a cluster of steroids along with several uncharacterised 
metabolites. 
Associations between protein concentrations and serum urate have been 
investigated, but not yet in a high-dimensional analysis – usually, only a few proteins 
are assessed in any given study. Often, they have only been detected in vivo, with 
physiologically unrealistic concentrations of uric acid, or in species other than 
humans. While studies in other species are never an ideal way to make inferences 
about human physiology, they are particularly dubious in the case of uric acid. Uricase 
inhibitors can be used to reduce the oxidation of urate in model systems, but this can 
only be an approximation, as human metabolisms have had millions of years to evolve 
in the presence of high and highly variable levels of serum urate (as loss of uricase 
activity predates the genus Homo), and consequently may respond very differently. 
Lipids are even more sparsely investigated, with most studies limited to HDL, LDL 
and total cholesterol and triglyceride levels. 
In two of our locally-held cohorts, CROATIA-Vis and ORCADES, we are fortunate to 
have multiple omic measures available on almost two thousand individuals, including 
lipids measured by untargeted mass spectrometry and protein concentrations using 
Olink targeted biomarker platforms (www.olink.com) for inflammation and CVD. Many 
of these molecular phenotypes have never been investigated in connection with uric 
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acid before. In the case of the Olink proteins particularly – as serum urate is closely 
linked to both inflammation and CVD – this may help deconvolve relationships 
between serum urate levels and the more complex disease phenotypes. 
This chapter aims to uncover and interpret novel associations between serum urate 
and the endophenotypes available in our cohorts. I hypothesise that while many of 
these phenotypes will be associated with serum urate levels, most of these will be 
mediated through a much smaller set of associations that persist after accounting for 
a large number of other phenotypes. Identifying these will highlight candidates for 
mechanistic associations with serum urate, which may be targets for further research 
into urate-associated disease.   
In addition to simple correlations, multi-phenotype methods will take advantage of the 
wealth of phenotypic data available. Partial correlations will be used to measure the 
strength of association between two variables after controlling for the effects of one 
or more covariates. This reduces the problem of confounding, which is likely to be 
high in a dataset of biomarkers of related function, and also allows known effects, 
such as the link between serum urate and BMI, to be taken into account. 
As an alternative method to account for high collinearity, lasso regressions will be 
used to identify minimal sets of urate-predicting phenotypes. Lasso regression is a 
regression method which penalises the number of non-zero coefficients in the model 
– effectively, it attempts to identify the simplest possible combination of phenotypes 
to predict the level of serum urate. By iterating the algorithm multiple times, it is 
possible to identify a small set of phenotypes whose combination of values best 
predict serum urate concentration. While partial correlations account for the effect of 
every phenotype, lasso regression instead discards uninformative phenotypes. 
Both methods should identify associations that are independent of other phenotypes 
in the dataset. Including such a wide range of other phenotypes should increase the 
chance that those detected are most directly relevant to serum urate levels. It should 
be noted that these statistical methods cannot account for complex non-linear 
biological relationships, such as feedback mechanisms, and so should be interpreted 
cautiously. However, they have the potential to identify new hypotheses which, 
following experimental verification, may lead to mechanistic insights into either serum 





The islands of the Dalmatian coast are home to a number of isolate populations, many 
of which have been studied for a number of years due to the potential of enrichment 
of rare genetic variation due to genetic drift and population bottlenecks121. The 
CROATIA-Vis cohort (also referred to as Vis in this thesis) is one of these research 
populations. It comprises 1,008 participants recruited from the Croatian island of Vis 
between 2003 and 2004122, with blood DNA, plasma and serum collected from fasting 
participants, as well as information from questionnaires (including lifestyle information 
such as diet) and anthropometric and physical measurements. Collected EDTA 
plasma was stored at -80°C until the date of Olink analysis in 2016.  
2.1.1.2 ORCADES 
The Orkney Complex Disease Study, or ORCADES, is another isolate population 
cohort from the Orkney islands off the north coast of Scotland. Individuals were 
eligible for recruitment if at least two grandparents resided in the Orkney Isles. A total 
of 2,080 participants were recruited between 2005 and 2011, with a variety of 
phenotypes measured by clinic visit and questionnaire. Fasting blood samples were 
taken from all participants and a subset stored at -80°C until used for Olink proteomics 
in 2016. 
2.1.1.3 INTERVAL 
The INTERVAL study was originally set up by the Universities of Cambridge and 
Oxford to identify the optimum interval for blood donation123. 45,000 individuals were 
recruited between mid-2012 and mid-2014, and Olink proteomic measurement was 
performed on a subset of 5,000 using blood drawn between 2014 and 2016. Blood 
samples were generally processed within one day of bleed and frozen. Demographic 
characteristics were obtained by online questionnaire. Because the sample is 
comprised of blood donors, participants were in good health at the time of recruitment, 
but samples were non-fasting.  
INTERVAL differs from the other cohorts in the analysis in that serum urate and serum 
creatinine were measured on the Metabolon platform rather than with standard 
biochemical assays. This method is a high-throughput mass spectrometry-based 
system that reports quantities in arbitrary units rather than absolute values. Because 
the following methods make use of data that has been rank-transformed to normality, 
this should not affect the results. This assumption has been tested (as detailed in 
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2.2.5.1) but there may still be differences, and as such caution is warranted when 
results from INTERVAL are inconsistent with the other cohorts. Because estimated 
glomerular filtration rate (eGFR) is calculated based on absolute units of creatinine, it 
is not possible to exclude CKD cases based on eGFR values in this cohort. However, 
since the cohort was comprised of blood donors, it is unlikely that many, if any, 
individuals would have been CKD patients.  
2.1.1.4 The Estonian Biobank (EGCUT) 
The Estonian Biobank is a cohort run by the Estonian Genome Center of the 
University of Tartu (EGCUT). The EGCUT cohort comprises over 50,000 individuals 
from Estonia, recruited from the general population by GPs, who performed health 
examinations as well as taking blood, plasma and DNA124. Lifestyle factors were 
assessed by questionnaire. Olink data is available on a subset of the population. 
Blood was drawn from non-fasting individuals between 2011-2012 and stored as 
aliquots in MAPI straws in liquid nitrogen until analysis in May 2017. 
2.1.1.5 Lifelines DEEP 
Lifelines DEEP is a prospective, general population cohort study from the 
Netherlands125. It is a deeply-phenotyped sub-cohort of the Lifelines cohort 
comprising 1,539 individuals aged 18 and over. The cohort has extensive molecular 
phenotyping, which includes Olink proteomics on the CVD-III panel only (see Section 
2.1.2.1.1). Fasting blood samples were collected between April and August 2013 and 
stored at -80°C until the date of analysis in 2018. Uric acid and creatinine are 
measured by liquid chromatography-mass spectrometry, and so units are not 
comparable to other cohorts. 
2.1.1.6 PIVUS 
The Prospective Investigation of Vasculature in Uppsala Seniors (PIVUS) is unique 
amongst the studies included in this thesis in that all 1,000 participants are the same 
age – 70 years old at the time of recruitment. The cohort was recruited between 2001 
and 2004, with the aim of investigating cardiac function in seniors from the Swedish 
city of Uppsala. The cohort was recalled for additional phenotyping at age 75 and is 
currently being updated with age 80 measurements. Olink protein measures are 
available at age 70 on the CVD-I panel (see Section 2.1.2.1.1), which has some 
overlap with the phenotypes investigated on our panels. Blood samples were 
collected after an overnight fast at baseline in 2001-2004 and were frozen without 
thawing at -80°C until the date of analysis in 2014. 
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 Phenotypes 
2.1.2.1 Non-omic phenotypes 
Initial investigation included a wide range of phenotypes with possible links to serum 
urate: body mass index (BMI), A Body Shape Index (ABSI, a measure of body shape 
designed to assess the effect of body shape independently of BMI126), waist-to-hip 
ratio, systolic and diastolic blood pressure, HDL and LDL cholesterol, triglycerides, 
total cholesterol, C-reactive protein (CRP), fasting glucose, alcohol consumption 
(grams/week), insulin, creatinine and eGFR. 
Final lipidomic analyses retained all covariates. Olink analyses were limited to BMI, 
eGFR and alcohol consumption, as these were the only phenotypes available in all 
replication cohorts. These are categorised as ‘non-Olink phenotypes’ in all figures and 
tables, as detailed in Supplementary Table 1.  
2.1.2.1.1 Olink proteomics 
Olink Proteomics’ Olink platform (initially sold under the ‘Olink Proseek’ name) is a 
targeted system for quantifying protein biomarkers. This method uses their ‘Proximity 
Extension Assay’ technology127, in which each target protein is bound by pairs of 
antibodies. Each antibody has a unique DNA oligomer bound that can hybridise only 
with the second antibody for the target protein. Hybridised sequences are extended 
and amplified, and quantitative PCR is used to measure the concentration of the 
hybridised oligomers as a proxy for the concentration of the target protein. 
Mismatched oligomers do not hybridise and are not detected, improving the specificity 
of the technology. Ninety-two proteins are measured simultaneously by each panel.  
Proteins were measured on the ‘Cardiovascular II’ (CVD-II), ‘Cardiovascular III’ (CVD-
III) and ‘Inflammation’ (INF) panels in the Vis, ORCADES, EGCUT and INTERVAL 
cohorts. A total of 266 proteins were used in the final analyses. Lifelines DEEP used 
only the CVD-III panel. PIVUS has measurements from the retired ‘Cardiovascular I’ 
(CVD-I) panel, which includes a mix of proteins measured on the INF, CVD-II and 
CVD-III panels. A full list of proteins, abbreviations and names used in analyses is 
given in Supplementary Table 1. 
2.1.2.1.2 Lipidomics  
Lipids were measured in Vis and ORCADES by electrospray ionisation tandem mass 
spectrometry (ESI-MSMS) as described in Liebisch et al. 1999128 and 2004129. Lipids 
were identified by class, chain length and number of double bonds. 
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2.2 Methods 
 Data processing 
2.2.1.1 Non-omic phenotypes 
eGFR was calculated from standardised serum creatinine measured in mg/dL using 
the 4-variable MDRD study equation130:  
eGFR = 186 × creatinine . × age . × 0.742 (if female) × 1.212 (if AA) 
Where AA refers to individuals of African American ancestry (my analyses are 
exclusively European ancestry, but the term is included here for completeness). 
Individuals with eGFR < 60 mL/min/1.73m2 were classified as Chronic Kidney Disease 
(CKD) cases, as per the classification used in the CKDGen Round IV meta-analyses 
(see Section 4.2.1.2).  
It should be noted that the MDRD equation is no longer the preferred method for 
calculating eGFR, having been superseded by the CKD-EPI equation131. I was 
unaware of this at the time of analysis, and it is a potential limitation of this work. 
However, as my own analysis only uses rank-transformed eGFR, I do not believe that 
using it would greatly change the results beyond changing the classification of a few 
CKD cases.  
BMI was calculated using height in metres and weight in kilogrammes using the 
standard formula: 




2.2.1.2 Olink phenotypes 
Protein measurements were provided by Olink Bioscience as Normalised Protein 
Expression (NPX) values, an arbitrary unit on a log2 scale. NPX values are calculated 
using the inverse of the Ct values from the qPCR stage of the Olink process, meaning 
a high NPX corresponds to a high protein concentration in the sample. Where a 
measurement was below the Lower Limit of Detection value (LLOD) provided by 
Olink, that measurement was set to the LLOD value for that protein. Table 1 lists all 
proteins with more than 5% of their measurements set to LLOD, based on the original 
full set of 1,920 participants in the discovery cohort before filtering for complete 
phenotype data. No proteins were filtered on LLOD percentage, as this may have 
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differed between replication cohorts and may have resulted in incomplete overlap of 
phenotypes. 
The measurements for BDNF and CCL22 were removed from the dataset as the 
assays were withdrawn by Olink due to quality issues. 
A batch effect was identified in the Olink measurements – linear regression identified 
a significant effect of sample plate ID on many Olink proteins. To correct for this, plate 
ID was included as a covariate when adjusting phenotypes (see Section 2.2.1.4). 
Table 1 - Olink proteins with more than 5% of samples set to LLOD before filtering. 


































2.2.1.3 Lipidomic phenotypes 
Measurements for Vis showed clear signs of batch effects (examples are shown in 
Figure 6), but no information was available on technical covariates to correct for this.  
 
Figure 6 - An example of the technical bias visible in the lipidomics measurements. 
Colour corresponds to inferred batch number with a batch size of 61. 
  
As an interim solution, it was postulated the technical bias was connected to sample 
batch, possibly corresponding to analysis day. An algorithm was devised to establish 
how many samples to assign to each batch. This was based on the theory that each 
batch would have a distribution of data points around a mean, and that the ‘correct’ 
batch would minimise the standard deviation, as it would contain only points drawn 
from a single distribution. 
1. Assign individuals to batches of equal size batch based on ID order 
2. Adjust all phenotypes to range between 0 and 1 
3. For each phenotype, calculate the standard deviation of measurements within 
that batch. 
4. Take the mean of the standard deviations across all batches. 
5. Iterate this across batch sizes from 50 – 100 
6. For each batch size, sum the mean standard deviations across all phenotypes.  
7. This assigns each batch size a score that represents how well it minimises 
standard errors across all phenotypes. The batch size with the lowest score is 
the best performing. 
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8. For each phenotype, rank the batch sizes based on their mean batch-wise 
standard deviation. Batch sizes which accurately capture the batch effect seen 
in the data have low ranks. 
9. The best batch size is the one with the lowest mean rank across all 
phenotypes. 
Figure 7A shows the mean batch-wise SD across all phenotypes and batch sizes. 
The optimum batch size was 61, which can be seen more easily in  Figure 7B, where 
it clearly has the lowest mean rank of any batch size. Consequently, individuals were 
assigned to batches of 61, and this was included in covariate adjustment, as 
described below.  
Figure 7B also compares the batch effect in Vis to that in ORCADES. In Vis, several 
batch sizes minimise the mean per-batch standard deviation across many 
phenotypes: 61, 65 and 75. In ORCADES, this is not seen – most batches perform 
roughly equally, showing that the cross-phenotype batch effect seen in Vis is not 
present in this cohort.  
Unfortunately, when uric acid was regressed on batch number, a significant 
association was identified for several lipid species. A similar effect was seen when 
regressing age on batch number, and it was noted that the distribution between sexes 
was highly uneven. Taken together, these likely explain the effect on serum urate 
levels.  
Given this association between supposed technical batch and phenotypes which were 
not connected to the lipidomic measurements, I decided to drop the attempt to correct 
the data, to avoid removing genuine biology, or worse, introducing bias. Lacking a 
reliable statistical method to separate unreliable-looking phenotypes from reliable 
ones – judgement by eye being too subjective – I have decided to retain all 
phenotypes in the models. It is my belief that the inclusion of the cleaner ORCADES 
data in the analysis will limit the ability of these distortions to drive false positives.  
This is an imperfect solution to the problem of bias in the data, but given the lack of 






Figure 7 – Comparison of mean standard errors across batch sizes. 
A. Mean standard error across all batch sizes. 
Each line is a single lipid phenotype in CROATIA-Vis. X-axis is batch size, y-axis is the 
mean standard deviation across all batches for a given batch size. The highly visible 
troughs in the graph are batch sizes that minimise the mean standard error for many 
phenotypes. 
B. Mean rank across all phenotypes of each batch size 
Lower mean ranks mean the batch size minimises mean SD across more phenotypes. 
The top panel shows the results for ORCADES, the lower panel for Vis. 
 
2.2.1.4 Adjustment for covariates 
Data from the CROATIA-Vis and ORCADES cohorts were merged into a single 
dataset henceforth referred to as the discovery dataset.  
All raw measurements were rank transformed to normality using the ‘rntransform’ 
function from the R package GenABEL132. Linear models were run using the ‘lm’ 
function in R (package stats, included in base R), regressing normalised phenotypes 
on age, sex and cohort to remove the effect of these covariates. Olink phenotypes 
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were additionally regressed on sample plate ID to remove batch effects from the 
original assay. 
The residuals from these models were used as input phenotypes for the correlation, 
partial correlation and lasso regression analyses; all further reference to ‘phenotype’ 
in this chapter refers to these residuals unless otherwise specified. 
2.2.1.5 Adjustment for kinship 
The discovery cohort was initially adjusted for relatedness by fitting a random genetic 
effect in addition to the covariates above, using the ‘polygenic’ function in the 
GenABEL package instead of ‘lm’. However, this was not performed in the replication 
cohorts, as these were composed of unrelated individuals, and while the adjustment 
led to negligible differences in the partial correlation results, it completely removed 
the known association with eGFR in lasso regression, which was identified in all other 
cohorts. Because of this, I decided to drop the kinship adjustment, to ensure 
consistency between discovery and replication, and to retain this known biologically 
relevant association in the models. 
 Correlations 
Spearman’s rank correlations were calculated between serum urate and all 
phenotypes using the ‘rcorr’ function from the Hmisc R package133, which additionally 
returns p-values. Bonferroni correction was used to correct for multiple testing (269 
tests for Olink), resulting in a significance threshold of p < 1.86 x 10-4. Correlations 
were calculated for the whole dataset, for both sexes separately and sex-combined 
with CKD cases excluded. Differences in effect between sexes were tested using 
Fisher’s r-to-z transformation. 
 Partial correlations 
Partial correlations were calculated using the ppcor package134 for R, which also 
returns p-values for each partial correlation. Partial correlations were calculated using 
the Spearman’s rank method between serum urate and all phenotypes in the analysis. 
False Discovery Rate (FDR) correction (implemented in the ‘p.adjust’ function in R) 
was used to adjust p-values for multiple testing (269 tests for Olink proteomics data, 
191 for lipidomics) A significance threshold of Q < 0.05 was used to identify significant 
partial correlations. 
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2.2.3.1 Partial correlation network 
To provide context to the correlated phenotypes, partial correlations were also 
calculated for each phenotype that was significantly associated with uric acid. These 
primary and secondary correlations were then converted to a network, where each 
vertex is a phenotype and each edge represents a significant partial correlation 
between two phenotypes. Any phenotype with a partial correlation p-value < 0.05 
(significant before multiple testing correction) with serum urate was highlighted in the 
network, as these are most likely to provide relevant context to the relationship. 
Networks were created using the igraph R package135 and plotted using Cytoscape 
v3.5.1136.  All sets of phenotypes associated with a given urate-associated phenotype 
were also tested for gene ontology term enrichment against the set of all Olink 
proteins using the GOrilla137,138 web tool.  
2.2.3.2 Sensitivity analysis 
Before replication data was available, a sensitivity analysis was performed to provide 
a measure of confidence that the partial correlations detected were not purely 
artefacts of the data. Partial correlations were recalculated 1,000 times, randomly 
removing 20% of the dataset each time, and each phenotype scored for the number 
of times it was identified as a significant partial correlation with serum urate.  
To further test the robustness of the identified correlations, random sampling with 
replacement was used to create a bootstrapped dataset of equal size to the full 
discovery. This was then used to calculate partial correlations. This was again 
repeated 1,000 times, with phenotypes scored for the number of times they were 
included as a significant partial correlation. 
 Lasso regression 
As an alternative method for identifying phenotypes with a significant association with 
uric acid levels, lasso regression models were run using uric acid as the response 
variable and other phenotypes as predictors. Each regression model assigns all 
phenotypes a coefficient, the majority of which will be zero. Regressions were run 
using the glmnet R package139. Regressions were run 1,000 times, to account for the 
stochasticity inherent in the algorithm, and the mean non-zero coefficient per 
phenotype recorded, along with the number of times it was included in the final model. 
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 Replication 
I identified potential collaborators for replication through the SCALLOP consortium, a 
group set up to conduct meta-analyses of GWAS for Olink proteomic measurements. 
Two studies were identified that had serum urate measurements as well as the CVD-
II, CVD-III and INF panels – the EGCUT cohort in Estonia and the INTERVAL study 
in Cambridge. Non-omic phenotypes included in the analysis were reduced to match 
those available in the replication cohorts as described in section 2.2.1.1. Additionally, 
the Lifelines-DEEP cohort analysed correlations with the CVD-III panel only. Sex-
separate partial correlations and lasso regression were not analysed in EGCUT due 
to insufficient sample size. Additionally, exclusion of CKD cases from INTERVAL was 
not possible, due to the arbitrary units of creatinine measurement making the 
calculated eGFR values incomparable to the normal classification scheme. 
I provided replication analysts with an R script to align and automate the processing 
and analysis of their data.  
2.2.5.1 Checking INTERVAL results 
In the INTERVAL cohort, serum urate and serum creatinine were measured on the 
metabolon platform, rather than using traditional assays. Because of this, I performed 
additional tests to confirm the results in this cohort.  
Metabolon data is also available in the ORCADES cohort, allowing comparison with 
the biochemistry measures. Serum urate measured with metabolon had a Spearman 
correlation of 0.874 with clinical biochemistry laboratory-measured serum urate, while 
creatinine had a corresponding correlation of 0.793. Considering that the original 
measurements were made shortly after collection, but the Metabolon analysis was 
performed 6-12 years later on samples that had been stored at -80°C, I consider this 
correlation to be high.  
Because eGFR is sensitive to creatinine units, and has a non-linear relationship with 
creatinine values, ‘eGFR’ calculated in from Metabolon creatinine in ORCADES did 
not correlate with true eGFR. To test the suitability of raw creatinine as a replacement, 
the above analyses were rerun in both the discovery cohort and INTERVAL using 
creatinine in place of eGFR, and in both cases the results were identical to four 
decimal places. This means that although there is not a 1:1 mapping between eGFR 
and metabolon-eGFR, the results of the analysis do not appear to be affected by this. 
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 Serum urate GWAS lookups 
A protein quantitative trait locus (pQTL) is a region of the genome containing variants 
which are associated with levels of a protein. If a pQTL is also significantly associated 
with a trait of interest, it can be indicative that the protein in question is linked to that 
trait. In the case of a cis-pQTL (a pQTL in the region of the gene encoding the protein), 
it supports a causal role for the protein. 
2.2.6.1 Vis and ORCADES meta-analysis 
To identify pQTLs for the Olink proteins in our data, I made use of meta-analyses of 
Olink proteins in Vis and ORCADES (individual GWAS run performed by Andrew 
Bretherick, University of Edinburgh, meta-analysis by Anne Richmond and Thibaud 
Boutin, in our group). I defined pQTLs in this data using the genome-wide significance 
threshold of 5x10-8, and additionally using the commonly accepted threshold for 
suggestive significance (P < 1x10-5) as the power of the GWAS was limited by sample 
size.  
For this analysis, I defined a locus as a region of 1Mb centred around the index SNP, 
the SNP with the lowest suggestively significant P-value in a chromosomal region. 
Index SNPs were then looked up in the CKDGen serum urate transethnic meta-
analysis (see 4.2.2) to check for a significant association with serum urate levels. 
SNPs were additionally looked up in the PhenoScanner database140, which includes 
data from the NHGRI-EBI GWAS catalogue141, NHLBI GRASP142 and NCBI dbGaP143 
catalogues in addition to 137 GWAS datasets generated by the developers. This 
reports any published associations between a given SNP and all phenotypes in the 
database – the GWAS, pQTL and eQTL databases were queried, using a significance 
threshold of P < 5x10-8.  
2.2.6.2 OLINK-IMPROVE CVD-I GWAS lookup 
Under the OLINK-IMPROVE project, Folkersen et al. have published summary 
statistics from meta-analyses of 3,394 individuals for all proteins on the Olink 
Cardiovascular Disease 1 (CVD-I) platform115. The larger sample size in this meta-
analysis compared to ours confers greater power to detect associated SNPs, but due 
to the use of a different Olink panel, only four of the proteins identified as correlated 
with serum urate have association signals in this data: FGF-23, CCL3, FABP4 and 
CHI3L1.  
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Initially, the index SNPs identified for these proteins were also looked up as above, 
except that the standard GWAS threshold for significance (5 x 10-8) was used to select 
SNPs. However, for FABP4 and CCL3 an excessively large number of loci (of the 
order of 50 and 100 respectively) were identified using the provided summary 
statistics, while the accompanying publication lists only two pQTLs for CCL3 and none 
for FABP4. As this is far in excess of the number of significant loci I would expect for 
an endophenotype GWAS with a sample of this size I have sought clarification from 
the authors of the study on whether this is an error in the database, or whether 
additional filtering is required. At time of writing, this has not been resolved. 
For the current analysis, the pQTL index SNPs reported in the paper for CCL3 and 
CHI3L1 have been used for lookup, as well as two SNPs for FGF-23 which were 
present in the summary statistics, but not explicitly referenced in the paper. 
2.2.6.3 SOMAscan lookup 
The INTERVAL study has published pQTLs for 3,622 plasma proteins in 3,301 healthy 
participants, measured on the SomaLogic SOMAscan platform  
(www.somalogic.com). Rather than using antibodies, the technology uses DNA-
aptamers to bind proteins and measure their abundance. This allows it to cover a 
wider range of proteins than Olink, but it ultimately remains a targeted approach. Full 
GWAS results have been made available online, including results for FGF-23, CCL3, 
CHI3L1, FABP4, IGFBP-2, LDL-receptor and MMP2. No results were available for 
Ep-CAM, FGF-21, PLC or PON3.  
Index SNPs were identified using the 5 x 10-8 threshold for genome-wide significance 
and 1Mb window, as in Section 2.2.6.1, and the SNPs looked up in the serum urate 
meta-analysis results. 
2.2.6.4 Colocalisation analysis 
A SNP associated with multiple traits can be an indication of a mechanistic link 
between those two traits. An apparent shared signal can arise from linkage 
disequilibrium (LD) between two separate causal signals or through genuine 
pleiotropy – a causal signal having an effect on two otherwise independent traits. 
Distinguishing between these two scenarios is useful when interpreting associations, 
as a shared causal SNP is much stronger evidence for a shared aetiology.  
Colocalisation analysis is one way to compare signals from two traits. This is a 
Bayesian statistical method using two sets of GWAS summary statistics to calculate 
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the posterior probabilities of five scenarios: H0, the null hypothesis, is that there is no 
signal in a region for either trait. H1 and H2 are the hypothesis that there is one causal 
SNP associated with either trait one or trait two only. H3 is the hypothesis that there 
are two separate causal SNPs, one associated with each trait. The final hypothesis, 
H4, is the scenario representing true colocalisation – one causal SNP affecting both 
traits.  
Colocalisation analyses were performed using the ‘coloc.fast’ function in the gtx R 
package144, which implements a modified version of Giambartolomei’s colocalisation 
method145. This method does not require individual-level genotypes, taking only 
GWAS summary statistics as input. It fits a model assuming that of all SNPs in the 
dataset, a maximum of one can be truly causal for each trait. The method integrates 
across all possible combinations of causal SNPs and calculates a posterior probability 
for the data observed under each hypothesis. The prior probability of a SNP being 
associated with a trait was set at the default for the function: 10 -4 for each SNP being 
causal for one trait, and 10-5 for being causal for both. A posterior probability of ≥0.8 
was taken as the threshold for accepting a hypothesis. The window was defined as 
the region of 1Mb centred around the index SNP. All SNPs within this window present 
in both sets of summary statistics were included in the calculation. 
It must be caveated that the method assumes the two populations are unrelated and 
drawn from the same ethnic group – in this case, the Olink meta-analysis populations, 
Vis and ORCADES, have also contributed to the serum urate meta-analysis. 
However, as these two studies contribute fewer than 3,000 individuals to a study 
containing over 450,000 samples, the impact of this overlap should be minimised. 
Furthermore, the transethnic serum urate GWAS results were used, as I did not have 
access to the European-ancestry summary statistics at the time the colocalisation 
analysis was run. 
 GENOSCORES 
The GENOSCORES software package146 uses GWAS summary statistics and 
population genotype data to calculate genetic risk scores on a per-locus basis for a 
trait. Though not the primary aim of the software, it can be used to obtain a measure 
of a regional genetic correlation, achieved by calculating multiple scores for a single 
analysis population and obtaining the correlation between them.  
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For all SNPs in a locus, the genotypes of the analysis population are weighted by the 
GWAS effects and summed to obtain a score. For each pair of traits, a correlation can 
then be calculated for all regions on the same chromosome. 
This differs from more traditional genetic risk scores in that it focuses on all SNPs in 
a single region, rather than a single index SNP from all regions across the genome, 
and from LD-score regression based genetic correlations in that it considers each 
region separately. In this way, it attempts to capture the modularity of complex traits. 
The summary statistics from the Olink meta-analysis described in Section 2.2.6 were 
uploaded to the GENOSCORES database. These were then used by Athina 
Spiliopoulou in conjunction with the summary statistics for the Köttgen et al. 2012 
GWAS of uric acid74 and the genotypes from to calculate genetic score correlations 
between serum urate and Olink proteins for the 503 individuals in the 1000 Genomes 
Project European subset147. Scores for Olink were compiled using all SNPs with a P-
value of less than 1 x 10-5, with separate scores for cis and trans-eQTLs. I used these 
pre-calculated scores to provide additional context to the serum urate-Olink 
associations reported in this chapter.  
 Genetic correlation with LD-score regression 
Genetic correlation reflects the amount of covariance between two traits due to 
genetics. Essentially it is a measure of the extent to which two phenotypes are 
explained by common genetics – the phenomenon known as pleiotropy. The 
existence of a genetic correlation between two phenotypes can be evidence of a 
mechanistic link between them, and so it is a valuable tool in genetic analysis. Genetic 
correlation is expected to be strong if there is a causal relationship between an 
intermediate trait and an outcome of interest.  
It has an advantage over Mendelian randomisation (MR) in that it does not use only 
significant SNPs – this makes it more useful in cases where a significant fraction of 
the heritability of the trait cannot be explained by multiple significant SNPs. The 
disadvantage is that genetic correlation is a necessary but not sufficient condition for 
a causal relationship. A genetic correlation between two traits is not definitive proof of 
causality – any apparent correlation can be driven by an unmeasured trait that is the 
true mediator of the genetic effects on one or both of the measured traits. However, 
the problem of confounding is considerably less than for straight phenotype-
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phenotype correlations, as any unmeasured trait must be genetic rather than 
environmental in origin.  
Cross trait LD-score regression is a method developed by Bulik-Sullivan et al.148 that 
uses summary-level GWAS results to estimate genetic correlation between two traits. 
It can be applied to summary-level data if a reference population of similar ancestry 
is available to determine LD pattern, meaning access to individual level genotypes is 
not required.  
The method is an extension of single-trait LD-score regression149, where GWAS χ2 
statistics are regressed against LD-score, a measure of the extent to which a SNP is 
in LD with its neighbours, to estimate SNP heritability. The method can be extended 
by substituting the product of the Z scores for two traits for each SNP in place for χ2. 
In this scenario, the regression coefficient is proportional to the genetic correlation 
coefficient rg.  
Cross-trait LD-score regression was performed using both the LDSC software 
package148,149 and the LD-Hub website150, an online database and analysis tool that 
aggregates published GWAS summary statistics for the purpose of calculating genetic 
correlations.  
2.3 Olink Results 
 Cohort summary 
Table 2 summarises cohort size, sex and CKD status. Table 3 contains phenotype 
summary statistics broken down by cohort, prior to any adjustment or transformation. 
Table 2 – Sample sizes and phenotype summary statistics for serum urate-Olink 
correlation analyses.  
Cohort n % male % CKD 
CROATIA-Vis 698 41.69% 8.02% 
ORCADES 881 45.29% 2.38% 
EGCUT 475 52.21% 3.16% 
INTERVAL 687 59.53% - 
Lifelines DEEP 1,052 42.30% 0.48% 
PIVUS 827 50.42% 3.51% 
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Table 3 – Non-Olink phenotype summary statistics. 
Phenotype Cohort Mean SD Median Min. Max. Notes 
Age 
Vis 56.62 15.22 57.00 19.00 91.00  
ORCADES 52.39 15.12 52.65 17.12 91.47  
EGCUT 53.87 14.10 55.00 23.00 87.00  
INTERVAL 59.54 6.26 58.80 48.90 76.20  
Lifelines 
DEEP 
45.23 13.47 45.54 18.00 81.42  
PIVUS 70.15 0.15 70.14 69.80 70.71 
All cohort 
participants 





Vis 99.18 164.74 30.56 0.00 1500.00  
ORCADES 85.51 109.14 42.00 0.00 1176.00  
EGCUT 47.65 117.01 12.55 0.00 1159.20  
INTERVAL 71.34 58.24 48.00 1.60 208.00  
Lifelines 
DEEP 
76.77 117.92 45.01 0.00 1300.60  
PIVUS 46.83 53.87 30.30 0.00 428.80  
BMI 
(kg/m2) 
Vis 27.41 4.21 27.31 17.08 43.60  
ORCADES 27.64 4.88 26.91 16.97 51.11  
EGCUT 28.54 5.66 27.76 17.30 52.77  
INTERVAL 26.58 4.22 26.06 16.26 43.99  
Lifelines 
DEEP 
25.18 4.06 24.58 16.67 44.92  
PIVUS 27.02 4.25 26.57 16.56 49.77  
eGFR 
Vis 87.99 22.64 86.82 9.27 214.58  
ORCADES 100.08 24.00 96.71 26.98 243.57  
EGCUT 102.91 25.11 101.25 40.29 209.15  








112.05 23.35 109.93 41.32 199.40  
PIVUS 92.50 19.18 90.75 24.88 188.28  
Serum uric 
acid (mg/dL) 
Vis 5.19 1.59 5.07 1.24 11.57  
ORCADES 4.97 1.16 4.94 1.18 9.15  
EGCUT 5.38 1.49 5.23 1.16 10.66  












PIVUS 5.73 1.37 5.59 2.26 10.81  
 Correlations 
Correlations between all phenotypes are shown in Figure 8. Most correlations are 
positive, and there are clear inter-panel correlations, particularly on CVD-III. Because 
Olink phenotypes are biomarkers selected for their connection to cardiovascular or 
inflammatory diseases or biological processes, some correlation is to be expected. 
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Correcting for the panel effect would not be straightforward, and would risk removing 
actual biological effects, so these have not been adjusted for. 
Forty-nine phenotypes had significant correlations with serum urate in at least one 
discovery sub-analysis after Bonferroni multiple testing correction (p < 0.000173 = 
0.05/289) (Figure 9). Of these, 43 replicated in at least one replication sub-analysis 
(p < 0.00102 = 0.05/49). Interestingly, CVD-II and CVD-III have many more correlated 
phenotypes than INF, despite the panels all being of similar size. 
In the whole cohort discovery, the strongest correlation identified was with BMI  
(r 0.314, SE 0.024, p < 2x10-16); the strongest Olink correlation was with Leptin (LEP)  
(r 0.275, SE 0.024, p < 2x10-16 ), an anti-obesity hormone known to correlate positively 
with BMI in healthy individuals. The strongest negative correlation was with IGFBP-2  
(r -0.215, SE 0.025, p < 2x10-16). Figure 9 shows a heatmap of correlations for all 
phenotypes that were significant in at least one discovery sub-analysis.  
Excluding CKD cases identified additional significant correlations with matrix 
metalloproteinase 2 (MMP-2), which replicated in Lifelines DEEP and IL-18, which did 
not replicate.  
Tests for significant differences in correlation coefficient between sexes identified four 
Olink proteins after multiple testing correction (p < 0.000173 = 0.05/289). These are 
listed in Table 4. 
Table 4 – Phenotypes with significantly different correlations with SUA between sexes 
(nfemale = 1083, nmale = 809) 
Phenotype rfemale rmale Pdiff 
CVD2_113_IL.6 0.254 0.077 9.53E-05 
CVD2_120_TRAIL.R2 0.276 0.096 6.40E-05 
CVD3_114_CSTB 0.297 0.124 9.84E-05 







Figure 8 - Heatmap of correlation coefficients between all phenotypes 
Spearman correlations were calculated on residuals after adjusting rank-normalised 
phenotypes for age, sex and Olink plate ID. “Non-Olink” category comprises BMI, eGFR, 
and alcohol consumption (see Supplementary Table 1 for complete list of phenotypes 






Figure 9 - Heatmap of Spearman's rank correlations between serum urate and Olink 
phenotypes.  
Cell colour corresponds to direction of correlation and intensity to magnitude. ‘*’ denotes a 
significant P-value. In the case of discovery (Vis.ORCADES), this is P<0.05/289. For 
replication analyses this is P < 0.05/49. X-axis is grouped by sub-analysis and then by 
cohort. Y axis is sorted by increasing correlation coefficient in the complete discovery 
analysis. Only phenotypes with a significant correlation with serum urate in the discovery 
cohort in at least one analysis that replicates in at least one discovery cohort are shown. 
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 Partial correlations 
In the full discovery cohort, significant partial correlations (Q < 0.05) with serum urate 
were identified with three Olink proteins: Fibroblast Growth Factor 23 (FGF-23), 
Epithelial Cell Adhesion Molecule (Ep-CAM) and Insulin-Like Growth Factor Binding 
Protein 2 (IGFBP-2). Excluding CKD cases identified only FGF-23 and Ep-CAM as 
significant, though the differences in correlation coefficients are small, and the loss of 
IGFBP-2 may be simply due to smaller sample size.  
Directions of correlations were consistent in males and females for all three 
phenotypes, although none were identified as significant, likely due to small sample 
size. In FGF-23, partial correlation coefficients were smaller in sex-stratified results, 
which may indicate a bias due to sex. 
Table 5 – Partial correlations in the discovery sample. 
Includes all phenotypes which are significant after multiple testing correction in any sub-





Std. Err. P-value Q-value 
FGF-23 
All 0.109 0.028 7.81 x 10-5 0.01 
CKD-excluded 0.114 0.029 6.35 x 10-5 0.01 
Female 0.077 0.040 0.0556 0.50 
Male 0.088 0.049 0.0725 0.88 
Ep-CAM 
All 0.100 0.028 2.69 x 10-4 0.02 
CKD-excluded 0.101 0.029 3.83 x 10-4 0.03 
Female 0.111 0.040 5.45 x 10-4 0.25 
Male 0.085 0.049 0.0827 0.88 
IGFBP-2 
All -0.104 0.028 1.53 x 10-4 0.01 
CKD-excluded -0.094 0.029 9.37 x 10-4 0.06 
Female -0.105 0.040 8.85 x 10-3 0.30 
Male -0.082 0.049 0.0945 0.88 
 
2.3.3.1 Partial correlation network  
Partial correlations were calculated for the three phenotypes identified in the 
discovery analyses, and the results plotted as a correlation network (Figure 10A). 
IGFBP-2 was significantly partially correlated with a much larger number of 
phenotypes than either FGF-23 or Ep-CAM. Removing CKD cases from the sample 
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removed IGFBP-2, as above, and additional partial correlations were detected 
between FGF-23 and Selectin-E (SELE), and Ep-CAM and Galectin-4 (Gal-4) (Figure 
10B).  
Several of the phenotypes in the network had significant partial correlations with 
serum urate before FDR-correction (p < 0.05). These are highlighted in the network 













Figure 10 - Partial correlation networks  
A: the whole discovery cohort and B: with CKD cases excluded. Vertices are phenotypes, 
colour denotes Olink panel. Vertices with black borders have significant partial correlations 
with serum urate before multiple testing correction (P < 0.05). Edges represent a significant 
partial correlation between two phenotypes (Q < 0.05), (note that partial correlations were 
only calculated for serum urate, FGF-23, Ep-CAM and IGFBP-2). Edge thickness is 
proportional to partial correlation coefficient magnitude. Red edges denote positive 
correlations, blue edges denote negative. (Due to the large number of phenotypes partially 
correlated with IGFBP-2, nodes are shown only for phenotypes which also had a partial 
correlation P < 0.05 with serum urate). 
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2.3.3.1.1 Gene Ontology enrichment 
No enrichment for any gene ontology category was detected for the set of all proteins 
included in the network, the set of proteins partially correlated with FGF-23 or the set 
correlated with EpCAM. The set correlated with IGFBP-2, which is by far the largest 
set, showed significant enrichment for the ‘negative regulation of endopeptidase 
activity’ GO term (Enrichment: 4.34, P = 8.24 x 10-4) but this was not significant after 
FDR-correction for multiple testing. 
2.3.3.2 Sensitivity analysis 
Only the three phenotypes detected in the full analysis were identified in more than 
10% of the iterations (Figure 11A). The only other phenotype to appear in more than 
5% of the iterations was ST2 (ST2 Protein). 
Many more phenotypes appeared in the analysis of the bootstrapped sample (Figure 
11B), as would be expected from a sample that is likely to contain duplicated 
individuals. The most commonly identified phenotypes are FGF-23, Ep-CAM and 
IGFBP-2, all appearing in nearly 800 iterations, with ST2 appearing in over 500 
iterations. 
In both analyses there is a clear separation between the number of times FGF-23, 
Ep-CAM and IGFBP-2 were identified and all other phenotypes, although this gap is 
narrower in the bootstrapped sample. 
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Figure 11 – Partial correlation sensitivity analysis results for whole discovery.  
Plots show the number of times a phenotype was identified as a significant partial correlation 
in 1,000 iterations using either A: a random 80% of the full discovery sample (only 
phenotypes appearing 5 or more times are shown), or B: a randomly generated dataset of 
equal size to the full discovery, generated using random sampling with replacement (only 




The results of the partial correlation replication are shown in Figure 12. Partial 
correlation results from Lifelines DEEP and PIVUS are also shown, although only for 
comparative purposes, as the correlations were only adjusted for proteins on CVD-III 
and CVD-I respectively. 
None of the three significant partial correlations identified in the full discovery were 
significantly partially correlated with serum urate after multiple testing correction, but 
this is likely at least partly due to reduced sample size in replication cohorts. However, 
FGF-23 is significant before multiple testing correction in PIVUS and matches in 
direction and approximate magnitude in both EGCUT and INTERVAL (as the protein 
was measured on CVD-II no data from LIFELINES Deep is available).  Ep-CAM 
matches in direction in INTERVAL only. IGFBP-2 has a consistent negative 
correlation in EGCUT, Lifelines DEEP and PIVUS, although none are significantly 
different from zero. 
Additionally, eGFR was identified as a partial correlation in both INTERVAL and 
PIVUS. Though serum creatinine and serum urate were measured on Metabolon in 
INTERVAL, this association seems reliable as it replicates in PIVUS, and is significant 




Figure 12 – Partial correlation replication.  
Partial correlation coefficients for all phenotypes significant in the full discovery analysis for 
any cohort. Thick borders indicate significance after FDR-correction for multiple testing in 
that cohort. Error bars are 95% confidence intervals. Lifelines DEEP only included Olink 
proteins from the CVD-III panel, and PIVUS only overlapping proteins from the CVD-I panel. 
As such these should be compared to the other cohorts with caution. 
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 Lasso regression 
A phenotype was considered to be identified as consistently predictive of serum urate 
levels by the lasso regression approach if it had a non-zero coefficient in > 500 
iterations in at least two cohorts. The results are shown in Figure 13, which compares 
the mean regression coefficient over all 1000 runs for all urate-predictive phenotypes. 
In all cases, the sign of the coefficient is consistent between cohorts (where it is non-
zero). Full numerical data is shown in  
Supplementary Table 2. 
Of the phenotypes identified in the partial correlation analysis, FGF-23, IGFBP-2 and 
eGFR are identified as urate-predictive, with IGFBP-2 assigned the largest absolute 
coefficient of any phenotype (-0.137). eGFR is included in all models for all cohorts, 
while IGFBP-2 is present in all models for the discovery and LIFELINES Deep, and 
85% of models with a smaller mean coefficient in EGCUT. FGF-23 is only included in 
models for the discovery and PIVUS cohorts, but in both cases, it is retained in all 
1000 iterations. For all three phenotypes, the sign of the coefficients matching the 
sign of the partial correlation coefficient.  
The only phenotype other than eGFR identified in all cohorts that it was included in is 
Fatty Acid Binding Protein 4 (FABP4), which was positively associated with serum 
urate (0.101 in discovery). BMI and PON3 were identified in all models for three 
cohorts, and IGFBP-2 and FGF-21 in two with a third identifying them a large 
percentage of the models. 
Figure 14 shows all phenotypes included in more than 95% of regression models in 
any cohort. As observed in the correlation analysis (Section 2.3.2) CVD-II and CVD-
III again have many more urate-predictive phenotypes than INF.  
48 phenotypes were identified in the discovery cohort, 10 in EGCUT and PIVUS, 7 in 
Lifelines DEEP and only 3 in INTERVAL. This may partly be a consequence of sample 
size, and, in the case of PIVUS and Lifelines DEEP, the reduced set of phenotypes 
included in the regression. However, in INTERVAL, serum urate and creatinine were 
measured on the same Metabolon platform, which may mean that uncorrected 
technical correlations are driving the strong association between serum urate and 




Figure 13 - Mean lasso regression coefficients. 
Plotted for all phenotypes retained in the regression model in > 950 iterations in at least two 
cohorts. Error bars are ± 2 standard deviations (in some cases this is a very narrow range 
and the error bars are masked by the point). The numbers on the right hand side of each 
plot are the proportion of times out of 1,000 that the phenotype had a non-zero coefficient 




Figure 14 - Mean lasso coefficients for phenotypes included in >95% of models, per 
cohort.  
Error bars are ±1 standard deviation. 
 
 Serum urate GWAS lookups 
All proteins with significant partial correlations with serum urate or identified as urate-
predictive in the lasso analysis in at least two cohorts were checked for shared genetic 
associations with serum urate. This set included FGF-23, Ep-CAM, IGFBP-2, FGF-
21, CCL3, LDL-receptor, PLC, FABP4, REN, MMP-2, CHI3L1 and PON3. Table 6 
summarises which proteins were present in each lookup dataset and whether any 
pQTLs were identified. 
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Table 6 – pQTLs identified in each dataset 
Protein Vis & ORCADES OLINK-IMPROVE INTERVAL 
CCL3 
Cis &  
suggestive trans 
Cis & trans Cis 
CHI3L1 Cis Cis & trans Cis 
EpCAM Trans N/A N/A 





FGF23 Trans None None 
IGFBP-2 Trans N/A None 
LDL-receptor None N/A None 
MMP2 Trans N/A Cis 
PLC None N/A N/A 
PON3 Cis & trans N/A N/A 
REN None Trans Cis 
 
2.3.5.1 Vis & ORCADES 
562 significant SNPs were identified and assigned to 10 loci across 9 proteins (Figure 
15). The index SNPs are detailed in Table 7. No pQTLs were identified for PLC, LDL-
receptor or REN. Cis-pQTLS were identified for CHI3L1, CCL3 and PON3; the 
remainder of signals were in trans to the gene encoding the protein, including one 
additional signal for PON3. None of the index SNPs were associated with serum urate 
using a Bonferroni-corrected p-value threshold of 0.05/10. One trans pQTL for 
EpCAM, at the FUT2 loci, associated with serum urate at a nominal level of 
significance. 
When the p-value threshold was lowered to include suggestively-significant SNPs, a 
total of 1,873 were identified with p-values < 1x10 -5 across all 11 proteins. These were 
assigned to 467 loci distributed across the genome. Of these, three had significant 
associations with serum urate after Bonferroni correction (P < 0.05 / 467). These 
SNPs are listed in the upper panel of Table 8. All three SNPs are in trans of the 
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associated protein. Two of these are associated with FGF-21, the third with CCL3, 
although the locus in the latter consists of a single rare variant. 
The rare variant rs547836333, associated with CCL3, is imputed and present only in 
ORCADES. In the CCL3 meta-analysis, one ORCADES individual is heterozygous 
for the effect allele and 17 others have an imputed dosage between 0.15 and 0.65 
copies. In the CKDGen meta-analysis, the SNP is present only in the Million Veteran 
Program (MVP) European subcohort – the variant was removed from the ORCADES 
results prior to meta-analysis due to the MAC > 10 filter. In ORCADES, the SNP is 
weakly negatively associated with associated with serum urate (-0.50, p = 0.049), but 
in the MVP it is strongly positively associated (5.56, p = 8.58x10-153). Due to the very 
low allele frequencies and discrepancy of effect on serum urate, this genetic 
association can be assumed to be a false positive. 
2.3.5.1.1 FGF-21 colocalisation 
As the SNP rs780094 in the GCKR gene was significantly associated with serum 
urate and borderline significant with FGF-21 levels, a colocalisation analysis was 
performed for the 1Mb region centred on this SNP. These results are detailed in 
Table 9.  
The strongest support was obtained for H2, that the region contains a causal SNP 
for serum urate levels only (posterior probability = 0.83). However, the colocalisation 
test is sensitive to the sample size of the studies, and the trans-association for FGF-
21 at the GKCR locus is only suggestively significant. The posterior probability of 
two separate causal SNPs was calculated as 0.16, and of one shared causal SNP at 
0.004. With the available data, it appears to be more likely that the effects of the 
GCKR locus on serum urate and FGF-21 are driven by different variants. A larger 
GWAS of FGF-21 levels will confirm whether this trans-pQTL is real and allow 
clarification of the colocalisation result. 
The region around the intergenic SNP rs799167 was also tested, and again the 
most likely scenario was that the region contained a causal SNP for serum urate 
levels but not for FGF-21 levels. (posterior probability = 0.820).  
2.3.5.2 OLINK-IMPROVE CVD-I 
The data available from the Olink IMPROVE website was found not to be in 
agreement with the results published in Folkersen et al.115, in that I identified very 
different index SNPs in the online data from those in the paper. Additionally, CCL3 
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and FABP4 had in excess of 100 and 50 pQTLs respectively – this very large number 
is highly unlikely to be correct and calls the reliability of the online data into question. 
I have been in communication with the senior author to obtain updated results but 
have yet to acquire these at the time of writing.  
As an interim solution, I have used index SNPs reported in the paper for CCL3, 
CHI3L1 and REN and looked these up directly in the serum urate meta-analysis 
results. Five index SNPs were looked up, two in CCL3 and two in CHI3L1, one in cis 
and one in trans in each protein, in addition to one trans pQTL for REN. None of these 
pQTLs were significantly associated with serum urate after Bonferroni correction (P < 
0.05 / 157), but rs28601761 was associated at a nominal level (P < 0.05) - a trans-
pQTL for CHI3L1 in RP11-136O12.2. These results are detailed in the middle panel 
of Table 7. 
2.3.5.3 INTERVAL SOMAscan  
Four of the eight proteins present in the SOMAscan data (FGF-23, CCL3, CHI3L1, 
FABP4, IGFBP-2, LDL-receptor, MMP2 and REN) had significant pQTLs. Three of 
these were in cis, for CCL3, CHI3L1 and REN, and the third was in trans of MMP2 at 
the HSF2 locus. None of these loci were significantly associated with serum urate, 
either at a nominal (P<0.05) or a Bonferroni-corrected threshold. (P < 0.05/4). The 






Figure 15 – Distribution of index SNPs from Olink meta-analyses of Vis & ORCADES. 
Each track corresponds to one protein. X-axis corresponds to genome position. Each point represents an index SNP. Cis-pQTLs are plotted in red, 
trans-pQTLs in blue. SNPs marked with a circle (●) are significantly associated with levels of the corresponding protein (Table 7). SNPs marked with 
a triangle (▲) are suggestively associated with the protein but significantly associated with serum urate (Table 8). The location of the corresponding 
gene encoding the protein is given with a cross (х). 
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Table 7 – Lookup in CKDGen meta-analysis of serum urate (see Chapter 4) of pQTL Index SNPs from Vis & ORCADES, OLINK-IMPROVE and 
INTERVAL. 
OLINK-IMPROVE Loci were taken from Table S1 in Folkersen et al115. Locus size data was not available for these SNPs. EAF from INTERVAL was also not 
available. SUA: serum uric acid. EAF: Effect allele frequency. 
Protein rsID Chr. Position 
Locus 
size 







Gene Cis / Trans 
Vis & ORCADES (Olink) 
CCL3 rs1719134 17 34,416,946 138 A/G 0.239 0.442 8.26E-33 0.265 -0.005 0.196 CCL3 Cis 
CHI3L1 rs7556099 1 203,166,198 112 C/G 0.220 -0.623 8.76E-64 0.181 0.007 0.133 CHI3L1 Cis 
Ep-CAM rs570794 19 49,207,651 51 T/C 0.517 0.191 9.32E-09 0.509 -0.008 0.024 FUT2 Trans 
FABP4 rs17060743 3 59,445,698 27 T/C 0.966 -0.531 6.92E-09 0.873 0.008 0.163 RP11-719N22.2 Trans 
FGF-21 rs148345770 8 80,261,015 2 A/G 0.990 -1.038 1.40E-09 0.992 -0.018 0.438 RP11-1114I9.1 Trans 
FGF-23 rs10504917 8 93,579,847 7 T/C 0.005 1.500 3.67E-09 0.254 -0.001 0.875 RP11-587H10.2 Trans 
IGFBP-2 rs139234454 21 36,570,322 1 T/C 0.994 1.518 2.98E-08 0.983 -0.006 0.866 RUNX1 Trans 
MMP2 rs183411833 21 40,733,749 7 T/C 0.013 -0.894 1.93E-08 0.010 -0.029 0.433 PCP4 Trans 
PON3 rs773888624 2 4,865,648 1 A/G 0.006 -1.825 4.49E-08 0.005 0.008 0.958 SNORA31 Trans 
PON3 rs149867961 7 95,025,744 216 T/C 0.947 0.736 9.06E-23 0.974 -0.007 0.589 PON3 Cis 
OLINK-IMPROVE (Olink) 
CCL3 rs184243355 5 153,249,953 - T/C 0.940 ‐0.41 2.2E‐08 0.997 0.1271 0.527 CTB-95D12.1 Trans 
CCL3 rs2188974 17 34,414,636 - A/G 0.810 -0.310 4.90E-18 0.744 0.0046 0.210 CCL3 Cis 
CHI3L1 rs2153101 1 203,168,474 - A/T 0.210 ‐0.62 7E‐108 0.181 0.0069 0.125 CHI3L1 Cis 
CHI3L1 rs28601761 8 126,500,031 - C/G 0.610 0.140 5E‐09 0.375 -0.0104 0.002 RP11-136O12.2 Trans 
REN rs116661163 1 204,610,672 - C/G 0.024 -0.718 1.03E-08 0.027 -0.0022 0.865 LRRN2 Trans 
INTERVAL (SOMAscan) 
CCL3 rs712042 17 34,392,880 155 A/G - -0.714 1.35E-94 0.1801 -0.0019 0.695 CCL18 Cis 
CHI3L1 rs884209 1 203,147,289 457 A/G - -1.013 ~ 0 0.4629 -0.0022 0.498 MYBPH Cis 
MMP2 rs192645761 6 122,750,510 9 T/C - -0.573 4.79E-08 0.0148 0.008 0.697 HSF2 Trans 
REN rs193280350 1 204,148,649 5 A/G - 1.199 1.32E-15 0.010 -0.0002 0.994 REN Cis 
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Table 8 – Vis & ORCADES Index SNPs from suggestively significant loci (P < 1 x 10-5), with a significant association with serum urate (P < 0.05/467).  




















FGF-21 rs780094 2 27,741,237 14 T/C 0.391 0.183 5.77E-08 0.431 0.063 1.93E-87 GCKR Trans 
FGF-21 rs799167 7 73,051,306 35 T/C 0.703 0.185 3.59E-07 0.738 0.025 4.13E-12 Intergenic Trans 
CCL3 rs547836333 1 12,807,942 1 A/G 0.003 -2.994 5.90E-07 0.0002 5.556 8.58E-153 C1orf158  Trans 
 
Table 9 – Colocalisation results for rs780094 and rs799167. 
Phenotype 1 is serum FGF-21 level, phenotype 2 is serum urate level. 
 rs780094 rs799167 
Hypothesis Prior Bayes Factor 
Posterior 
Probability 
Prior Bayes Factor 
Posterior 
Probability 
H0 No association 0.547 4.51E-87 0.000 0.543 3.83E-47 0.000 
H1 
One variant associated with 
phenotype 1 only 
0.186 2.60E-87 0.000 0.187 1.70E-47 0.000 
H2 
One variant associated with 
phenotype 2 only 
0.186 1.00E+00 0.833 0.187 1.00E+00 0.820 
H3 
Two variants separately 
associated  
with phenotypes 1 and 2 
0.063 5.76E-01 0.163 0.064 4.43E-01 0.125 
H4 
One variant associated with 
phenotypes 1 and 2 




Correlations of greater than 0.1 were identified between 10 regions genetically 
associated with an Olink protein and 7 regions associated with serum urate. These 
are detailed in Table 10. Score-score correlations between these regions are shown 
in Figure 16. The strongest correlation identified was 0.79, between FGF-21 and 
serum urate in a region on the short arm of Chromosome 2. This region contains 
several genes, among which is glucokinase (hexokinase 4) regulator (GCKR), 
reported as the gene of interest in the GUGC serum urate GWAS. This protein was 
also identified as urate-predictive in the lasso regression (Section 2.3.4). FGF-21 was 
also weakly correlated (0.11) with a second region on Chromosome 2, in an intergenic 
region that had a negative correlation with MERTK. 
The next strongest correlation is a negative correlation of -0.24 between CCL25 and 
serum urate on Chromosome 16, containing the genes MIR1538, NFAT5 and NQO1. 
NFAT5 was suggested as the likely causal gene in this region in the Köttgen et al. 
(2013) publication74. CCL25 had a nominally significant correlation with serum urate 
(r = 0.050, P = 0.0462) but was not significant in the partial correlation analysis, nor 
included in any lasso regression models.  
No other correlations of magnitude larger than 0.2 were identified. 
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Table 10 – All GENOSCORES regions with a serum urate-Olink correlation > 0.1. 














Chr 2:  
27,166,327 - 28,309,442 
156 rs1260326 1.31x10-40 0.0002 2 27,166,327 
Chr 2:  
120,548,195 - 120,583,705 
12 rs17050272 9.36 x10-9 0.0039 2 120,548,195 
Chr 5:  
73,135,630 - 73,164,602 
26 rs575416 3.63 x10-9 -0.0024 5 73,135,630 
Chr 6:  
25,330,310 - 26,602,787 
588 rs3799352 9.69 x10-60 -0.0005 6 25,330,310 
Chr 8:  
23,857,479 - 23,930,882 
28 rs17786744 8.82 x10-8 0.0014 8 23,857,479 
Chr 12:  
110,953,995 - 112,468,611 
13 rs653178 2.45 x10-10 -0.0046 12 110,953,995 
Chr 15:  
75,866,642 - 76,020,780 
13 rs1394125 9.78 x10-11 0.0099 15 75,866,642 
Chr 16:  
69,508,575 - 69,741,597 
10 rs7193778 2.36 x10-8 -0.0037 16 69,508,575 






Chr 2: 27,375,230 - 27,636,484 
13 rs780094 5.77 x10-8 0.0234 2 27,375,230 
MERTK, Chr 2:  
111,887,673 - 112,157,553 
270 rs13386914 2.79 x10-22 0.0007 2 111,887,673 
ST1A1, Chr 5:  
177,400,814 - 177,415,473 
7 rs2545801 1.77 x10-08 0.0209 5 177,400,814 
IL-4RA, Chr 8:  
20,304,455 - 20,380,215 
23 rs2086882 6.64 x10-8 0.0007 8 20,304,455 
TNFRSF10A, Chr 8:  
22,722,044 - 23,389,632 
113 rs13278062 6.19 x10-48 0.0467 8 22,722,044 
EPHB4, Chr 12: 
8,655,410 - 8,823,009 
10 rs11047432 4.51 x10-08 -0.0071 12 8,655,410 
IL16, Chr 15:  
81,237,069 - 81,825,241 
48 rs4778639 6.15 x10-101 0.0404 15 81,237,069 
AP-N, Chr 15:  
89,785,074 - 89,902,214 
56 rs73478036 2.68 x10-11 -0.0019 15 89,785,074 
CCL25, Chr 16:  
71,248,643 - 71,469,540 
31 rs6499508 3.81 x10-8 -0.0055 16 71,248,643 
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Figure 16 – GENOSCORES score-score correlation plot for serum urate and Olink 
loci. 
Serum urate loci are plotted on the y-axis, Olink loci on the y axis. Correlation coefficient is 
given by the numerical value in each cell, as well as the colour-coding. Only loci with at least 
one correlation of absolute value greater than 0.1 with another locus are shown, for clarity. 
 Genetic correlation with LD-score regression 
Genetic correlations are shown in Table 11. No traits had significant genetic 
correlations. Traits could not be calculated as the LDSC algorithms are unstable for 
samples with n < 3,000. FGF-23 has a near-significant P-value for a correlation of 
0.07 in the Vis + ORCADES dataset, but although the correlation is stronger using 
OLINK-IMPROVE data, the standard error is also much larger, resulting in a non-
significant correlation. This may be because the sample size is still below the 
recommended minimum of 3,000 but may also be a consequence of the problems 
identified earlier with the IMPROVE data. The heritability of the OLINK traits would 
also affect the genetic correlation; unfortunately, these have not yet been calculated 
to my knowledge. Rerunning this analysis when the SCALLOP CVD-II, CVD-III and 
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INF results are published should clarify this. FABP4 displayed the strongest genetic 
correlation with serum urate, 0.30 (P = 0.09). 
Table 11 – Serum urate-Olink genetic correlations from LDSC. 
Missing values are from algorithm failure due to low sample size. 












FGF-23 0.0727 0.0405 0.0724 
CCL3 -0.0428 0.0691 0.5355 
LDL-receptor - - - 
PLC - - - 
FABP4 - - - 
Ep-CAM 0.0644 0.0913 0.4805 
MMP.2 -0.0016 0.0519 0.9762 
CHI3L1 0.0121 0.0312 0.6992 
PON3 0.0013 0.0449 0.9777 
IGFBP-2 - - - 






 CCL3 0.2017 0.3847 0.6001 
CHI3L1 - - - 
FABP4 0.3016 0.1783 0.0907 
FGF-23 0.2244 0.3952 0.5702 
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2.4 Lipidomics results 
 Analysis sample sizes 
The samples sizes for each cohort and sub-analysis are displayed in Table 12. These 
are consistent across all subsequent analyses. 
Table 12 – Sample sizes for serum urate-lipidomic correlation analyses.  




Females only 390 




Females only 294 




Females only 684 
Males only 555 
 
 Correlations 
Correlations between serum urate and lipidomic measurements are shown in Figure 
17. A total of 99 lipidomic phenotypes were significantly correlated with serum urate 
after FDR correction for multiple testing for 191 tests. Additionally, 4 of the non-omic 
phenotypes included were significant, including HDL and LDL cholesterol, which were 
not included in the Olink analysis. The strongest absolute correlation was again with 
BMI, and the strongest lipidomic correlation was with phosphatidylethanolamine 40:6 
(PE_40__6, r = 0.267). The strongest negative correlation was with 
phosphatidylcholine O-34:2 (PC_O_34__2, r = 0.180).  
There were three cases where a significant difference in effect between sexes was 
detected. These are detailed in Table 13. All of these are phosphatidylcholines, two 
of which have negative correlations in females and positive in males, and the third 
has a strong positive correlation in males and a near-zero correlation in females. 
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Table 13 – Serum urate-lipidomic correlations with a significant difference in effect 
between sexes.  
PC_38__6 – Phosphatidylcholine 38:6; PC_38__7 – Phosphatidylcholine 38:7; PC_O_40__6 
- Phosphatidylcholine O-40:6, nF = 906, nm = 710. 
Phenotype rF rM Psex effect 
PC_38__6 0.005 0.200 8.27E-05 
PC_38__7 -0.084 0.101 2.16E-04 






Figure 17 - Heatmap of serum urate-lipidomic 
correlations. 
Cell colour corresponds to direction of correlation 
and intensity to magnitude. ‘*’ denotes 
correlations which are significant after FDR-
correction (Q < 0.05). Y axis is clustered by 
similarity across strata – this is intended to 
highlight groups of proteins with similar effect 
differences due to sex.  
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 Partial Correlations 
Three phenotypes were significant in the partial correlation analysis (Table 14, Figure 
18). In contrast to the Olink partial correlation analysis (Section 2.3.3) two of these 
were non-omic phenotypes. The third, phosphatidylcholine 38:6 (PC_38__6), is 
negatively correlated with serum urate levels in all four subsets of the data, in contrast 
to the results observed in normal correlation analysis, where all correlations were 
positive or zero, and a significant difference in effects was observed between males 
and females. 
Table 14 – Partial correlation coefficients for BMI and eGFR in serum urate-lipid models. 





Std. Err. P-value Q-value 
BMI All 0.128 0.026 3.41E-05 2.17E-03 
BMI CKD excluded 0.139 0.031 1.17E-05 1.12E-03 
BMI Female 0.122 0.037 6.66E-03 3.24E-01 
BMI Male 0.102 0.043 5.13E-02 6.70E-01 
      
eGFR All -0.186 0.026 1.34E-09 1.28E-07 
eGFR CKD excluded -0.129 0.031 4.65E-05 2.96E-03 
eGFR Female -0.139 0.037 1.94E-03 1.85E-01 
eGFR Male -0.235 0.043 5.58E-06 5.33E-04 
      
PC_38__6 All -0.096 0.026 1.82E-03 8.68E-02 
PC_38__6 CKD excluded -0.109 0.031 6.15E-04 2.94E-02 
PC_38__6 Female -0.119 0.037 8.20E-03 3.24E-01 
PC_38__6 Male -0.090 0.043 8.41E-02 6.70E-01 
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Figure 18 - Partial correlation coefficients for BMI and eGFR in serum urate-lipid 
models. 
Error bars are 95% confidence interval.  
 Lasso regression analysis 
Phenotypes were considered urate-predictive if they appeared in more than 950 
models. Results are displayed in Figure 19.  
The phenotypes with the strongest contribution to the models were BMI, eGFR and 
phosphatidylethanolamine 40:6 (PE_40__6). No other phenotypes had coefficients 
with magnitude larger than 0.1. Coefficient sign was consistent for 
lysophosphatidylcholines (LPC_x__y, negative), acyl-group phosphatidylcholines 
(PC_O_x__y, negative) and phosphatidylethanolamines (PE_x__y, positive). No 
consistent direction of effect was seen between sphingomyelins or between 




Figure 19 – Mean lasso regression coefficients for serum urate-lipidomics analysis. 
Means are calculated over 1000 runs. All phenotypes appearing in 95% of models in at 
least one subset are shown. 
 
2.5 Combined analysis 
Data from both Olink and lipidomics were combined to investigate the overlap 
between these sets of measurements. Pairwise correlation analyses are independent 
of other phenotypes, hence these would not be changed in the merged analysis, so 
these were not re-run. Partial correlation and lasso regression analyses are both 
sensitive to covariates included, so these were performed de novo using the 
combined dataset. 
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No phenotypes were significantly partially correlated, although the strongest 
correlation, with FGF-23 (r = 0.131, P = 2.42E-4, Q = 0.055), was very close to the 
threshold of significance. 
The lasso regression includes many of the phenotypes observed in the separate 
analyses, including the strong associations with eGFR, IGFBP-2, PON3, LPC 22:4, 




Figure 20 - Mean lasso coefficients for serum urate regressed on all phenotypes. 
Only phenotypes included in all 1000 iterations of the model are plotted.  
 
2.6 Conclusions 
The analyses in this chapter, though broadly similar in theme, identify a range of 
different circulating proteins and lipids as being associated with serum urate. 
Correlation analysis identifies a large number of associations, many of which are likely 
attributable to confounding with phenotypes such as BMI or eGFR, which are known 
to be correlated with serum urate. Partial correlation analysis identifies the fewest 
associations but is restrictive in that it fixes the effect of all covariates and cannot 
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account for combined effects of multiple phenotypes. Lasso regression attempts to 
find a small set of phenotypes whose combination of values best predicts serum urate 
levels, in this way, it is less restrictive than partial correlations, as it can allow more 
than one phenotype to be assessed at a time, but it is less subject to confounding 
than basic correlations, as redundant phenotypes add little information to the model 
and are pruned. One limitation of the lasso method is that it enforces sparsity. In a 
biological context, this may not necessarily reflect the mechanisms regulating a 
relationship, which are often multiple and complex. Partial correlations allow the 
analyst to consider each protein individually in the context of any other phenotypes of 
interest – a non-significant correlation may still be of interest – while lasso regression 
simply sets some coefficients to zero. 
All these analyses detect known associations between serum urate and protein levels, 
suggesting that they are at the very least technically correct in their execution. More 
interestingly, several phenotypes are identified which have not been previously 
reported as correlated with serum urate. Though many studies have investigated the 
relationship between serum urate and a limited number of phenotypes, to my 
knowledge this dataset represents the broadest study of urate-phenotype 
associations, particularly with respect to cardiovascular- and inflammatory-related 
omic phenotypes.  
In addition, the genetic architectures of molecular phenotypes are often simple, with 
a few variants conferring strong effects on abundance151–153 – for example, six pQTLs 
collectively explain up to 52% of the variance in VEGF levels154. These variants can 
be used to interrogate relationships; Figure 21 summarises the possible mechanisms 
for a genetic variant affecting both biomarker and serum urate levels. Of particular 
interest is the middle scenario: where a variant is both a QTL for serum urate and a 
strong cis-pQTL for the variant of interest. In this case, it is likely that the change in 
protein levels is not caused by variation in serum urate, rather that the change in 
serum urate levels is mediated by the altered protein levels. If the variant is not 
pleiotropic, it can be used as an instrumental variable in Mendelian randomisation 
analysis to formally test the causality in the relationship.  
Unfortunately, none of the cis-pQTLs identified or previously reported for the proteins 
selected as urate-associated showed any association with serum urate, even at a 
nominal significance level (p < 0.05). This could be due to the alternative hypothesis 
that serum urate levels influence the abundance of some of these protein biomarkers. 
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Alternatively, as the GENOSCORES data suggests in some cases, some of the 
associations may be independent consequences of the same underlying pathway. 
For example, GCKR is a QTL for serum urate and a borderline significant trans-pQTL 
for FGF-21 (P ~ 5x10-8), suggesting they may be independent consequences of the 
glucokinase regulation pathway. Two trans-pQTLs are nominally significant with 
serum urate levels, FUT2 for Ep-CAM in our data (p = 0.024) and RP11-136O12.2 for 
CHI3L1 in IMPROVE (p = 0.002) which could mean the trans-genes have 
independent regulatory effects on both serum urate and the protein.  
 
 
Figure 21 - Possible mechanisms driving an association between serum urate (U) 
and omic biomarker (O) levels where a shared genetic variant (G) can be identified. 
 
 FGF-23 
FGF-23 was identified as positively associated with serum urate in both partial 
correlation and lasso regression analyses. It is part of a subfamily of fibroblast growth 
factors that includes FGF-19, 21 and 23, which are noteworthy within the FGF family 
for being endocrine hormones – the other five FGF subfamilies operate in a paracrine 
manner, affecting mainly the tissues from which they are secreted155. FGF-21 was 
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also implicated in these analyses as being linked to serum urate, though FGF-19 was 
not.  
FGF-23 is a hormonal regulator of phosphorus and vitamin D metabolism, most highly 
expressed in bone cells. Amongst other known roles, it regulates reabsorption of 
phosphate in the kidneys by modulating sodium phosphate co-transporters. 
Glycosylated FGF-23 binds to the membrane-spanning receptor protein FGFr1 in the 
kidney, causing a signalling cascade that reduces the reabsorption of phosphate into 
the blood. FGF-23 also downregulates enzymes which activate vitamin D. Because 
activated vitamin D enhances intestinal absorption on phosphate, this means FGF-23 
decreases phosphate levels though an additional pathway155. 
FGF-23 is increased in cases of non-alcoholic fatty liver disease (NAFLD), 
independently of low vitamin D156 – a condition also associated with hyperuricaemia 
in both East Asian and European populations157,158. Elevated FGF-23 levels are 
observed in CKD, but the persistence of this correlation in the CKD-excluded analyses 
suggests that the association goes beyond impaired renal function. FGF-23 protein 
and mRNA levels were found to be increased in the kidney of a CKD model rat159, and 
is a strong predictor of insulin resistance in CKD patients160. 
In a rat hepatocyte model using a uricase inhibitor, increased uric acid production was 
found to be an indicator of com promised ATP synthesis14. As urate is the end product 
of AMP oxidation, this may suggest that the link between serum urate and FGF-23 is 
driven by phosphate homeostasis – high FGF-23 leads to low phosphorus levels, 
causing reduced ATP synthesis and more AMP build-up, which is consequently 
oxidised to uric acid. 
Positive associations between FGF-23 and uric acid have been reported in healthy 
adult males161, CKD cases162 and children with kidney damage but preserved kidney 
function163. These studies incorporate various covariates, including BMI and eGFR, 
but none have adjusted for such a large number and range of phenotypes. The fact 
that the association persists even after the adjustment for so many medically-relevant 
phenotypes is good evidence that the association between FGF-23 and serum urate 
is genuine. 
Unfortunately, the absence of a cis-pQTL for FGF-23 in our data makes it difficult to 
test the causality of the association. None of the trans-pQTLs identified were 
associated with serum urate, even at a nominal threshold of p < 0.05, making it 
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unlikely that any of these genes are driving the correlation between FGF-23 and 
serum urate.  
 FGF-21 
FGF-21 was positively predictive of serum urate in the lasso regression. It is a 
mediator of the fasting response that increases glucose uptake and increases insulin 
sensitivity, and is expressed in the liver, thymus, adipose tissue and islet β-cells in the 
pancreas. Elevated levels have been linked to insulin resistance, metabolic syndrome 
and NAFLD. The mechanism by which it increases glucose uptake is partly due to 
upregulating transcription of GLUT1164, a glucose transporter in the same family as 
the high-capacity urate transporter GLUT9, encoded by SLC2A9. This regulatory 
activity means FGF-21 has a beneficent impact on type 2 diabetes165.  
FGF-21 has been previously positively correlated with uric acid levels, adjusted for 
age and BMI in a small study of 210 Mexican ancestry individuals, where it was also 
found to correlate with fasting glucose and physical activity166, but to my knowledge 
has not been reported elsewhere. Cuevas-Ramos et al. suggest that the association 
between metabolic syndrome and FGF-21 may explain the link with serum urate, but 
their associations persist even after excluding metabolic syndrome cases.  
GCKR encodes glucokinase regulatory protein (GKRP), a hepatocyte-specific 
inhibitor of glucokinase, one of the enzymes which convert glucose to glucose-6-
phosphate. A mutation in GCKR has been reported to affect expression of FGF-21167.  
This SNP, rs1260326 (P446L), has been well characterised – in vitro experiments 
showed that it results in elevated hepatic glucose uptake and disposal, which 
increases lipid synthesis and reduces fasting glucose168. In GWAS, it has been 
associated with reduced T2D risk169, reduced fasting plasma glucose and increased 
triglyceride and CRP levels170.  
GCKR has also been associated with serum urate levels171. This is borne out by the 
strong GENOSCORES correlation near GCKR between FGF-21 and serum urate. A 
genetic association between the two traits supports a hypothesis that increased 
glucokinase activity leads to more ATP depletion and thus higher serum urate levels. 
Unfortunately, the pleiotropy of the GCKR locus means it would not be an ideal 
instrument for MR.   
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 IGFBP-2 
IGFBP-2 was consistently negatively associated with serum urate across the 
analyses, particularly strongly in the discovery cohort. Association strength was 
affected, although it remained suggestive, after removal of CKD cases, in line with 
IGFBP-2 as a biomarker of renal pathology in CKD and lupus nephritis patients172 .  
This protein modulates the activity of Insulin-Like Growth Factors, binding IGF-I and 
IGF-II in the blood and many different ligands inside the cell. IGFBP-2 has been linked 
to modulation of metabolism, with lower levels associated with diabetes173, obesity174 
and metabolic syndrome175, as well as bone development  in mice, directly stimulating 
osteoblast differentiation176. A GWAS hit for type 2 diabetes  has been found in an 
intron of the IGFBP2 gene169. Additionally, high expression of the IGFBP2 gene has 
been shown to promote the growth of several types of tumours.  
In a study of changes of protein abundance in obese individuals following a low-calorie  
diet by Carayol et al., IGFBP-2 levels were strongly negatively associated with BMI at 
baseline, but this effect was greatly reduced in magnitude following intervention117. 
This is consistent with my finding that IGFBP-2 is negatively correlated with serum 
urate, which is increased in obesity. However, the fact that IGFBP-2 was retained in 
the partial correlation and lasso predictive models despite the inclusion of BMI as a 
separate covariate suggests that the link between serum urate and IGFBP-2 is not 
simply mediated by BMI. 
A single trans-pQTL for IGFBP-2 was identified in the RUNX1 locus, but this was not 
associated with serum urate. RUNX1 encodes a transcription factor that plays a role 
in the differentiation of blood cells. 
 Ep-CAM 
Ep-CAM was identified in the discovery partial correlation analysis and had consistent 
positive correlation in INTERVAL but did not replicate in EGCUT or Lifelines DEEP. It 
was not identified as urate-predictive in the lasso regression analysis. The protein is 
a transmembrane mediator of cell-cell adhesion in epithelial tissue and has been 
reported as an oncogene. It is strongly expressed in glandular cells of the 
gastrointestinal tracts and the gall bladder, as well as in the cells of the kidney 
tubules177 – which are composed of epithelial tissue – but otherwise there is no 
obvious connection to serum urate levels. 
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A cis-pQTL was identified at rs201314303 by Enroth et al.178, but this SNP was not 
present in the CKDGen meta-analysis, and the nearest index SNPs were several 
megabases away. In our own meta-analysis, rs570794, a trans-pQTL in the FUT2 
gene was nominally significant with serum urate (p < 0.05).  
FUT2 encodes a fucosyltransferase involved in ABO antigen synthesis179. The SNP 
is also associated with alkaline phosphatase180, alcohol intake frequency140 and self-
reported high cholesterol140 in the UK Biobank. A pleiotropic association with alcohol 
could explain the serum urate association, but the relatively high p-value with serum 
urate makes this link tenuous. 
 Renin 
Renin (REN) was included in lasso models for the discovery and PIVUS cohorts as a 
positive predictor of serum urate levels. Renin is a regulator of blood pressure as part 
of the renin-angiotensin system (RAS), where it converts angiotensinogen to 
angiotensin I, which is subsequently converted to angiotensin II, a vasoconstrictor. 
Uric acid is known to be positively correlated with systolic and diastolic blood 
pressure181 and has been linked to the RAS. Transcript levels of the REN gene, which 
encodes renin, along with other components of the RAS pathway were shown to 
increase in a dose-dependent manner in differentiating mouse 3T3-L1 adipocytes 
incubated with uric acid182. This study goes on to suggest that RAS may be the 
mechanism by which uric acid is linked to obesity-related hypertension. Renin is also 
positively correlated with blood pressure183, but in the combined Olink and lipids 
analysis, where systolic blood pressure (SBP) was included as a covariate, both SBP 
and renin are identified as independent predictors of serum urate levels. This 
suggests that the relationship between serum urate and renin is not simply mediated 
by high blood pressure. The Carayol et al. obesity dietary intervention study did not 
find an association between REN and BMI or BMI decrease, suggesting that the 
serum urate association is unlikely to be mediated by BMI117. However, it has been 
suggested8 that serum urate could be increased due to dysregulation of the RAS in 
obesity – increased angiotensin II reduces fractional clearance of uric acid (the ratio 
of uric acid clearance to creatinine clearance) in the kidney184 and thus increased uric 
acid in the bloodstream.  
No pQTLs for REN were present in in our own meta-GWAS. A cis-pQTL was identified 
in INTERVAL, but it was not significantly associated with serum urate. Additionally, a 
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trans-pQTL was reported by Folkersen et al.115at rs116661163 in the LRRN2 locus, 
which was not significant with serum urate (P > 0.05)  
 LDL-receptor 
LDL-receptor was included in lasso regression models in the discovery and Lifelines 
DEEP cohorts. This protein is a cell surface receptor involved in receptor-mediated 
LDL endocytosis. Loss of function mutations of LDLR cause familial 
hypercholesterolaemia. LDL-cholesterol is positively correlated with serum urate 
levels185, which may explain the correlation with LDLR. As far as I can ascertain, no 
association between LDLR and serum urate has been reported in humans.  
In rabbits, LDLR protein was found to be expressed at a lower level in the liver of diet-
induced hyperuricaemic rabbits compared to controls, but its level restored to some 
extent following treatment with Losartan186. The hypertension drug Losartan is an 
angiotensin receptor blocker with a known effect on reducing serum urate level. 
Losartan directly inhibits URAT1187, a urate/anion exchanger encoded by SLC22A12. 
This transporter is one of several present on the apical membrane of the kidney 
proximal tubule cells, where it reabsorbs urate from the tubule lumen37. Losartan 
blocks this reabsorption, leading to uricosuria – high levels of uric acid in the urine. 
However, it must be noted that serum urate levels are much lower in rabbits than 
humans. Additionally, although it is commonly noted that Losartan has no effect on 
cholesterol levels, it cannot be completely ruled out that this is driving the effect on 
LDLR in the rabbit model. 
There is no pQTL for LDL-receptor either in our own data or in the literature. However, 
the multiple GWAS signals locating to the LDLR gene have no association with serum 
urate levels, while still being strongly associated with lipid levels188. Taken together, 
this evidence strongly suggests there is no causal link between LDLR and serum 
urate. However, with the available data, I cannot exclude a pleiotropic effect on both 
LDLR and serum urate, for example mediated by LDL levels, or serum urate level 
causally affecting LDLR. 
 FABP4 
FABP4 was one of only two phenotypes that was included in all Olink lasso models 
for all five cohorts – the other being eGFR, a known strong association with serum 
urate. This association persists in the combined Olink-lipids lasso analysis (Figure 
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20) and is assigned the largest positive coefficient of any phenotype. FABP4, a fatty 
acid binding protein also known as aP2, is primarily expressed in adipocytes and also 
in macrophages, though at a 10,000-fold lower level189.  Adipose tissue has been 
proposed to be a site of urate production in obese individuals based on work in 
mice190. The dual metabolic and inflammatory role of FABP4 mirrors the role of uric 
acid and suggests a link to diabetes and metabolic syndrome.  
I have found little evidence of the link between serum FABP4 and serum urate being 
explicitly stated before – a Chinese paper from 2010 appears to have reported a 
correlation between serum FABP4 levels and serum urate in pregnant women with 
preeclampsia, but the precise methodology is unclear to me, as only the abstract is in 
English191. A study in mouse 3T3-L1 preadipocytes found that the uricosuric drug 
benzbromarone, reduces levels of human FABP4, but the authors deduce that this is 
due to a direct interaction, making no mention of any association between FABP4 and 
serum urate192. Benzbromarone acts as a non-competitive inhibitor of XO, the enzyme 
which catalyses the conversion of hypoxanthine to xanthine, and xanthine to uric acid. 
However, the effects of XO inhibitors are often difficult to interpret, as they reduce the 
production of reactive oxygen species as well as serum urate.  
Another study using differentiating 3T3-L1 cells found that incubation with 
benzbromarone increased levels of FABP mRNA (referred to as aP2 in the study), 
although this response was reduced in the cells that had been differentiating for 
longer. Allopurinol and uric acid had no effect on FABP4 transcript abundance193. This 
would seem to suggest that serum urate is not directly stimulating FABP4 transcription 
under these conditions, although the effect could again be driven by reduced ROS 
production. It must also be noted that in vitro experiments on mouse cells do not 
necessarily represent the in vivo systems in humans.  
A trans-pQTL in RP11-719N22.2 in our meta-analysis was not significant in serum 
urate. No information on FABP4 was reported in either the IMPROVE or INTERVAL 
studies, but it will be included in the next round of SCALLOP meta-analysis results. 
 IL-1RA 
IL-1RA is not strongly predictive of serum urate levels in the discovery cohort but is 
retained in all models. It is more strongly predictive in PIVUS, which only included a 
reduced set of Olink phenotypes. The regression coefficient is positive in both, which 
contradicts a published finding that peripheral blood mononuclear cells (PBMCs)  
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stimulated with urate showed a downregulation of IL-1ra transcription194, although this 
study used uric acid levels that were much higher than those seen in clinical 
hyperuricaemia. This could also be an effect of the inclusion of many covariates in my 
models. 
 CCL3 
C-C Motif Chemokine Ligand 3 (CCL3) is a small inducible cytokine which was a weak 
association in the lasso regression for discovery and EGCUT. CCL3 has been shown 
to be produced by eosinophils in response to uric acid crystal stimulation195. 
A suggestive trans-pQTL (P < 10-5) is significantly associated with serum urate in the 
C1orf158 gene, which is uncharacterised. However, as detailed in section 2.3.5.1, this 
SNP is very rare, and is present only in ORCADES in the CCL3 meta-analysis and 
the MVP cohort in the serum urate meta-analysis, with opposite effects on serum 
urate, so, unfortunately, it is likely to be a false positive. 
 PLC 
Perlecan (PLC) was identified in the lasso regression in the discovery and EGCUT 
cohorts. It is a large multidomain proteoglycan that cross-links extracellular matrix 
components and cell-surface molecules and is a major component of the glomerular 
basement membrane. A study in canine kidney cells found that 8mg/dL of uric acid 
caused decreased expression of the perlecan core protein, but not 20mg/dL196. The 
lasso regression shows a mild positive association, but mechanism behind the 
possible link with serum urate is not clear. No pQTLs were identified. 
 PON3 
Paraoxonase 3 (PON3) is associated with HDL-cholesterol in the blood, and reduces 
the rate of LDL-cholesterol oxidation, low levels of which have been linked to a variety 
of conditions including inflammation in coronary artery disease (CAD) and insulin 
sensitivity in peripheral artery disease197. It is mainly expressed in the kidney and liver.  
PON3 was identified as urate-predictive in three of the four cohorts in which it was 
measured, absent only from INTERVAL. In all three cohorts it was negatively 
associated with serum urate levels. 
No previous associations with serum urate have been reported in the literature, but a 
strong negative correlation was reported between the activity of related protein PON1 
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and uric acid levels in the blood of patients undergoing haemodialysis198. This paper 
suggests that PON1 acts to protect cholesterol from oxidative damage which is less 
necessary at higher concentrations of serum urate. 
A cis-pQTL and a trans-pQTL in SNORA31 were identified in our meta-analysis, but 
neither were significantly associated with serum urate. 
 Lipid associations 
Interpretation of the lipidomic results is more complicated than the Olink, as the 
distinction between different lipids is less, and each has been studied far less than 
the disease biomarkers included on the protein panels. However, there are still a few 
notable phenotypic correlations. 
By far the strongest association between serum urate and a lipid was with 
phosphatidylethanolamine 40:6 (PE 40:6). Phosphatidylethanolamines (PEs) 
comprise 25% of all phospholipids in the body. It is not clear why PE 40:6 displays 
such a strong positive correlation with serum urate compared to the other PEs 
measured (Figure 17), but it persists in lasso regression in both lipids and the 
combined sample, and so can be considered to be an independent predictor of serum 
urate levels.  
Phosphatidylcholine 38:6 was the only lipid detected in the partial correlation analysis. 
The identified correlation was negative, which reflects previous findings that 
decreases in PC 38:6 are associated with progression from cognitive impairment to 
Alzheimer’s disease199  and development of Huntington’s disease200, both of which 
are associated with hypouricaemia. No association was detected in the lasso 
analysis. Interestingly, PC 38:6 is positively correlated with serum urate in the 
correlation analysis, but negatively partially correlated. This could mean that one of 
the covariates adjusted for accounted entirely for the positive correlation seen 
between serum urate and PC 38:6, revealing the true association. 
PC 38:6 is also notable for its strong sex effect: it is positively correlated with serum 
urate in males, but no correlation is detected in females. Sex effects were also 
detected in PC 38:7, PC 40:7 and PC O-40:6, in all cases the association was 
negative in females and positive in males. 
Lysophosphatidylcholine 22:4 has a moderate negative effect in the combined lasso, 
although the effect in the lipids-only lasso is comparatively weak. 
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Lysophosphatidylcholines (LPCs) are produced from PCs through the removal of one 
of the fatty acyl groups. They are minor components of the cell membrane but are 
present at higher levels in plasma and are major components of oxidised LDL. Most 
LPCs were negatively correlated with serum urate, and all the LPCs retained in 
regression models had negative coefficients. The PC:LPC ratio is altered in many 
different diseases, but I was unable to find a consistent pattern that might explain the 
negative associations with serum urate, or a record of a specific role for LPC 22:4. 
  Summary 
The association of several medically-relevant proteins with serum urate in these 
results is perhaps unsurprising, given that the Olink panels are populated with 
previously recognised disease biomarkers. However, these analyses have taken a 
high-dimensional dataset and reduced it to a dozen proteins with distinct roles, all of 
which appear to be independently associated with serum urate. The majority of these 
are positive associations, which is to be expected given the pro-inflammatory nature 
of serum urate and its elevation in CVD.  
The range of accepted roles played by these phenotypes is diverse, including 
phosphate metabolism and bone development, glucose metabolism, adipocyte 
function, blood pressure regulation and in the case of the lipid associations, possibly 
cognitive function. In some cases, such as FGF-23, these results reinforce previously 
reported findings, showing that they persist even after accounting for several hundred 
covariates. In others, such as FABP4 and PON3, they explicitly identify associations 
that were hinted at in work in on related proteins or in different species. And in many, 
there is no previous report of a link to serum urate. Future confirmation of these links 
may reveal novel aspects of the biology of serum urate. 
A key question that this set of phenotypes raises is why they specifically are 
associated with serum urate levels, when the dataset includes many other proteins of 
similar function. With the data currently available, it is difficult to answer this. 
Interestingly, a recent publication investigating associations between proteins on 
Olink CVD-I, CVD-II and CVD-III and lipid fractions identified significant associations 
with six of the eleven urate-associated proteins I have found – CCL3, FABP4, FGF-
23 and IL-1RA are all positively associated with triglycerides (TG) and negatively 
associated with HDL-cholesterol, CHI3L1 positively associated with TG  and 
negatively with LDL-cholesterol, and REN is positively associated with TG only. None 
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of these proteins were found to be causally associated with lipid fractions in MR 
analysis201. Of course, the nature of the Olink panel is that it contains a relatively small 
set of proteins known to be related to cardiovascular disease or inflammation, so the 
set of possible proteins which could be found is already enriched for ‘interesting’ 
combinations. Nonetheless it is intriguing to see such a large proportion of the same 
proteins appearing. Uric acid is positively and strongly correlated with TG.  An MR 
study in the ARIC and FHS cohorts found no evidence that serum urate levels were 
causal202, although the authors suggested that dietary sugar intake could be a 
confounding factor. 
When the SCALLOP consortium completes and publishes its ongoing GWAS of the 
INF, CVD-II and CVD-III panels it should become possible to perform mendelian 
randomisation analyses with serum urate – this may provide evidence of causality, 
which should guide further experiments. If any of these phenotypes prove to be a 
consequence of serum urate levels, it may mean that urate-lowering medication could 
be an option for treatment in the diseases with which they are associated. 
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 GWAS of serum urate 
3.1 Background 
 Genome-wide association studies 
Genome-wide association studies, commonly known as GWAS, have been referred 
to elsewhere in this thesis already, but it will be briefly expanded upon here. The 
purpose of a GWAS is to identify variation in the genome which significantly influences 
a phenotype. The central precept is that by identifying these genomic regions, we can 
identify biological mechanisms affecting the phenotype, information that can lead to a 
better understanding of health and disease. Phenotypes can be binary (e.g. disease 
status) or quantitative (e.g. concentration of serum uric acid). 
Most GWAS are run on single-nucleotide polymorphisms (SNPs), single-base 
locations in the genome that vary between individuals. Each SNP has two or more 
possible alleles, the frequencies of which are not necessarily equal and often vary 
between populations. Individuals can be homozygous at a SNP (with the same allele 
on each chromosome) or heterozygous (with different alleles on each chromosome). 
The exception to this rule is the non-pseudoautosomal region of the X chromosome 
in men, where only one copy of each SNP is possible. Generally, the contribution of 
each SNP across the genome is assumed independent of all other SNPs, allowing 
their effect on the trait to be assessed one at a time, greatly simplifying the statistical 
analysis. 
If one SNP allele is significantly more common in cases vs controls, or in individuals 
with high values of a quantitate trait vs low values, that SNP can be said to be 
associated with that trait. For quantitative traits, a generalised linear model (GLM) is 
used to carry out the association test.  Commonly and in unstructured samples, the 
trait value is simply regressed on the number of the chosen reference allele at a SNP 
(0, 1 or 2). Analysis of Variance (ANOVA) test which is equivalent to a linear 
regression is also being used frequently to test differences in mean trait values across 
genotype categories at the SNP (without any assumption on the relationship between 
these means).  For binary traits in unstructured samples, a logistic regression is often 
used. GLMs allow adjustment for covariates known to be associated with variation in 
the trait – age and sex are almost ubiquitously adjusted for, as most biological traits 
vary with both. More complicated adjustments include the use of mixed models to 
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account for population structure – related individuals within the population, who may 
have shared environments and genotypes that could confound the association 
between genotype and the trait of interest. The generally accepted threshold for a 
significant association after testing the whole genome is P < 5 x 10-8 – this is 
approximately equivalent to a Bonferroni-adjusted threshold of P < 0.05, based on a 
million independent tests being made. This is not equal to the number of SNPs being 
tested, as many SNPs are in LD with one another, meaning many tests are not 
independent. 
In the simplest case, one allele at a SNP in a coding region of the genome may directly 
alter the structure of a protein that regulates the phenotype of interest and change its 
function. Associations of this sort are generally strong, easier to detect, and above all 
rare in GWAS results. Most variants associated with a common trait/disease are 
expected to locate in non-coding regions where the causal variant(s) may alter gene 
regulation by modifying a binding site for a transcription factor or affecting local 
chromatin structure. Associated variants can also be in regions of the genome far 
from any coding genes, making it difficult to interpret the signal.  
A further complication due to the structure of the human genome is that the causal 
variant is in LD with a number of other variants – meaning individuals tend to keep 
the same combinations of alleles across several SNPs in a given region due to 
recombination hot spots distribution, creating correlations of allele across loci. This 
means that if one causal SNP is associated with the phenotype, several SNPs across 
an LD block are as well. Thus, the characteristic signature of a GWAS ‘peak’ a region 
of SNPs clustered together, all associated with the trait of interest. These peaks give 
‘Manhattan’ plots their name – when negative log10-transformed P-values for SNPs 
are plotted in order of their location along the genome, the resulting plot will tend to 
have several tall stacks of points that loosely resemble the Manhattan skyline (if the 
GWAS is sufficiently powered to detect associations). This set of SNPs may contain 
a causal variant, or several such variants, but sometimes the ‘true’ causal SNP is not 
genotyped, though its presence may be inferred from the significance of the SNPs in 
LD with it. Narrowing down the set to identify the most likely causal variants is known 
as ‘fine mapping’.  
A GWAS’s power to detect an association between a variant and a phenotype 
depends on four things – the LD between the assessed variant and the causal SNP, 
the size of the effect, the frequency of the allele tested and the size of the sample. 
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Effect size and allele rarity are essentially fixed (within a certain population, though 
both may vary between populations), so the easiest way to increase the power of a 
GWAS is to recruit more individuals.  
The second way to increase the ability of a GWAS to detect associations is to increase 
the number of markers tested across the genome. This increases the chances that a 
marker in high LD with the true causal SNP will be tested (or that the true casual SNP 
will be included). Many studies are turning to whole-genome sequencing to obtain 
denser information, but this remains expensive, limiting sample size, though it does 
have the advantage of allowing de novo mutations to be included in the GWAS. Most 
studies have historically used comparatively cheap genotyping ‘chip’ arrays that give 
the genotype at a pre-defined set of several hundred thousand SNPs. One could 
obtain denser marker information by re-typing samples on newer, denser chips, but 
this is expensive in terms of both money and biological samples. Instead, it is possible 
to use information about LD structure in the population of interest to statistically infer 
the genotype at a large number of untyped markers, a process known as genotype 
imputation. With a sufficiently dense reference panel, it is possible to impute a 
population genotyped with a few hundred thousand SNPs to as many as 40 million 
variants with a high degree of accuracy. This has the added benefit of allowing studies 
genotyped on a range of different arrays to be imputed to the same set of SNPs for 
meta-analysis. Almost all current GWAS studies are run using imputed genotype data. 
 GWAS of serum urate 
Over the last decade GWAS have become a major component of statistical genetics. 
Uric acid has been studied in GWAS since the field’s inception.  The detection of a 
strong association at the SLC2A9 locus66 and subsequent discovery that its encoded 
protein GLUT9 was in fact a urate transporter55,56 was an early example of the utility 
of the technique. GWAS have been performed on serum urate since 2007, advancing 
from single cohort studies genotyped on custom SNP arrays to consortium meta-
analyses using imputation panels to boost their power.  
A landmark meta-GWAS of serum urate was conducted on a discovery sample of 
110,347 European-ancestry individuals and replicated in a sample of 32,813 by the 
Global Urate Genetics Consortium (GUGC), published in 201374. Genotypes were 
imputed to version 2 of the HapMap reference panel203, and results were reported for 
around 2.5 million SNPs. This analysis identified 28 loci, of which 18 were novel. Since 
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then, there have been two major new imputation reference panels, first using the 1000 
Genomes Project147, and the second from the Haplotype Reference Consortium. The 
HRC panel is much denser than the HapMap2 panel – over 39 million SNPs after 
quality control filtering – allowing finer mapping of associated variants, and allows 
accurate imputation of variants as rare as 0.1% minor allele frequency (MAF)204.  
The most recent large GWAS of uric acid, at the time of writing, is in the Biobank 
Japan cohort. Serum urate was one of 58 quantitative traits regressed against 5.7 
million SNPs imputed to the 1000 Genomes Phase 1 version 3 panel in 109,029 
individuals of Japanese ancestry. The analysis identified 27 loci, of which 10 were 
novel77. This demonstrates that GWAS of comparable size using samples from 
different ethnic groups can detect quite different sets of signals, although in this case 
the use of a denser imputation panel makes it difficult to distinguish which new hits 
are due to ancestry. 
It has been shown that even on the same sample a newer, denser imputation panel 
can identify signals that are missed when compared to a less dense panel205. This 
can be through imputation of variants in regions previously missed, through closer 
tagging of causal variants or through more accurate imputation of SNPs. A new large-
scale serum urate consortium analysis has been orchestrated by the CKDGen 
consortium to take advantage of both the newer imputation panels and increasingly 
large number of cohorts willing to contribute data. My contribution to this project will 
be the subject of Chapter 4.  
However, large consortium analyses are slow to progress, due to the administrative 
and analytic burden of working with so many cohorts. I have access to uric acid data 
from several in-house population cohorts, including the CROATIA-Vis, CROATIA-
Korcula, ORCADES, VIKING and Generation Scotland: Scottish Family Health 
Study206 cohorts – combined this represents a sample of over 10,000 individuals, 
more than sufficient to identify new associations from the HRC imputation panel. 
Furthermore, all but Generation Scotland are isolate population cohorts – gathered 
from isolated populations where genetic drift can increase the frequency of rare 
variants to detectable levels. While the focus of the CKDGen meta-analysis is on 
identifying transethnic variants, SNPs which have detectable effects in individuals 
from any genetic background, a smaller meta-analysis enriched for isolate 
populations stands a chance of detecting signals driven by low frequency variants 
which may be overlooked in the larger analysis.  
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The aim of this chapter is to explore the potential of a meta-analysis of our own 
cohorts, imputed to the HRC reference panel, and establish whether I can detect any 




In addition to the CROATIA-Vis cohort described in Section 2.1.1.1, there are two 
other separate studies that are part of the 10,001 Dalmatians project122. CROATIA-
Korcula (Korcula) is another isolate population study, similar to Vis, but conducted on 
the island of Korčula. A total of 2,832 participants were recruited in three phases 
between 2007 and 2014. Uric acid measurements from collected serum aliquots are 
available for 2,673 participants.  
In both Vis and Korcula, serum urate was measured using the uricase UV photometry 
method in the Labor Centar Biochemical Laboratory, Zagreb Croatia.  
3.2.1.2 ORCADES 
The ORCADES cohort is described in Section 2.1.1.2. 1,964 participants had both 
serum urate measurements and genotype data. Serum urate was measured using 
the uricase/peroxidase method in the Balfour Hospital, Kirkwall, UK. 
3.2.1.3 VIKING 
The Viking Health Study (VIKING) is another Scottish isolate population, from the 
Shetland isles. Similar to ORCADES, though slightly less stringent, participants were 
recruited if they had at least two grandparents from the Shetland isles. A total of 2,105 
participants were recruited between 2013 and 2015. Measurements are available for 
2,090 individuals. Serum urate was measured using the uricase/peroxidase method 
in the Gilbert Bain Laboratory, Lerwick, Shetland. 
3.2.1.4 Generation Scotland 
The Generation Scotland: Scottish Family Health Study (Generation Scotland, or GS) 
is the largest cohort within the Generation Scotland project. It is a general population 
cohort with enrichment for families – recruitment was both through GPs and by directly 
contracting first degree relatives of people who had already been recruited. The cohort 
comprises 24,000 individuals, of which 20,032 have genotype data available206.  
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Uric acid was not included in the biochemical measures performed in this cohort. 
However, permission was obtained from 23,603 participants to link their GS data to 
their electronic health record (EHR) data held by the Scottish National Health Service 
(NHS Scotland), using their Community Health Index (CHI) number, detailed below. 
3.2.1.4.1 Generation Scotland Electronic Health Record Linkage 
Record linkage was performed by Dr Shona Kerr and Archie Campbell (University of 
Edinburgh), and I processed and analysed the data once records had been linked to 
the genetic data held by Generation Scotland. 
EHR linkage provided access to several databases of information, including the 
results of blood biochemistry tests. EHRs were first obtained from record linkage to 
11,125 Generation Scotland participants in the NHS Tayside region, where 21% of 
participants have had at least one test for uric acid. Subsequently, access was 
obtained for 8,264 individuals the NHS Greater Glasgow and Clyde region with 2,559 
separate measurements for uric acid. Data from the final region, NHS Aberdeen, was 
not available at the time this analysis was conducted. All serum urate measurements 
were performed in NHS laboratories according to NHS standard procedures, but no 
information is available on the specific assays used. 
In GS Tayside, 6,268 measures of uric acid were available for 2,356 individuals. 
Where multiple tests were available, the highest measurement was selected for 
analysis on the basis that this likely reflected the level prior to any intervention. 
Pregnant individuals were removed. Of these, 2,077 individuals were genotyped and 
also passed the necessary filtering to be included in the HRC-imputed data set (as 
described in Nagy et al.206)  and were used in the analysis. Age at measurement was 
calculated using reported date of birth and date of blood test. After applying the same 
criteria to measurements from GS Glasgow, 1,155 individuals were included in the 
GWAS.  
The results from the GS Tayside analysis were included in a descriptive paper of the 
cohort that was published separately206. These were analysed separately and 
compared to the results of a GWAS run only on the genotyped SNPs, to explore the 
potential of HRC imputation. The genotyped SNP GWAS was run entirely within the 
R GenABEL suite, as the number of SNPs was small enough to make this 
computationally efficient, while the imputed GWAS was run as described in Section 
3.2.3. 
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 Genotype imputation 
Genotyped SNPs were imputed to the HRC.r1-1 reference panel by Thibaud Boutin, 
using ShapeIt2 for data phasing and the Sanger Imputation Service server204 for 
imputation. Monogenic variants and variants with imputation quality of less than 0.4 
were filtered out, leaving 24,111,857 variants for analysis.  
 Regression analysis 
Analyses were run on each cohort individually, with the two Generation Scotland 
subsets treated as separate cohorts – this was a practical decision made because of 
the multi-stage data release. Three analyses were run per cohort – females-only, 
males-only and sex-combined. 
Phenotypes were adjusted for age and sex (in the sex-combined analysis only) and 
corrected for relatedness. This was performed with the GRAMMAR-Gamma 
method207, implemented in the polygenic function in GenABEL.  
GRAMMAR-Gamma is a computationally-efficient two-step method where 
phenotypes are adjusted for covariates and a genomic kinship matrix is fitted. The 
residuals from this are used as outcomes in the actual regression analysis. A 
correction factor is also calculated. In the second step, these residuals are regressed 
on genotypes, and the regression coefficients and P-values obtained are corrected 
using the GRAMMAR-Gamma correction factor, which adjusts for the biased effect 
estimates produced by the GRAMMAR models. The regression of the genotypes on 
the residuals was performed using RegScan v0.2208. 
3.2.3.1 Meta-analysis 
Meta-analysis was conducted in METAL (v2011-03-25)209 using the standard-error-
weighting method to combine effect sizes. Post-analysis results were filtered to retain 
only those SNPs with a Minor Allele Count (MAC) > 20 per cohort and which were 
present in at least two cohorts. The standard GWAS threshold of p-value ≤ 5×10-8 
was used to identify significant associations. Loci were defined as the region of 
±500kb around the SNP with the lowest P-value in the region – the ‘index SNP’ for 
that locus. Index SNPs with overlapping loci were merged and the SNP with the lowest 
P-value retained as the index SNP. Loci are named for the nearest gene to the index 
SNP, obtained from the Ensembl Variant Effect Predictor (VEP)40. Each locus was 
checked against the summary statistics from the 2013 GUGC meta-analysis from 
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Köttgen et al.74. Any locus which contained one or more significant SNPs in the GUGC 
meta-analysis was considered to have been identified in that analysis, although the 
name of the region was not always the same.  
Heterogeneity across analyses was assessed using the I2 statistic calculated by 
METAL, which represents the percentage of variation across studies that is due to 
heterogeneity rather than chance. 
 Conditional analysis 
To investigate an unusual signal on chromosome 11 (see Results), a conditional 
analysis was run on the SNP with the lowest P-value in the region, to check whether 
there were multiple independent signals. This was performed as above, with the only 
change being that the genotype of the top SNP was included as an additional 
covariate. Because this analysis was performed before the full meta-analysis was 
finalised, it did not include the GS Glasgow data, as it was not available at the time, 
and additionally used a reduced dataset of approximately 950 individuals from 
Korcula.  
3.3 Results 
 Cohort summary information 
Summary statistics for the cohorts included in the meta-analysis are given in Table 
15. All cohorts are similar in terms of being slightly biased towards females, and the 
mean serum urate levels are comparable. Standard deviations are slightly higher in 
the EHR-derived measurements in GS, which could be driven by the selection of the 
highest measure when multiple values were available for one person. It could also be 
due to more people being on urate-lowering medication.  
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Table 15 – Per-cohort summary statistics  
   Age 
Serum urate 
(mg/dL) 
Cohort N Female (%) Mean SD Mean SD 
Vis 948 58% 56.17 15.52 5.22 1.59 
Korcula 2,683 64% 53.96 15.85 4.94 1.35 
ORCADES 2,073 61% 53.22 15.29 4.91 1.19 
VIKING 2,093 60% 49.89 15.21 5.10 1.20 
GS Tayside 2,077 61% 50.59 15.09 5.76 1.85 
GS Glasgow 1,155 58% 54.73 14.62 5.75 1.89 
  GS Electronic Health Records 
3.3.2.1 Distribution of phenotype 
The distribution of uric acid measurements in the GS EHR cohorts is compared to the 
combined cohorts measured at baseline in Figure 22. While the mean and standard 
deviation for these cohorts are higher than the others, and the distribution has a longer 
upper tail, this is to be expected, as the highest measure was always selected for any 
individual with more than one measurement available. Additionally, because the 
measurements are obtained from NHS blood tests, the subset of individuals with 
serum urate measured may be enriched for people with a medical problem. Rank 
transformation to normality would eliminate this but could also remove genuine 
biological associations enriched in the GS sub-cohorts that are driving high serum 
urate levels, so I decided to analyse the data untransformed.  The means remain 
within the normal range of serum urate levels in healthy humans. 
118 
 
Figure 22 - Distribution of serum urate measurements in GS EHR records compared 
to all cohorts with directly-measured serum urate. 
 
3.3.2.2 GS Tayside EHR GWAS 
The results of the GS Tayside EHR GWAS are shown in Figure 23. The strongest 
peak is in the SLC2A9 region, which encodes the well-known urate transporter 
GLUT9. This association is the strongest known GWAS hit for serum urate and serves 
as a good positive control for the EHR-derived serum urate phenotype. Additional 
genome-wide significant signals were detected at three additional loci, none of which 
have been previously reported. The index variants (the SNPs with the lowest P-values 
within a ±500kb window) for these regions are shown in Table 16.  
All three novel index SNPs are rare (MAF < 1%) and are present only in the imputed 
GWAS as they were not directly genotyped. They all have large effects compared to 
the SLC2A9 lead SNP but also much larger standard errors due to their rarity (at the 
limit of our cut-off of MAC > 20). 
These results were published in Nagy et al. 2017206 along with several other 
biochemical and anthropometric traits. The purpose of this paper was to showcase 
the cohort and the value of the new, denser imputation possible with the HRC panel. 
The serum urate results additionally highlight that the value of the EHR linkage for 
normal quantitative trait GWAS, showing well that measurements taken for clinical 
purposes, replicate results from more traditionally measured cohorts. 
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Figure 23 - Miami plot of GS Tayside uric acid results 
The top panel shows the results using SNPs imputed to the HRC reference panel, 
while the bottom panel shows only directly genotyped SNPs. Genome-wide 
significance is indicated by the dark grey dashed line and the suggestive threshold 
by the light grey. Labels are the closest gene to the top SNP. SNPs with P-value 
>0.01 are not shown for clarity. (This figure is published in Nagy et al. 2017206.) 
 
Table 16 – Genome-wide significant index SNPs from the GS Tayside serum urate 
GWAS. 
SNP MAF Effect Std. Err. P-value Gene 
Imputation 
Quality 
rs6449213 0.1652 0.592 0.070 1.93 x 10-17 SLC2A9 1.00 
rs75869162 0.0054 2.245 0.397 1.57 x 10-08 FAM134B 0.80 




rs187171029 0.0060 1.999 0.355 1.84 x 10-08 ZNF160 0.91 
 
 Meta-analysis 
The sex-combined meta-analysis included a total of 10,908 individuals, and 6,622 and 
4286 in the female and male analysis respectively. The results of these are plotted in 
Figure 24. The index SNPs and details of the loci are reported in Table 17. 
The strongest association was, as expected, with SLC2A9. ABCG2 was detected in 
sex-combined and males but not in females, despite the larger sample size. This is in 
agreement with the known stronger effect in males than in females at this locus.  
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Six loci were identified in the sex-combined analysis, of which two were not reported 
in the GUGC 2013 paper despite the sample size being considerably smaller in this 
analysis. Four were identified in the female-specific analysis, three of which were not 
in the GUGC results, and four in the male-specific analysis, of which one was not in 
the GUGC results. 
All the new loci are driven by rare index SNPs (MAF < 1%) with the exception of 
rs139498948 at SYT1 in males, which is still uncommon at MAF = 1.1%. None of 
these SNPs are present in all six cohorts, and many of the loci show high 
heterogeneity (I2 > 50%). OR52I1 and CDC42BPB in females and SYT1 in males are 
below this threshold.  
Forest plots for the index SNPs at these loci are shown in Figure 25, as well as the 
index SNP for FCHSD2, which has an I2 value of 51.6%. These show that the signal 
in at rs573624409 in the FCHSD2 locus seen in the in sex-combined analysis is only 
significant in the ORCADES cohort, though the direction of effect agrees across all 
cohorts. The signal at rs1876025 in OR25I1 in females is significant in Korcula and 
VIKING but may be partially driven by an implausibly strong effect in GS Glasgow with 
a very large standard error. Also in females, rs576082236 in CDC42BPB shows a 
consistent, significant signal between VIKING and Vis, but non-significant effects in 
the opposite direction in the two GS cohorts. In males, rs139498948 at SYT1 has 
quite high heterogeneity, but the direction of effect appears to be consistent across 
studies. 
None of the index variants in the novel female-specific loci were significant even at a 
nominal level (P < 0.05) in males, but the index variant in SYT1 was nominally 
significant in females (Effect: 0.466, Std. Err:0.165, P = 0.00472). 
None of the three index variants from the GS Tayside analysis reach genome-wide 
significance in the meta-analysis, but two are significant at a lookup level (p < 0. 05 / 
3) and the third is nominally significant (Table 18). Effect directions match in all three 
cases, although the size of the effect is considerably smaller. However, in all three 
cases, heterogeneity is very high (I2 > 85%) suggesting these loci may not be reliable. 
Forest plots of the effect sizes from each cohort (Figure 26) confirm that the signals 
in the meta-analysis appear to be driven in large part by GS Tayside. In the case of 
rs141208451, ORCADES has a similar effect, but this falls in the unusual region on 
Chromosome 11 described below. 
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A wide area of significant SNPs with overlapping loci was identified in on 
Chromosome 11. This encompassed, amongst others, the known urate loci 
SLC22A11, SLC22A12 and NRXN2. To understand this unusual pattern, results for 
this chromosome were plotted separately for each cohort in Figure 27. The strong 
signals seen in the meta-analysis appear to be being driven by a wide region of 
associations in the ORCADES cohort. This region is unusual in that it not only spans 
almost 10Mb but also crosses the centromere. There is also a signal in the GS 
Tayside sample, this is the RP11-430H10.4 locus reported in Section 3.3.2.2. 
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Figure 24 - Manhattan plots of uric acid meta-GWAS. 
Labels are index SNPs, defined as the SNP with the lowest p-value in a window of ±500kb. Labels are the gene symbol of the closest gene, identified 
with the Ensembl VEP. Y-axes are truncated at 20 for clarity – SLC2A9 index SNP is consequently not shown on the Sex-Combined and Female 
analyses. Dark grey dashed line is the genome-wide significance threshold, light grey dashed line is the suggestive significant threshold. 
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Table 17 – Index SNPs from the sex-combined and sex-separate meta-analyses. 
In All, the COX8A locus contains 9 index SNPs with overlapping regions from 11:63,032,537 – 11:68,562,669, including one mapped to SLC22A12. In Males, 
the PACS1 locus contains 6 index SNPs with overlapping regions from 11:64,359,252 to 11: 67,846,680, also including one mapped to SLC22A12. Loci not 
reported in Köttgen et al. 2013 are highlighted in gold. Frequency of A1 is given for the meta-analysis population. 
 
 
 Index SNP 
rsID 
Chr. Position Locus 
SNPs in 
locus 












rs3775947 4 9,995,240 SLC2A9 1,194 T C 10,907 0.777 0.223 0.376 0.020 7.20E-81 6 19.80 Yes 
rs1481012 4 89,039,082 ABCG2 46 A G 10,907 0.897 0.103 -0.211 0.028 3.39E-14 6 54.60 Yes 
rs577353818 4 190,587,150 
RP11-
462G22.1 
1 T C 5,322 0.998 0.002 -2.488 0.454 4.32E-08 3 85.80 No 
rs13182742 5 72,425,458 TMEM171 1 T C 10,907 0.746 0.254 0.111 0.020 3.46E-08 6 0.00 Yes 
rs542534688 11 63,747,858 COX8A 27 T C 8,234 0.008 0.008 -1.031 0.132 6.53E-15 5 0.00 Yes 
rs573624409 11 72,799,547 FCHSD2 2 A G 7,286 0.994 0.006 0.895 0.160 2.34E-08 4 51.60 No 






 rs9994216 4 9,984,541 SLC2A9 1,120 T G 6,622 0.778 0.222 0.408 0.024 1.22E-63 6 52.90 Yes 
rs112029032 8 43,054,647 HGSNAT 1 A G 3,735 0.005 0.005 1.830 0.327 2.14E-08 4 72.00 No 
rs1876025 11 4,615,987 OR52I1 1 A C 4,886 0.998 0.002 -1.758 0.303 6.33E-09 4 0.00 No 
rs576082236 14 103,468,041 CDC42BPB 1 A G 3,735 0.003 0.003 3.938 0.681 7.35E-09 4 11.40 No 





rs3775947 4 9,995,240 SLC2A9 179 T C 4,286 0.774 0.226 0.308 0.034 1.57E-19 6 0.00 Yes 
rs3109823 4 89,064,602 ABCG2 10 T C 4,286 0.720 0.280 0.182 0.032 1.13E-08 6 0.00 Yes 
rs185509475 11 65,943,116 PACS1 14 T C 2,430 0.010 0.010 -1.827 0.287 1.87E-10 3 0.00 Yes 
rs139498948 12 79,289,619 SYT1 1 A G 2,911 0.011 0.011 1.184 0.214 2.97E-08 4 47.60 No 
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Figure 25 - Forest plots of novel index SNPs with I2 < 60%. 
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Table 18 – Lookup of GS Tayside novel loci in meta-analysis results. 
rsID Chr. Pos. Locus EA/NEA N Freq. A1 Effect Std. Err. P-value I2 (%) 
rs75869162 5 16,617,922 FAM134B A/G 7,286 0.004 0.419 0.181 0.02079 89.4 
rs141208451 11 45,538,920 RP11-430H10.4 A/G 7,286 0.008 0.429 0.150 0.00434 91.3 
rs187171029 19 53,599,256 ZNF160 T/A 7,286 0.007 0.488 0.140 0.00048 87.3 
 




Figure 27 – Per-cohort Chromosome 11 Manhattan plots. 
Only SNPs with P < 0.001 and MAC > 10 are shown. Dark grey dashed line is the genome-
wide significance threshold, light grey dashed line is the suggestive significant threshold. 
The centromere is delimited by the red lines. 
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 Conditional analysis 
The SNP with the lowest p-value on Chromosome 11 was rs542534688 in the COX8A 
locus (Table 17). Conditional analysis on this SNP was run in the ORCADES cohort, 
which removed all significant signals on Chromosome 11 (Figure 28A).  
Conditional analyses on rs542534688 were also run in Vis, ORCADES and GS-
Tayside cohorts along with a subset of the Korcula cohort. These were meta-analysed 
for a total of 8,164 individuals, which also showed no signals on Chromosome 11 
(Figure 28B). This suggests that broad signal identified in the meta-analysis is 




Figure 28 – Manhattan plots for chromosome 11 of conditional analysis on 
rs542534688. 
Top panel: in the ORCADES cohort alone with no conditional analysis; middle panel: in 
ORCADES conditioned on rs542534688; bottom panel: in a conditional meta-analysis 
of 8,164 individuals. Only SNPs with P-value < 0.001 and MAF > 0.001 are shown. Red 




 GS Tayside EHR linkage 
The results of the GS Tayside GWAS demonstrate the value of health record linage 
for biobanks. For the minimal cost of an access fee, and a small amount of data 
processing time, we have obtained an additional phenotype for a fraction of the cost 
of more traditional recall of participants. The results of the GWAS replicate the 
expected hits for a cohort of this size, addressing possible concerns that the subset 
of the population with blood biochemistry data available will have abnormal 
measurements due to illness. I also identified loci which had not been previously 
reported, though these loci showed high heterogeneity in the meta-analysis and may 
be driven largely by the GS Tayside sub-cohort alone. 
Serum uric acid is only one of a large number of phenotypes that are available through 
the clinical test results, which include several which are not available in many 
population cohorts. There is also the potential for time-series data, which was not 
explored here. Many individuals have multiple blood tests over time, which if sample 
sizes were sufficiently large and suitable controls could be identified, could be used 
to assess the effects of medication or treatment. The UK Biobank, an even larger 
cohort than GS at over 500,000 individuals, has been designed with record linkage in 
mind – though uric acid is unfortunately not available (as yet) either directly or through 
health records. Over time, as the participants age, it should yield sufficiently large 
numbers of individuals with health issues to investigate most diseases that are 
common in the UK without the need to design specific cohorts – and crucially, with 
information about individuals before they developed their disease. EHR studies are 
unlikely to – and should not – replace population cohorts entirely, which assess 
phenotypes in a standardised and high-quality manner, and include healthy 
individuals rather than those who have sought medical care. Rather they will provide 
an increasingly valuable source of additional information on the natural history of 
diseases. 
 Serum urate meta-analysis 
This meta-analysis demonstrates the value of a denser and more accurate imputation 
panel for discovery of variants associated with serum urate levels. The most recently-
published large-scale meta-analysis, Köttgen et al. (2013), was performed on version 
2 of the HapMap imputation panel203, which covers approximately 2.5 million SNPs, 
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most of which have a MAF over 5%. By contrast, the meta-analysis performed here 
on genotypes imputed to the HRC.r1-1 panel included nearly 22 million SNPs after 
filtering for imputation quality. The imputation accuracy of rare SNPs is much higher, 
allowing the use of much lower filters for minor allele frequency – here a cut-off of 
MAF > 0.001 was used, corresponding to approximately 20 copies of the minor allele 
across over 10,000 individuals. The improved performance of the HRC imputation 
panel has been documented before, but at the time of analysis, this meta-analysis 
was the first time that uric acid had been regressed on HRC-imputed genotypes.  
The strongest signals are unsurprisingly from the known and well-characterised 
serum urate loci SLC2A9 and ABCG2, as well as SLC22A11 and SLC22A12. 
However, the fact that a locus has previously been reported does not mean that its 
detection is not noteworthy – in particular, the locus at COX8A is interesting. This 
locus was identified in Köttgen 2013 with a sample size of over 140,000 individuals, 
but the earlier publication by Kolz et al. 2009171 (imputed to the HapMap version 1 
imputation panel) did not detect any signal in the region despite a sample size of over 
28,000, nearly three times the size of this study – a sample that included the Vis and 
ORCADES cohorts. Although the signal in my meta-analysis is only just borderline 
significant, it showcases the value of a denser imputation panel. Even though the 
sample size was relatively small, the association with COX8A was picked up where 
previous panels have missed it. This may be because the causal SNP linking the 
locus to serum urate levels is in higher LD with a SNP on the HRC imputation panel 
– or even present on the panel – leading to a less noisy relationship between genotype 
and phenotype, which can be detected with a smaller sample. 
The COX8A locus encompasses the broad signal seen on Chromosome 11, which 
appears to be driven primarily by the ORCADES cohort. There is some evidence of a 
signal in this region in GS Tayside at RP11-430H10.4, on the other side of the 
centromere from SLC2A9, but this much narrower signal does not look unusual for a 
GWAS. The pattern in ORCADES could be caused by a pericentromeric inversion in 
a few related individuals in the cohort, increasing the LD between all SNPs in the 
inversion. A serum urate-raising variant in SLC22A11 or SLC22A12 in these 
individuals would result in associations with serum urate levels being detected with 
any SNP associated with the inversion haplotype. Further investigation of this signal 
will soon be possible once sequencing data is available in the ORCADES cohort. The 
first step will be to check if the variants are correctly imputed. If the signal appears to 
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be real, it may be possible to identify structural variants in the region that might explain 
the unusual signal. 
RP11-462G22.1, also known as LINC01262, is a long non-coding RNA (lncRNA) on 
Chromosome 4. The functions of lncRNAs are often not well explored, but transcript 
levels of this particular lncRNA have been reported to be increased in PD patients, in 
both RNA-seq analysis in leukocytes and in RT-PCR in tissue from the substantia 
nigra, one of the relevant brain tissues in PD. Serum urate levels are reduced in the 
substantia nigra in PD patients211, and it has been proposed as a biomarker for both 
risk and progression of the disease212. The association detected here is a large serum 
urate-reducing effect from the major allele, which is common (EAF = 99.8%). It must 
be noted that this signal is not highly significant, and GWAS hits with borderline 
significance and low minor allele frequency should always be treated with much 
caution. The biological connection is compelling, but could easily be coincidence, 
particularly as uric acid is a prolific phenotype which is linked to a large number of 
different pathways. Unfortunately, the GTEx database reports no eQTLs for RP11-
462G22.1, making it difficult to establish whether the SNP identified is also an eQTL 
for the lncRNA.   
FCHSD2 encodes FCH and double SH3 domains protein 2. This gene has been 
associated with systemic lupus erythematosus213, an autoimmune disease associated 
with elevated serum urate levels in patients with normal renal function214. The locus 
has also been associated with inflammatory bowel disease in a Japanese 
population215. 
Three signals were unique to females. HGSNAT encodes Heparan-Alpha-
Glucosaminide N-Acetyltransferase, a lysosomal enzyme involved in the degradation 
of heparin sulphate. Mutations in this gene lead to Sanfilippo syndrome type C, a rare 
autosomal recessive condition that has no known treatment216,217. Symptoms include 
neurodegeneration, which account for the possible link to uric acid. The gene has also 
been linked to retinitis pigmentosa218. The index SNP, rs112029032, is a missense 
variant, but is only reported in Phenoscanner to be suggestively associated with “Self-
reported bowel or intestinal obstruction” in the UK Biobank140. The estimated impact 
of the mutant allele is inconsistent, with some metrics suggesting it is tolerated and 
others suggesting it is deleterious. The non-ancestral A allele appears to have a 
serum urate-increasing effect in women only. Purely speculatively, this could suggest 
serum urate is increased in females (who have lower serum urate levels) in response 
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to an increased risk of neurodegeneration, rather than the SNP lowering serum urate 
levels and leading to neurodegeneration. However, until the deleteriousness of the 
SNP is established, this is impossible to confirm. 
CDC42BPB encodes CDC42 Binding Protein Kinase Beta. This GTPase plays a role 
in cytoskeletal remodelling in cell growth, and has been shown to phosphorylate non-
muscle myosin light chain in rat219. I have not been able to find any obvious connection 
to serum urate, save the somewhat tenuous link that insertions of introns of 
CDC42BPB into other genes has been linked to ankylosing spondylitis220, a chronic 
inflammatory arthritis. Low levels of serum urate have been suggested to be linked to 
risk of low BMD in patients with this disease221.  
OR52I1 encodes Olfactory Receptor Family 52 Subfamily I Member 1. The index SNP 
is a missense variant, with consensus on Enseml from SIFT, PolyPhen and Mutation 
Assessor scores that it is likely deleterious to function. It has no associated 
phenotypes in Phenoscanner. OR52I1 is under-expressed in  substantia nigra in PD 
patients222; as mentioned above, uric acid is also reduced in this tissue in PD. 
 The only locus uniquely identified in males was SYT1, which was also nominally 
significant in females and consistent in direction of effect. The gene encodes 
Synaptotagmin 1, a membrane-anchored calcium sensor that plays a key in 
neurotransmitter release at the synapse223. SYT1 is highly expressed in the brain and 
central nervous system. A GWAS of serum creatinine levels (which included 
ORCADES and Vis in its discovery sample and Korcula in its replication) identified 
variants in the SYT1 gene, and the authors suggested that its expression in renal 
podocytes suggested it may be involved in regulation of glomerular activity224. If this 
is the case, it could explain its association with serum urate. 
The downstream analyses on the results of this meta-analysis are relatively basic, 
limited to closest-gene annotation of index SNPs defined. This is not uncommon for 
publications within the GWAS field, and was appropriate for this analysis, the purpose 
of which was to quickly query our in-house data for new signals present in the HRC-
imputed data. However, many cases have shown that the closest gene is not always 
the gene of interest. The following chapter will detail my contributions to the CKDGen 
Round IV analyses of uric acid and gout, which will include more sophisticated 
analyses of a much larger dataset.  
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 CKDGen Consortium meta-
analysis of serum urate 
4.1 Background 
 GWAS consortia 
Early GWAS efforts used small samples and could therefore identify only strong 
genetic associations with their traits, with SLC2A9 being the quintessential example 
of success for serum urate. However, as it became apparent that increasingly large 
sample sizes were successfully returning more associations, of smaller effect 
magnitudes, in a manner expected under a highly polygenic model of complex traits, 
these individual small cohorts were no longer analysed on their own.  
Collecting larger and larger cohorts would require a long time and large investment, 
though several such investments were made, such as the UK Biobank and the Million 
Veteran Program – long term projects which would take years to reach fruition. In the 
first instance, meta-analysis allowed multiple groups to combine their results without 
needing to share sensitive personal data.  Early collaborations evolved into 
‘consortia’, semi-formal organisations centred around particular groups of traits which 
any cohort with the correct phenotypes was invited to join.  
The general approach of a GWAS consortium analysis is a small group of lead 
analysts, often comprising a mix of senior researchers who guide the project and early 
career researchers who do most of the analysis. This small group will identify a 
research question and design an analysis plan that is distributed to collaborating 
cohorts. This details the exact analyses to be performed to minimise the heterogeneity 
in analysis results. ‘Study-level’ analysts – analysts affiliated with each cohort who 
can access individual level data – will perform the analyses according to the analysis 
plan, and results are returned to a central location for quality control (QC) and meta-
analysis. The level of involvement for each study is typically quite low, as the bulk of 
the analysis is typically performed by the meta-analysts.  
Today, years into the ‘GWAS era’, most consortia are mature, with established 
working practices and frequent in-person meetings. As there is only a finite number 
of cohorts with any given phenotype, some, such as GIANT and CHARGE have 
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become ‘mega-consortia’, with almost every cohort study available involved in their 
analyses.  
  The CKDGen consortium 
The Köttgen et al 2013 paper previously referred to several times in this thesis was 
the work of the Global Urate Genetics Consortium (GUGC), and at >140,000 
individuals, still represents the largest GWAS of uric acid to date – though not the 
most recent, as the Biobank Japan recently published results from their own cohort 
with > 109,000 individuals and identified several new loci. This will have been in part 
due to the different ancestry of the cohort (East Asian compared to European) and 
also due to the use of a denser imputation panel (1000 Genomes phase 1 version 3 
compared to the much older and smaller HapMap version 2). 
Due to considerable overlap between research interests and membership, the GUGC 
has been incorporated into the existing CKDGen consortium, which focuses on traits 
related to kidney function and disease. Serum urate and gout are new additions for 
their ‘round IV’ analyses – the fourth large set of meta-GWAS run by the consortium. 
This round aims to be the largest and most efficient yet run, using HRC-imputed data 
where possible.  
 An analysis plan was released to collaborators in July 2016, and, shortly after this, I 
joined the analysis group to co-run the serum urate and gout meta-analyses. The 
project is nearing completion, with papers for eGFR and UACR (urinary albumin-to-
creatinine ratio) both submitted at the time of writing. My contribution to these projects 
was to run the study-level GWAS for our six cohorts (see Section 4.2.1.2) , and also 
sharing code I developed for the serum urate meta-analysis (for genetic risk scores 
and circos plot generation). At time of writing, our paper is under review at Nature 
Genetics. 
The analyses performed evolved over time as the results of each step shaped our 
priorities and new methods were identified or developed. Figure 29 is an overview of 
the workflow of the serum urate analyses as it appears in the final paper. My 
contributions to each section are detailed in Section 4.2 (Methods).  
 A note on contributions 
The collaborative nature of a consortium meta-analysis means that much of the work 
in this chapter has been done as part of a team, with different people contributing to 
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different stages.  In some places I have detailed work done by others to allow a 
complete explanation of later work. I have endeavoured to make it clear where my 
own contributions begin and end.  
The bulk of the statistical analysis on this project was performed by myself and 
Adrienne Tin (Johns Hopkins Bloomberg School of Public Health). At the time of 
writing, the writing group for our paper comprised myself, Adrienne Tin, Yong Li 
(University of Freiburg), Karsten Sieber (GlaxoSmithKline, Pennsylvania), Holger 
Kirsten (University of Leipzig), Matthias Wuttke (University of Freiburg), Mathias 
Gorski (University of Regensburg), Markus Scholz (University of Leipzig), Adriana 
Hung (Vanderbilt University), Alexander Teumer (University Medicine Greifswald), 
Cristian Pattaro (University of Lübeck), Veronique Vitart (University of Edinburgh) and 





Figure 29 - Overview of the CKDGen serum urate analysis workflow.  
Sex-specific and non-European ancestry specific meta-analyses are not shown here, as 
they did not feed directly into later analyses. 
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4.2 Methods 
 Study level analysis & QC 
The writing of the analysis plan and phenotype processing pipelines were completed 
before I joined the CKDGen consortium. I ran the study-level GWAS for our own 
cohorts, but I was not part of the study level quality control (QC) step. Details are 
included here for context.  
4.2.1.1 Phenotype preparation script 
Studies were recruited to the meta-analysis if they had genotype data imputed to the 
HRC v1.1 (preferred for studies of European ancestry) or 1000G phase 3 version 5 
(for studies of non-European ancestry), although those imputed to the 1000G phase 
1 version 3 panel were also included in some cases. Phenotypes were processed 
using an automated script written by Dr Matthias Wuttke and Dr Mathias Gorski that 
performed all necessary transformations and corrections to produce analysis-ready 
phenotypes, as well as diagnostic plots and statistics.  
4.2.1.2 Study-level GWAS 
My contribution to the study-level analysis was to prepare the phenotypes for the 
CROATIA-Vis, CROATIA-Korcula, CROATIA-Split, ORCADES, VIKING and 
Generation Scotland: Scottish Family Health Study cohorts and adapt the output of 
the phenotype generation script for our RegScan GWAS pipeline described in Section 
3.2.3, which included the necessary adjustment for relatedness for our cohorts. The 
summary statistics submitted to the CKDGen meta-analysis were not exactly the 
same as those analysed in Chapter 3 due to slightly different filtering criteria in the 
pre-regression stage but were broadly similar. CKD was defined in CKDGen as eGFR 
< 60 mL/min/1.73m2.  Our cohorts did not contribute to the binary phenotypes included 
due to low case numbers, and our HRC-imputed binary analysis pipeline not being 
implemented at the time.  
The CROATIA-Split study (Split) was not included in the Chapter 3 meta-analysis as 
it was only imputed to the 1000Gv1p3 panel at the time of analysis. Split is the third 
cohort in the CROATIA study includes 976 individuals from the city of Split on the 
Croatian mainland. Unlike Vis and Korcula, it is not an isolate population. 
138 
4.2.1.3 Quality Control 
Once study-level GWAS results had been returned to the CKDGen analysis group, 
QC was partially-automated using GWAtoolbox225 to check for distribution of allele 
frequencies, inflation of p-values, imputation quality and genotype completeness, all 
of which can be a sign that a study has not correctly run or filtered the analysis. Metrics 
were also compared across studies to identify outliers.  
 Meta-analysis 
Meta-analysis was performed by two analysts in parallel to minimise the possibility of 
human error affecting the results. Dr Adrienne Tin (Johns Hopkins Bloomberg School 
of Public Health) and I conducted the meta-analyses for serum uric acid, with the 
additional assistance of Zhi Yu (Johns Hopkins Bloomberg School of Public Health) 
for the meta-analyses of gout. We used a modified version of METAL (provided by 
the author) which outputted floating point values to six decimal places, a higher level 
of precision than is normally available. Meta-analyses were run on the entire 
combined sample (trans-ethnic), separately by sex (sex-specific) and separately by 
ancestry (ancestry-specific).  
4.2.2.1 Pre-analysis filtering 
Study-level results were pre-filtered before meta-analysis to include only biallelic 
SNPs with a MAC > 10 and an imputation quality score > 0.6 (the precise metric to 
define this varied depending on the imputation software used by each cohort, but they 
are sufficiently comparable that a consistent filter can be used).  
4.2.2.2 Genomic control 
Study-level p-values were corrected for inflation using the GC genomic control 
factor226. This optional adjustment is implemented within METAL.  
Genomic control is a commonly-used method within the GWAS community as a fast 
and reasonably effective way to correct inflation of p-values due to population 
structure. The underlying assumption is that most SNPs are not truly associated with 
the trait of interest, so the distribution of test statistics should follow a chi-squared 
distribution with a mean of 1, but population structure can lead to an inflation of the 
test statistics by a factor . This factor can be estimated as median of the 2 test 
statistics divided by 0.456. Dividing the 2 values for each SNP by this GC factor 
increases the p-values to compensate for inflation. 
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Criticisms have been made of the genomic control factor, suggesting both that it is 
anti-conservative227 and that it is overly conservative when estimated over large 
numbers of loci228. Studies often apply two levels of GC correction, first at the study 
level and then again on the meta-analysis results, though this too has been 
criticised229, and with a study of this size, inflation is expected from the true positive 
findings alone under a polygenic trait architecture. However, it remains a commonly-
used technique within the community, and its performance and limitations are well 
understood. Coupled with the study-specific corrections for relatedness and 
population structure implemented by the study analysts, who are familiar with the 
requirements of their cohorts (adjustment for PCs, for example or fitting a mixed model 
with a kinship matrix as I did with our own cohorts), we decided that  single genomic 
control (correction at the study level, but not at the meta-analysis level) was an 
appropriate method to use in this case. 
4.2.2.3 Post-analysis filtering 
Post-analysis filters were applied on a per-meta-analysis basis to exclude SNPs 
present in fewer than half the studies or with a combined MAC < 400. Ancestry-
specific meta-analyses were additionally filtered on the heterogeneity I2 statistic > 
95%, to exclude SNPs influenced by a small number of studies within that ancestry 
group. These filters were selected to reduce the number of single-SNP loci seen in 
the analysis results – in a sample of this size, a single significant SNP was considered 
by the analysis group to be likely a false positive.  
4.2.2.4 LD-score regression 
After analysis, GC was calculated on the meta-analysis results to check for inflation. 
LD-score regression was also used to distinguish between inflation of p-values due to 
polygenicity and inflation due to confounding149. This was calculated using the LDSC 
software package148,149 
Briefly, a SNP’s LD score is a measure of how much genetic variation is tagged by a 
SNP. Variants which are in LD with a causal variant will have higher test statistics. 
SNPs with high LD scores – SNPs that are in LD with a larger number of other SNPs 
– have a higher probability of being in LD with a causal SNP. Thus, inflation that 
correlates with LD scores is due to polygenicity – the trait being controlled by large 
numbers of SNPs with increasingly small effects. Inflation that is uncorrelated with LD 
score is due to confounding from population structure or relatedness. Regressing 
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GWAS 2 statistics on LD-score (hence the term LD-score regression) allows the 
contribution of confounding to inflation to be estimated. 
4.2.2.5 Locus definition 
Loci were defined with the same definition as used in Chapter 3. SNPs with the lowest 
p-values were defined as index SNPs and any significant SNPs (p-value < 5 x 10-8) 
within ±500kb assigned to the locus of that index SNP. This process was performed 
iteratively until all significant SNPs were assigned to loci. Overlapping loci were 
combined and the index SNP with the lower p-value used as the index SNP for the 
combined locus 
Ancestry-specific loci were defined as loci in which the index SNP did not fall within a 
locus identified in the transethnic meta-analysis. 
4.2.2.6 Sex-specific effect differences 
A two-sample t-test was used to compare the effects of SNPs between sexes. T 
statistics were calculated using the following equation: 
𝑇 =  
𝛽 −  𝛽
𝑆𝐸 + 𝑆𝐸
 
Where βF and βM are the regression coefficients for a SNP in females and males 
respectively, and SEF and SEM are the standard errors of the regression coefficient in 
females and males respectively. 
 Trans-ethnic meta-regression in MR-MEGA 
Heterogeneity in effect sizes between studies can be a sign that no true association 
between genotype and phenotype exists – this is one reason for running a meta-
analysis, as it allows spurious associations in one cohort to be identified as 
discrepancies. However, heterogeneity can also be real and in a transethnic meta-
analysis, can be correlated with ancestry, leading to a loss of power and inability to 
detect an effect that may be real. 
Ancestry-associated heterogeneity can arise because of varying LD patterns between 
ethnic groups. A SNP in high LD with a causal SNP in one population will have a lower 
p-value than the same SNP in another population where the LD between the SNPs is 
lower. In a sufficiently ethnically diverse sample, this effect can be used to fine-map 
the locus and identify the causal SNP. Heterogeneity can also be due to 
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environmental factors. A risk factor which modifies the effect of a SNP may have 
different exposures across populations. Unless this risk factor is explicitly accounted 
for in the model, it will increase heterogeneity in the effect and reduce the power to 
detect the association in the meta-analysis. Variation in imputation quality can also 
drive ancestry-associated heterogeneity. Most meta-analyses use imputation panels 
to impute all study populations to the same set of SNPs. The performance of the panel 
depends on how accurately it reflects the study population – a less well-matched 
panel will lead to lower imputation quality, which will tend to bias allelic effects 
downwards. 
To account for these problems, several software packages have been developed. We 
made use of MR-MEGA230 (Meta-Regression of Multi-Ethnic Genetic Association) 
from the Morris lab, an evolution of the method previously implemented in 
MANTRA231Similar to MANTRA, MR-MEGA uses a matrix of mean pairwise allele 
frequency differences to quantify genetic similarity between studies. This is 
constructed by taking the mean difference in allele frequency over all shared SNPs 
between every pair of studies. While MANTRA uses a computationally demanding 
Markov chain Monte Carlo implementation of a Bayesian method that fits genetic 
similarity between studies as a prior, MR-MEGA instead takes principal components 
of the same matrix of genetic similarity and includes them as covariates in a linear 
regression framework.  
MR-MEGA outputs an estimate of the effect of each SNP after adjusting for the 
ancestry principal components, as well as a p-value for this effect. Additionally, it 
provides p-values for ancestry-associated heterogeneity at the SNP (Panc-het) and for 
residual heterogeneity after ancestry has been corrected for (Pres-het). It also provides 
effect sizes for each of the ancestry principle components, allowing some 
interpretation of which groups are contributing to the heterogeneity.  
Our sample is not sufficiently ethnically diverse to make use of the fine-mapping 
potential of MR-MEGA, comprising mostly European samples, but accounting for 
heterogeneity may reveal additional associations that the more transethnic meta-
analysis in METAL lacked power to detect. Additionally, the MR-MEGA methodology 
is more sophisticated than simply including self-reported ancestry group as a 
covariate: it is able to distinguish between genetically distinct subgroups of cohorts 
which may share a self-reported ancestry group. For example, a Finnish population 
would be expected to be quite genetically distinct to an Iberian population.    
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The MR-MEGA trans-ethnic meta-regression analysis for the CKDGen project is 
entirely my own work, with the exception of the study-level QC which was shared with 
the main meta-analysis.   
4.2.3.1 Pre-analysis filtering 
The same study-specific filters were applied as used in the trans-ethnic meta-analysis 
(imputation quality > 0.6, MAC > 10). To reduce the influence of very large studies, 
an additional filter of MAF > 0.0025 was applied. This greatly reduced the amount of 
noise in the results driven by very rare SNPs that passed the MAC filter through the 
sheer size of the contributing study. 
4.2.3.2 Principal components 
Three PCs were fitted, as per the author’s recommendation, which proved sufficient 
to separate the cohorts into self-reported ancestry groups, as well as further 
separating isolate populations within groups, as shown in Figure 30. Due to 
restrictions of the software, SNPs had to be present in a minimum number of cohorts 
equal to or greater than the number of PCs plus three. Consequently, any SNPs that 
were present in five or fewer cohorts were excluded from this analysis. 
4.2.3.3 Post-analysis  
Results for MR-MEGA were reported both for the index SNPs identified in the 
transethnic meta-regression; these are included in our paper currently under 
preparation. MR-MEGA was also run genome-wide. As in the METAL meta-analysis, 
SNPs were filtered to remove any which were present in fewer than half the cohorts 
(N cohorts > 37) and assigned to loci as specified in Section 4.2.2.5. If an index SNP 
was within ±500kb of one of the 183 METAL index SNPs, it was considered to be the 





Figure 30 - Principal component plots from MR-MEGA 
Each point is one cohort. Point colour corresponds to ancestry reported by cohort, 
European (EA), African (AA), East Asian (EAS), Hispanic (HIS) or South Asian 
(SA). 
  Conditional Analysis in GCTA 
Conditional analysis for the CKDGen meta-analysis was performed by Adrienne Tin, 
but is described here because I made use of the results in downstream analyses. 
In GWAS, conditional analysis is a method of determining whether multiple signals 
are present within a region. In the purest and most straightforward sense, this 
constitutes including the genotype of the lead SNP in a region as a covariate in the 
regression model. If a signal is still detected in the region after accounting for the lead 
SNP, it is demonstrably independent of the conditioned SNP. This is the methodology 
used in Section 3.2.4.  
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While this method is theoretically straightforward, it is non-trivial to implement on the 
scale of a consortium meta-analysis. Each individual cohort in the meta-analysis must 
re-run the study-level analysis including the genotype of the SNP to be conditioned 
on, and then all subsequent steps of the meta-analysis must be re-performed, 
including QC - the burden of time and resources is not dissimilar to that required for 
the original meta-analysis, which can take months to organise, and this process would 
have to be repeated until every signal has been accounted for. While this is possible 
on a small scale where one analyst has access to all the individual level data, and 
there is only one region of interest, as with the analysis detailed in 3.2.4, it is a 
prohibitively time consuming and administratively complex process for a GWAS 
consortium. 
To address this problem, a method was developed by the Visscher lab that allowed 
an approximation to conditional analysis to be performed using only meta-analysis 
summary statistics – “approximate conditional and joint association analysis”232, 
implemented in GCTA as the ‘cojo-slct’ option233. This method requires a reference 
sample with individual-level genotype data from which estimated LD can be 
calculated.  
The method is a step-wise selection procedure based on p-values – in approximate 
terms, it uses LD structure in a reference population to generate a joint model of 
‘conditionally independent’ SNPs that together explain the variation in the phenotype, 
without needing access to the individual level phenotype data. The method iteratively 
adds the SNP with the lowest conditional p-value to the model until no more SNPs 
can be added that significantly improve the model fit.  
Because the LD structure of the reference population needs to reflect that of the meta-
analysis population, we were not able to perform conditional analysis on the trans-
ethnic results – no suitable reference population exists. Instead, conditional analysis 
was performed on the European sub-analysis, with the UK Biobank selected as the 
reference population from which to estimate LD. After filtering, 13,558 individuals 
were retained, and 16,969,363 randomly-selected SNPs used to calculate an LD 
reference panel.  
Index SNPs and loci were defined as per Section 4.2.2.5.  Neighbouring loci with 
correlated index SNPs (r2 ≥ 0.2) were combined into independent regions. GCTA was 
then used to identify independent SNPs within each region, using a threshold of r2 < 
0.01. For any region with more than one independent SNP, conditional analysis was 
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conducted using the ‘cojo-slct’ option in GCTA. These conditionally independent 
SNPs were used as input in several of the downstream analyses. 
 Genetic risk score and gout in UK Biobank 
To assess the link between our identified serum urate loci and gout, we investigated 
the relationship between a genetic risk score (GRS) for serum urate and gout status 
in the UK Biobank cohort75,234. This analysis was performed under UK Biobank 
Projects 19655 and 20272. 
The GRS was constructed using the conditionally-independent index SNPs identified 
in the EA ancestry-specific meta-analysis. The EA index SNPs were used rather than 
the transethnic firstly to most closely match the genetic background of the cohort, and 
secondly because the approximate conditional analysis in GCTA was only performed 
on the EA-ancestry results (see Section 4.2.4). 
The cohort was filtered using UK Biobank provided metadata to select only those with 
genetically defined ‘White British’ ancestry, remove related individuals with a kinship 
coefficient greater than 0.0313 and remove any cases of mismatch between self-
reported and genomically-inferred sex or sex chromosome aneuploidy. 
Gout status was primarily ascertained from self-report at initial clinic visit. Hospital 
admission records were also used to exclude individuals who developed gout after 
recruitment, using the ICD10 code that corresponds to gout (M10). This exclusion was 
done because the ‘age’ variable used in the model reflected the age of the participant 
at the time of clinic visit, not at the age at which they had gout. The final analysis 
dataset comprised 334,880 individuals, of whom 4,908 were gout cases. 
The GRS for each individual was calculated as the sum of the additive imputed 
dosages of the serum urate-increasing index SNP alleles (‘risk alleles’) weighted by 
the effect of each allele on serum urate levels as obtained from the EA-specific meta-
analysis (of which Biobank UK was not part).  
Once GRS had been calculated, the UK Biobank sample was divided into ten bins of 
equal width between the maximum and minimum GRS values. The lowest bin did not 
contain any gout cases, which made later analyses nonsensical, so it was merged 
with the second lowest. 
Using the bin with the largest number of individuals as the reference category, a 
logistic regression model was run regressing gout status on GRS bin, including age 
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and sex as covariates. This allowed calculation of each GRS bin odds ratios for gout, 
relative to that of the most common GRS. 
Additionally, the GRS was tested for its utility in the prediction of gout status. The 
dataset was divided into a 90% training sample and a 10% testing sample. Logistic 
regression models were run in the training set regressing gout status on GRS bin 
alone (the ‘genetic model’), on age and sex alone (the ‘demographic model’) and on 
GRS, age and sex together (the ‘combined model’). Each model was then used to 
predict gout status in the testing set, and the performance of the predictor assessed 
by comparing predicted to true gout status, using the area under the curve (AUC) in 
a receiver operating characteristic (ROC) curve. 
 DEPICT pathway analysis 
A meta-analysis of this size identifies a large number of significant loci, which are 
likely to have complex and biologically-meaningful relationships, for example through 
shared biological pathways or tissue expression. However, manual annotation is time-
consuming, so a variety of bioinformatic tools have been developed to aggregate data 
and automate some of the processing.  
We used DEPICT235 to annotate the results of the meta-analysis. This tool takes 
GWAS summary statistics as input and outputs a causal gene for each locus, as well 
as reporting pathways or tissue expression enriched in the results. 
I did not run the DEPICT software myself – this was done by Yong Li – but I performed 
the downstream processing of the pathway enrichment analysis, so the methodology 
is described here (DEPICT was additionally used to identify tissue expression 
enrichment, detailed in our paper, but I was not directly involved).  
The exact set of SNPs used as input is a decision left to the user, but the developers 
suggest two runs, one using independent genome-wide significant SNPs (P < 5 x 10-
8) and another using all independent SNPs with P < 10-5. The final results reported in 
our paper use all variants from the trans-ethnic meta-analysis with P < 10-5 as initial 
input. We used Plink v1.9236 to identify independent SNPs in this set using the ‘clump’ 
function, which aims to retain only one SNP from each LD block. LD blocks were 
defined based on r2 > 0.1 in the 1000 genomes phase 1 version 3 data. Summary 
statistics for these independent SNPs were used as input for DEPICT. 
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DEPICT uses input SNPs to generate a list of loci, including genes for consideration 
as potentially causal if they are within r2 > 0.5 of the lead SNP. Loci containing 
overlapping genes are merged into one locus. The programme then uses a ‘guilt-by-
association’ model to predict the most likely candidate from the genes in the loci, 
prioritising genes that have similar biological functions across loci. 
To do this, DEPICT integrates 14,461 existing gene sets, including manually curated 
pathways from KEGG237, Gene Ontology238 and REACTOME239, a database of 
protein-protein interactions240 and mouse knock-out phenotypes from the Mouse 
Genome Database241. Instead of assigning a binary classification for membership in 
a gene set, the authors instead created what they refer to as ‘reconstituted gene sets’ 
(RGS). Rather than a set including a specified number of genes, each RGS assigns 
a probabilistic membership value to all genes in the database. These probabilities are 
assigned based on similarities across gene co-expression data previously published 
by the developers242. The biological function of a gene is thus characterised by its 
probabilities of membership across all 14,461 RGSs. This step is pre-computed, and 
the database of RGSs is available for download with the software. 
To predict causal genes, DEPICT tests whether any of these RGSs are significantly 
enriched for genes in these loci. Candidate genes within loci are prioritised based on 
shared annotations with other loci - for example, if the ‘lipid metabolism’ pathway is 
enriched in the results, genes with a high probability of inclusion in that RGS are 
prioritised within their respective loci.  
As well as prioritising candidate genes, DEPICT outputs the results of the RGS 
enrichment analysis, to provide information on the pathways that appear to be 
enriched in the GWAS results. I used the output from this in the clustering described 
in Section 4.2.6.1. DEPICT also uses data from 37,427 microarrays to assess whether 
genes are highly expressed in any of 209 tissue and cell type annotations, the results 
of which are described further in our paper. 
4.2.6.1 Affinity Propagation Clustering 
DEPICT outputs a very large number of enriched gene sets – more than the number 
of significant loci to interpret in the first instance. This is in part due to overlap between 
the RGSs – each database may capture the same biological process separately. To 
reduce the dimensionality of the dataset, I used affinity propagation clustering (AP 
clustering)243 to group together RSGs containing overlapping sets of genes.  
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Affinity propagation clustering (AP clustering) is a clustering algorithm that aims to 
group together related datapoints and select a single ‘exemplar’ that best represents 
the points within the cluster. It does not require pre-specification of the number of 
clusters, making it ideally suited to this use case, where we have no prior information 
on the number of pathways to expect to be enriched. It does, however, require an 
‘input preference’ to be specified, which is the propensity of all data points to become 
an exemplar – this indirectly affects the number of clusters that are identified.  
I implemented AP clustering using the R package ‘APCluster’244. Reconstituted gene 
sets identified as significantly enriched in the meta-analysis results (FDR-corrected 
P-value < 0.01) were clustered based on the similarity of the genes they contained.  
DEPICT reports the top ten genes from the meta-analysis assigned to each gene set, 
along with a z-score representing the probability of that gene’s inclusion within the 
set. This information was converted into a matrix of genes by pathways, where each 
element contained a z-score. AP clustering was applied to the similarity matrix derived 
from this data using a tuning parameter of 0.5, as per the package defaults.  
To understand the relationships between the exemplars RGSs, the set of exemplars 
were then used to create a correlation matrix, calculated from Z-score of each gene 
within the exemplar gene sets. This matrix was converted into a network by taking all 
exemplar RGSs as vertices and all correlations > 0.2 as edges. The network was 
plotted in Cytoscape136. 
 FUMA gene function annotation 
FUMA is a web-based platform that integrates a variety of resources for annotation of 
GWAS results245. Like DEPICT, it aggregates information from a variety of databases, 
and its primary function is to take raw GWAS output, which can be as little as a list of 
RSIDs and P-values, and identifying likely causal genes (“SNP2GENE” function). 
Independent SNPs are assigned to genomic risk loci based on defined LD blocks. 
SNPs in these blocks are annotated for function consequences, based on gene 
function, deleteriousness score, potential regulatory function and chromatin state. 
Functionally-annotated SNPs are then assigned to genes based on their functional 
consequence on that gene – based on position relative to the gene, eQTL 
associations and chromatin interaction mapping. 
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It can then take this gene list and perform enrichment analyses for tissue expression, 
pathways and gene sets as well as eQTL lookups chromatin mapping 
(“GENE2FUNC”). It is similar to DEPICT in its aim to aggregate, but it does not 
introduce the additional complication of the reconstituted gene set method. 
Although FUMA is capable of assigning SNPs to genes, the SNP2GENE step is highly 
customisable, and properly investigating the appropriate parameters to use (for 
example whether to use only exonic SNPs for positional mapping, or which tissues to 
restrict eQTL mapping to) would have required more time than was available. Instead, 
I elected to use only the GENE2FUNC aspect of the FUMA tool on the list of 183 
genes identified from our transethnic meta-analysis. This does not provide an entirely 
fair comparison to DEPICT, as this list of genes is based on the closest gene to each 
SNP, but it did allow me to gain experience using another annotation tool, and the 
information on gene-set enrichment allows some comparison to DEPICT. The tool 
additionally reports tissue enrichment.  
 Genetic correlations 
The genetic correlation analyses described on the CKDGen serum urate paper 
currently under preparation were run by Yong Li for the sex-combined European-
ancestry meta-analysis. All 832 traits in LD-Hub were tested. 
In fact, prior to this, I been performing my own genetic correlation analyses on the 
published results of the Köttgen et al. (2013) meta-analysis using cross-trait LD-score 
regression on LDHub, as described in Section 2.3.7. In addition to performing my own 
updated genetic correlation analysis on the sex-combined results analysis, I 
performed additional LD-score regression on the results of the male and female 
European-ancestry meta-analysis. A two-sample t-test was used to test for significant 
differences in genetic correlation between sexes, with T statistics calculated with the 
equation below. 
𝑇 =  
𝑟 −  𝑟
𝑆𝐸 + 𝑆𝐸
 
Genetic correlations were calculated with all traits in the LDHub catalogue except 
those classified as ‘metabolites’ or those derived from the UK Biobank. These 
datasets do contain potentially informative phenotypes, but they are both large and 
contain many very similar phenotypes (for example, measurements for impedance for 
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multiple body parts in the UK Biobank) leading to a very large multiple testing penalty 
on significance for little immediate benefit. In total 128 traits were tested. 
4.3 Results 
 Summary of participants 
A summary of the sample sizes for the serum urate and gout meta-analyses is given 
in Table 19, broken down across the five cohort-reported ancestry groups – African 
ancestry (AA), European ancestry (EA), East Asian ancestry (EAS), Hispanic 
ancestry (HIS) and South Asian ancestry (SA). Mean serum urate across studies 
ranged from 4.1 mg/dl to 7.1 mg/dl. 
Table 19 – Sample sizes for serum urate and gout meta-analyses 
Ethnicity 
Serum urate  Gout 
N N cohorts  N total N cases N cohorts 
AA 33,671 7  3,271 282 2 
EA 288,649 60  739,330 12,643 17 
EAS 125,725 2  - - - 
HIS 608 1  - - - 
SA 9,037 4  6,548 253 1 
Total 457,675 74  749,149 13,178 20 
Women Total 172,102 66  68,265 438 1 
Men Total 174,111 69  84,734 712 1 
 
As is almost always the case in consortium GWAS, the largest and most diverse group 
was EA, with an order of magnitude more cohorts than any other group. We also have 
a large sample of EAS, but this is almost entirely composed of the Biobank Japan76 
cohort, which has already published a GWAS of uric acid, limiting our ability to detect 
new association in this ancestry group77. However, taken together, we have over 
169,000 non-European ancestry individuals in our analysis, around 37% of the 
sample. Our transethnic approach should identify signals which are universal across 
all populations 
 Transethnic meta-analysis 
Seventy-four studies were included in the primary uric acid trans-ethnic meta-
analysis, with 40,534,360 autosomal SNPs retained after study-level filtering. There 
was no evidence for confounding due to population stratification – the LD-score 
regression coefficient was 1.01 and λGC was 1.04, so no post-meta-analysis correction 
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of p-values was performed. After post-meta-analysis filtering, 8,249,849 SNPs were 
retained for downstream analysis. 
One hundred and eighty-three loci were identified containing at least one SNP with P-
value below the threshold for genome-wide significance (P < 5 x 10-8), spanning a 
region of maximum 1Mb around the index SNP. Of the 183 loci, 36 contained at least 
one SNP previously reported as genome-wide significant in a GWAS of serum 
urate51,66,74,77,246–249. The remainder were considered novel. The average absolute 
effect size was small (mean effect 0.04 mg/dL, SD 0.03), but sizes ranged from 0.017 
mg/dL for rs11940694 at the novel KLB locus to 0.28 mg/dL at rs3775947 at the well-
characterised SLC2A9 locus.  These results are plotted in Figure 31, in the blue 
Manhattan plot track. Index SNPs are fully detailed in Supplementary Table 4. Loci 
were identified in parallel by myself and Adrienne Tin, who also annotated the index 
SNPs with the name of the closest gene and prepared the original table from which 
mine is modified.   
The heritability and variance explained by these variants were calculated by Adrienne 
Tin. Together, all 183 index SNPs explained 7.7% of trait variance, compared to just 
5.3% when restricting to index SNPs in previously-reported loci. The heritability 
explained was calculated in the large ARIC study, and the index SNPs were found to 
explain 17% of the genetic heritability of serum urate. Index variants in the three major 
loci SLC2A9, ABCG2 and SLC22A12 alone explained 5%. 
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Figure 31 - Circos plot summarising 
the sex-combined trans-ethnic meta-
analysis results. 
Serum urate meta-analysis results 
are shown in the blue Manhattan 
plot track, gout results in green. The 
red lines denote the threshold for 
genome-wide significance.  
The track key describes each track 






 Ancestry-specific analyses 
4.3.3.1 European-ancestry 
In the EA-specific serum urate meta-analysis, 8,217,339 of the 24,830,632 autosomal 
SNPs analysed by METAL were retained for downstream analysis, with an LD-score 
regression intercept of 1.0, indicating no confounding due to population stratification. 
123 loci were identified in the EA analysis, of which five loci were not in the trans-
ethnic analysis.  
4.3.3.2 Non-European ancestry 
Ancestry-specific annotation was performed by Adrienne Tin. The results are outlined 
here to allow comparison to the MR-MEGA results. Five of the fourteen loci identified 
in the AA analysis were unique to that ancestry group, and seven of the 46 identified 
in EAS. These unique loci are detailed in Table 20. 
Table 20 – Ancestry-specific loci not identified in the transethnic meta-analysis. 
Ancestry SNP Gene Name 
EA rs2480712 SKI 
EA rs55781567 CHRNA5 
EA rs35396326 NECTIN2 
EA rs12037861 HLX-AS1 
EA rs98270 NIPAL1 
AA rs334 HBB 
AA rs7100851 HABP2 
AA rs10769187 PHF21A 
AA rs2306027 LRP4 
AA rs7114004 LOC101929497 
EAS rs117247077 KMT5B 
EAS rs78863347 CPT1A 
EAS rs74896528 SESN2 
EAS rs7645142 EIF5A2 
EAS rs60808706 KCNQ1 
EAS rs35612982 CDKAL1 
EAS rs703978 ZMIZ1 
 
 Trans-ethnic meta-regression in MR-MEGA 
4.3.4.1 Trans-ethnic index SNPs 
Most transethnic SNPs showed low heterogeneity, indicated by low I2 values from 
METAL (median 2%, interquartile range 0-14%). Fourteen of the 183 index SNPs 
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identified in the primary transethnic meta-analysis showed significant ancestry-
associated heterogeneity at a threshold of P < 0.000273 (0.05/183). These were in 
the SLC2A9, SLC22A12, CNIH2, CAPN1, HRASLS2, MACROD1, ABCG2, CLNK, 
AIP, SLC22A6, MYL2, CPT1C, INHBC and DEFB131A loci. These results are 
displayed on the Panc-het track in Figure 31, and detailed in full in Table 21. The most 
significant ancestry-associated heterogeneity was observed at the SLC2A9 locus for 
the index variant rs3775947 (Panc-het = 1.5 x 10-127). This was reflected in the by effect 
size differences across the different ancestry-specific analyses (0.34 mg/dL in EA, 
0.26 mg/dL in AA, 0.17 mg/dL in EAS, 0.41 mg/dL in HIS and 0.21 mg/dL in SA), and 
is consistent with known heterogeneity at this locus250.  
 
4.3.4.2 MR-MEGA-specific loci 
MR-MEGA analysis was run across whole genome and, after filtering, loci were 
identified from the SNP-phenotype association p-values. Nine loci were identified in 
the MR-MEGA analysis which did not contain an index SNP in the METAL analysis. 
These are detailed in Table 22. Of these, two were overlapping with the locus 
surrounding a METAL index SNP (i.e. the MR-MEGA and METAL index SNPs were 
within 1Mb of each other). These were the ALDH5A1 and KCNQ1, both of which were 
single-SNP loci in MR-MEGA. All loci except KCNQ1 and RP11-576N17.4 have 
significant ancestry heterogeneity, with Panc-het < 0.05/9. The strongest effect was at 
the TAPT1-AS1 locus, with an effect size of 1.481 mg/dL. This was also the most 
significant locus. The locus with the largest number of SNPs was SLC2A2 with 18, 
which encodes the GLUT2 glucose transporter, a glucose transporter from the same 
family as GLUT9. Table 23 shows the results for these SNPs in the ancestry-specific 
meta-analysis. 
The signals at KCNQ1 and ZMIZ identified in the EAS-specific meta-analysis were 
also picked up with the MR-MEGA method using the whole sample. None of the five 
EA-specific or the five AA-specific loci were identified in the MR-MEGA results.  
In the case of the AA-specific signal at rs334 at HBB (encoding the sickle cell allele) 
this is a consequence of post-analysis filtering on the number of cohorts. The index 
SNP is detected as significant by both METAL and MR-MEGA in the trans-ethnic 
analysis, but is present in only eight cohorts, leading to its exclusion from the results. 
This is not the case for the other ancestry-unique SNPs. Supplementary Table 5 
contains the unique MR-MEGA index SNPs with the cohort constraint relaxed. 
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Table 21 – METAL index SNPs with significant ancestry-associated heterogeneity (Panc-het < 0.05 / 183) 
rsID Novel? Chr. Position Gene Novel Function EA/NEA EAF Effect (mg/dL) SE p-value I2 (%) Panc-het Pres-het 
rs6820627  4 9,491,205 DEFB131A  upstream A/G 0.071 -0.100 0.011 4.66E-21 28.6 2.54E-02 3.20E-05 
rs3775947  4 9,995,240 SLC2A9  intron T/C 0.691 0.277 0.003 0.00E+00 90 1.10E-109 1.50E-127 
rs12504795 * 4 10,499,344 CLNK Y intron T/C 0.741 0.075 0.004 4.25E-101 51.4 2.74E-07 1.70E-18 
rs74904971  4 89,050,026 ABCG2  intron A/C 0.196 0.217 0.004 0.00E+00 73.7 1.58E-25 3.90E-25 
rs148838714 * 11 62,732,352 SLC22A6 Y intron A/G 0.066 -0.074 0.009 2.14E-16 46.6 8.48E-05 1.40E-09 
rs143825439 * 11 63,319,993 HRASLS2 Y near-gene-3 T/G 0.054 -0.224 0.012 1.23E-76 76.4 1.69E-17 4.80E-27 
rs1006207  11 63,849,812 MACROD1  intron T/C 0.563 -0.047 0.004 3.54E-41 64.7 4.72E-14 3.20E-26 
rs531763  11 64,352,063 SLC22A12  intergenic A/G 0.565 -0.116 0.004 1.58E-246 83.7 2.30E-55 1.50E-67 
rs34888828 * 11 64,968,104 CAPN1 Y intron A/G 0.110 -0.057 0.006 1.45E-23 75 6.91E-27 1.10E-49 
rs4073582  11 66,050,712 CNIH2  intron A/G 0.310 -0.041 0.004 5.41E-28 79.2 4.14E-37 1.00E-66 
rs11227805 * 11 67,246,757 AIP  upstream T/C 0.180 -0.027 0.005 8.72E-09 49.4 4.61E-06 4.00E-15 
rs73119306  12 57,826,982 INHBC  near-gene-5 A/G 0.786 0.071 0.004 7.45E-65 33.5 3.69E-03 6.80E-06 
rs17550549 * 12 111,357,471 MYL2 Y intron T/C 0.144 -0.035 0.005 5.18E-11 33.9 3.29E-03 4.60E-09 
rs62128132 * 19 50,217,955 CPT1C Y downstream T/C 0.967 -0.115 0.014 1.99E-15 72.7 7.42E-16 3.00E-07 
 
Table 22 – MR-MEGA loci which did not contain a METAL index SNP 
rsID Chr. Position Gene Function EA/NEA EAF N N cohorts N eth. N SNPs Effect SE P Panc-het Pres-het METAL Effect METAL I2 (%) 
rs3774046 3 170,737,003 SLC2A2 Intron A/G 0.840 457,616 74 5 18 0.050 0.048 1.84E-09 4.40E-04 0.161 0.0207 25 
rs697238 10 80,947,668 ZMIZ1 Intron T/G 0.386 456,290 73 5 5 -0.026 0.034 2.46E-09 1.37E-03 0.0291 -0.016 32.3 
rs17325213 4 11,955,802 TAPT1-AS1 Intergenic T/C 0.056 239,512 48 4 4 -1.481 0.258 3.59E-09 5.51E-08 0.378 -0.0301 42.4 
rs11601310 11 48,085,189 PTPRJ Intron A/G 0.236 443,108 69 5 1 -0.011 0.039 8.60E-09 3.40E-05 0.412 0.0179 22.8 
rs73728140 6 24,507,003 ALDH5A1 Intron A/G 0.954 445,653 69 5 1 0.064 0.056 1.03E-08 2.88E-09 0.514 -0.0073 32.3 
rs144074240 12 67,657,757 GGTA2P Downstream T/C 0.061 330,887 70 4 3 0.121 0.127 1.60E-08 1.33E-03 0.968 0.0385 0 
rs60808706 11 2,857,233 KCNQ1 Intron A/G 0.160 446,270 72 5 1 -0.013 0.055 1.67E-08 0.0586 0.753 0.0253 0 
rs1346144 4 79,625,361 RP11-576N17.4 Intergenic A/G 0.631 422,278 72 5 1 -0.186 0.052 2.24E-08 7.53E-03 0.893 -0.0172 0 




Table 23 – Lookups of MR-MEGA unique index SNPs in ethnic-specific meta-analyses. 
SNPs significant at a nominal threshold of P < 0.05 are highlighted in yellow. Genome-wide 
significant SNPs are highlighted in green. 
SNP Gene Eth. EA/NEA EAF Effect Std. Err. P-value N I2 
rs3774046  SLC2A2 
AA A/G 0.895 0.061 0.022 5.60E-03 33,671 0 
EA A/G 0.838 0.009 0.005 9.34E-02 288,575 12.8 
EAS A/G 0.822 0.044 0.008 1.42E-08 125,725 0 
SA A/G 0.890 0.011 0.032 7.32E-01 9,037 0 
rs697238 ZMIZ1 
AA T/G 0.426 -0.033 0.013 1.24E-02 33,670 20.3 
EA T/G 0.412 -0.008 0.004 3.01E-02 288,614 30.8 
EAS T/G 0.322 -0.032 0.006 2.09E-07 125,725 27.1 
SA T/G 0.368 -0.027 0.021 1.97E-01 9,037 0 
rs17325213  TAPT1-AS1 
AA T/C 0.017 -0.073 0.072 3.11E-01 28,882 48.4 
EA T/C 0.063 -0.023 0.010 1.74E-02 256,970 41.3 
EAS T/C 0.040 -0.046 0.067 4.91E-01 9,037 0 
rs11601310 PTPRJ 
AA A/G 0.816 0.074 0.017 6.55E-06 33,671 0 
EA A/G 0.199 0.024 0.005 7.70E-07 274,067 5.8 
EAS A/G 0.173 -0.007 0.008 3.69E-01 125,725 0 
SA A/G 0.125 -0.006 0.030 8.38E-01 9,037 0 
rs73728140 ALDH5A1 
AA A/G 0.719 -0.036 0.015 1.36E-02 33,670 0 
EA A/G 0.972 -0.032 0.012 7.26E-03 276,614 0 
EAS A/G 0.973 0.088 0.018 7.26E-07 125,725 0 
SA A/G 0.969 0.055 0.059 3.52E-01 9,037 0 
rs144074240 GGTA2P 
AA T/C 0.011 -0.138 0.066 3.62E-02 32,653 0 
EA T/C 0.069 0.038 0.008 9.95E-07 288,590 0 
SA T/C 0.055 0.147 0.045 1.13E-03 9,037 0 
rs60808706 KCNQ1 
AA A/G 0.197 0.012 0.017 4.98E-01 33,671 0 
EA A/G 0.057 0.010 0.009 2.48E-01 278,593 0 
EAS A/G 0.390 0.035 0.006 5.63E-09 125,725 67.9 
SA A/G 0.028 -0.091 0.071 2.01E-01 9,037 0 
rs1346144 RP11-576N17.4 
AA A/G 0.238 0.026 0.019 1.63E-01 33,670 0 
EA A/G 0.646 -0.016 0.004 1.22E-04 278,592 0 
EAS A/G 0.609 -0.022 0.006 1.60E-04 125,725 0 
SA A/G 0.538 -0.014 0.020 4.94E-01 9,037 0 
rs508926 RP5-1092A3.5 
AA A/G 0.507 -0.013 0.013 3.38E-01 33,670 0 
EA A/G 0.670 0.010 0.004 1.17E-02 278,591 15.5 
EAS A/G 0.888 0.049 0.010 2.13E-07 125,725 0 
SA A/G 0.760 -0.024 0.024 3.08E-01 9,037 0 
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 Sex-stratified analysis 
Four loci were detected in females that were not present in males or the sex-combined 
analysis – i.e., there was no significant SNP in either GWAS within a 1Mb window 
centred on the index SNP. These loci are detailed in Table 24. All are small loci (< 10 
SNPs) with P-values relatively close to the threshold for significance. They are not 
explicitly reported in the CKDGen paper, due to limited space. Of these SNPs, only 
rs75523587 was reported in PhenoScanner as being strongly associated with another 
trait, namely heel bone mineral density (BMD) in the UK Biobank (P = 6.47 x 10-16). 
The p-values for the formal test of effect size difference between sexes are displayed 
as in a Manhattan plot in Figure 32. Significant differences (Pdiff < 5x10-8) were 
identified for SNPs in SLC2A9 and ABCG2, both of which have been previously 
reported. Additional SNPs with suggestive differences are listed in Table 25.  
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Table 24 – Female-specific loci for serum urate. 






I2 (%) Known associations 
rs494889 1 234851020 C/T 
RP4-
781K5.7 
0.431 -0.028 0.0049 1.586E-08 1 0.0 - 
rs2588983 10 63566778 A/G 
RP11-
491H19.1 
0.1812 0.032 0.0058 3.749E-08 6 12.1  
rs75523587 10 134413583 T/A INPP5A 0.2107 0.033 0.0058 1.206E-08 2 0.0 Heel BMD, hypertension (UKBB) 




Figure 32 - Manhattan plot of the p-values for effect size differences between females and males. 
Blue horizontal line denotes suggestive significance (P = 10-5), red denotes genome-wide significance (P = 5 x 10-8). 
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Table 25 – SNPs with suggestive sex-effect differences (Pdiff < 10-5) 
Index SNP Chr. Position A1/A2 Locus Effect (male) Effect (female) SE (male) SE (female) Sex difference P-value 
rs358716 3 155,526,790 T/C AC104472.3 -0.019 0.015 0.006 0.005 7.32E-06 
rs17246501 4 9,985,710 A/C SLC2A9 0.083 0.234 0.005 0.004 0.00E+00 
rs3815493 4 15,512,390 A/G CC2D2A 0.023 -0.017 0.006 0.005 4.78E-07 
rs2199936 4 89,045,331 A/G ABCG2 -0.231 -0.166 0.007 0.006 3.06E-13 
rs7002838 8 27,758,391 C/G SCARA5 0.036 -0.036 0.012 0.011 8.07E-06 
rs60866856 9 79,751,986 A/C VPS13A -0.076 0.090 0.027 0.023 2.32E-06 
rs1904619 10 69,048,533 T/C CTNNA3 -0.037 0.059 0.016 0.014 9.54E-06 
rs2244608 12 121,416,988 A/G HNF1A -0.002 -0.034 0.005 0.005 2.42E-06 
rs11647020 16 53,823,990 T/C FTO -0.007 0.030 0.006 0.006 7.36E-06 
rs184568395 22 50,720,874 A/C PLXNB2 0.115 -0.070 0.032 0.026 9.13E-06 
 
Table 26 – Lookup of Chapter 3 novel SNPs in CKDGen meta-analyses 
Analysis rsID  Chr. Position Locus EA/NEA N EAF Effect SE P-value N. cohorts I2 (%) 
All rs577353818 4 190,587,150 RP11-462G22.1 T/C 55,994 0.001 0.198 0.231 0.3899 1 0 
All rs573624409 11 72,799,547 FCHSD2 A/G 37,219 0.004 -0.452 0.106 1.91E-05 7 66.6 
Female rs112029032 8 43,054,647 HGSNAT G/A 44,699 0.010 -0.021 0.059 0.7272 7 54.3 
Female rs1876025 11 4,615,987 OR52I1 A/C 5,546 0.050 0.131 0.069 0.05836 7 0 
Female rs576082236 14 103,468,041 CDC42BPB G/A 31,407 0.003 0.056 0.134 0.6762 1 0 
Male rs139498948 12 79,289,619 SYT1 G/A 40,498 0.049 -0.011 0.049 0.8142 15 57.8 
GS Tay. rs75869162 5 16,617,922 FAM134B G/A 204,884 0.003 0.061 0.058 0.2912 17 63.8 
GS Tay. rs141208451 11 45,538,920 RP11-430H10.4 G/A 101,215 0.004 0.111 0.071 0.1208 10 76.6 
GS Tay. rs187171029 19 53,599,256 ZNF160 A/T 221,502 0.005 0.086 0.037 0.02066 24 59 
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 Lookup of Chapter 3 SNPs 
The index SNPs for the novel loci identified in Sections 3.3.2.2 and 3.3.3 were looked 
up in the results of the corresponding CKDGen meta-analyses. The results are shown 
in Table 26.  
Of these index SNPs, only rs573624409 at FCHSD2 in the sex-combined analysis 
was significant after multiple testing correction (two tests for All, three for female, one 
for male and three for GS Tayside), though heterogeneity at this locus was relatively 
high (I2 = 66.6%) despite the SNP only being present in the meta-analysis in seven 
cohorts (of which only one was a cohort from the Chapter 3 meta-analysis, 
ORCADES, the others having not passed the pre-meta-analysis filtering).  
The forest plot for this SNP is shown in Figure 33, with details for each cohort in Table 
27. These show that direction is consistent across most cohorts, with the strongest 
signal coming from ORCADES. Despite this being the smallest cohort contributing to 
this SNP, the minor allele frequency is highest here, and the imputation quality is 
higher than any other cohort, which suggest this signal may be real. This may be an 
example of a rare allele being enriched in a population isolate, making it possible to 
detect in a much smaller sample. 
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Figure 33 - Forest plot for rs573624409 in CKDGen cohorts. 
 
Table 27 – Study-specific GWAS summary statistics for rs573624409. 
Cohort MAF MAC n 
Imputation 
quality 
Effect Std. Err. P-value 
CHRIS (EA) 0.0022 20.14 4,661 0.721 -0.129 0.287 0.653 
FHS (EA) 0.0017 25.87 7,699 0.662 -0.237 0.307 0.440 
KORA F3 (EA) 0.0018 10.73 2,996 0.675 -0.378 0.443 0.393 
ORCADES 0.0084 33.75 2,003 0.894 -1.110 0.193 8.05E-09 
QIMRB adult (EA) 0.0021 46.69 11,389 0.669 0.006 0.218 0.980 
Rotterdam Study 1 (EA) 0.0018 15.48 4,415 0.793 -0.373 0.367 0.310 
SHIP-0 (EA) 0.0019 15.49 4,056 0.696 -0.266 0.364 0.465 
Meta-analysis 0.0040 168.15 37,219 - -0.452 0.106 1.91E-05 
 
 
 Genetic risk score and gout in UK Biobank 
4.3.7.1 Gout Odds Ratios 
Gout prevalence increased across the serum urate GRS bins, ranging from 0.1% in 
the lowest category (3.61-4.17 mg/dl) to 12.9% in the highest category (6.15 - 6.44 
mg/dl, Table 28, left panel, Figure 34a). The most common risk score category was 
4.74 - 5.02 mg/dl, with almost a third of the sample falling within this range. This was 
used as the reference category for expressing age- and sex-adjusted odds ratios (OR) 
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of gout (Table 28, right panel). ORs ranged from 0.09 (95% CI 0.02 - 0.37, P = 7.8 x 
10-4) in the lowest category to 13.6 (95% CI 7.2 - 25.7, P = 1.4 x 10-15) in the highest 
category, corresponding to a >100-fold range (Figure 34b).  
A sizeable proportion of the UK Biobank, 3.46%, has a greater than three-fold 
increased risk for gout (OR > 3) compared to the most common risk category.  
4.3.7.2 Gout prediction 
Gout risk prediction models were built by regressing gout status in the UK Biobank 
dataset on the GRS alone (“genetic model”), on age and sex (“demographic model”), 
and finally on the GRS as well as on age and sex (“combined model”) in a training 
sample consisting of 90% of the individuals. These models were then used to predict 
gout status in the remaining testing set and compared to the actual gout status. The 
area under the curve (AUC) of the corresponding Receiver Operating Characteristic 
(ROC) curves showed the genetic model to be a moderately accurate predictor of 
gout status (AUC = 0.68), weaker than the demographic model (AUC = 0.79). The 
combined model led to a statistically significant increase in predictive ability (AUC = 
0.84, DeLong’s test Z = -8.43, p-value < 2.2 x 10-16). These results are displayed in 
Figure 34c. 
Table 28 – Summary of serum urate GRS bin demographics and logistic regression 
model. 
     Gout ~ age + sex + GRS 





OR 95% CI P-value 
3.61 < GRS <= 4.17 2,095 2 0.10%  0.093 0.023 - 0.371 7.80E-04 
4.17 < GRS <= 4.46 15,743 61 0.39%  0.363 0.28 - 0.47 1.67E-14 
4.46 < GRS <= 4.74 57,758 321 0.56%  0.528 0.466 - 0.599 1.87E-23 
4.74 < GRS <= 5.02 105,697 1,097 1.04%  Reference 
5.02 < GRS <= 5.3 97,471 1,622 1.66%  1.616 1.495 - 1.746 9.61E-34 
5.3 < GRS <= 5.59 44,513 1,280 2.88%  2.890 2.662 - 3.138 6.75E-141 
5.59 < GRS <= 5.87 10,246 423 4.13%  4.240 3.775 - 4.763 4.68E-131 
5.87 < GRS <= 6.15 1,264 90 7.12%  7.713 6.121 - 9.717 2.83E-67 










Figure 34 - Serum urate genetic risk 
score and gout prediction 
a Histogram of serum urate GRS in the 
UK Biobank. Gout prevalence within 
each GRS bin is plotted on the 
secondary axis; b Gout odds ratios for 
GRS bins, adjusted for age and sex; c 
Comparison of the ROC curves of 
demographic (age + sex), genetic (GRS 
only) and combined (GRS + age + sex) 
gout predictor models. 
165 
 
 DEPICT Pathway Analysis 
DEPICT pathway analysis identified 383 significantly enriched reconstituted gene sets 
(FDR P-value < 0.01), containing 867 genes. The most commonly seen gene was 
NPHS2, which appeared in 46 sets, while 302 genes appeared in only one set – 
interestingly SLC2A9 was among this number, appearing only in the “FOXO1 PPI 
Subnetwork” set. ABCG2 appeared in three sets: “Renal Tubular Necrosis”, “TGF-
Beta Receptor Binding” and “Abnormal Embryonic Growth/Weight/Body Size”. 
SLC22A12 appeared in 41. 
It is a noteworthy demonstration of the limitations of pathway analysis methods that 
although urate-related gene sets exist within the DEPICT database – GO terms alone 
include several – the only reconstituted gene set with a urate-related name was 
“GO:0046415: urate metabolic process”, which had a nominal P-value of 0.06 and 
contained NAT8 (7.8), SLC7A13 (7.3), SLC22A11 (7.0),  SLC22A24 (6.3), 
ENSG00000204872 (6.0), PKHD1 (5.8), CUBN (5.7), ACMSD (5.5), 
ENSG00000223985 (5.4) and  SLC22A6 (5.3) as its top ten genes. 
Affinity propagation clustering of these 383 reconstituted gene sets identified 57 
exemplar gene sets. Constructing a correlation network between these exemplars 
revealed a large group of inter-correlated gene sets related to kidney development, 
morphology and function (Figure 35, Supplementary Table 6).  
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Table 29 – DEPICT Exemplar Gene Sets. 
Gene set source refers to the data source of the original gene set used to construct the 
DEPICT RGS. The P-value is the nominal P-value before multiple testing correction for 
enrichment of the gene set in the GWAS results. Cluster size refers to the number of RGS 
summarised by this exemplar. 







Abnormal Bone Ossification Mouse Phenotype 0.000442 5 
Abnormal Glucose Homeostasis Mouse Phenotype 0.000151 10 
Abnormal Kidney Physiology Mouse Phenotype 1.48E-06 8 





Apical Part of Cell Gene Ontology 3.17E-08 6 





Decreased Circulating Cholesterol Level Mouse Phenotype 0.000164 1 
Decreased Embryo Size Mouse Phenotype 2.47E-09 11 
Decreased Urine Osmolality Mouse Phenotype 1.68E-10 4 
Electron Carrier Activity Gene Ontology 6.32E-05 6 
Embryonic Morphogenesis Gene Ontology 8.93E-05 6 


















Hexose Metabolic Process Gene Ontology 5.34E-07 3 
Hydronephrosis Mouse Phenotype 9.75E-07 3 
Increased Circulating Aldosterone Level Mouse Phenotype 5.63E-05 2 
Increased Circulating Potassium Level Mouse Phenotype 3.52E-05 1 
Increased Glomerular Capsule Space Mouse Phenotype 1.38E-05 4 
Increased Urine Calcium Level Mouse Phenotype 1.79E-06 4 





Kidney Cortex Atrophy Mouse Phenotype 6.84E-06 3 
Kidney Development Gene Ontology 2.61E-06 4 
Liver Development Gene Ontology 0.000237 6 
Mesangial Cell Hyperplasia Mouse Phenotype 5.31E-07 4 





Negative Regulation of Growth Gene Ontology 4.75E-05 28 
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Nuclear Hormone Receptor Binding Gene Ontology 2.11E-05 5 









Ppara Activates Gene Expression REACTOME Pathway 6.83E-05 3 
Regulation of Carbohydrate Metabolic Process Gene Ontology 3.07E-05 3 
Regulation of Organ Morphogenesis Gene Ontology 9.18E-06 6 
Respiratory Tube Development Gene Ontology 0.000304 2 
Response to Hypoxia Gene Ontology 6.67E-05 2 
Response to Nutrient Levels Gene Ontology 6.53E-05 12 





Slc-Mediated Transmembrane Transport REACTOME Pathway 0.000137 4 
Small Molecule Catabolic Process Gene Ontology 0.00034 2 
Steroid Hormone Receptor Activity Gene Ontology 7.49E-05 3 
Thoracic Vertebral Transformation Mouse Phenotype 0.000106 4 
Transforming Growth Factor Beta Receptor Cytoplasmic 
Mediator Activity 
Gene Ontology 2.71E-05 12 













Figure 35 - Correlation 
network of exemplar gene 
sets from DEPICT pathway 
analysis. 
Nodes represent exemplar 
gene sets, edges represent a 
Spearman’s correlation of r > 
0.2 between the Z-scores of 
the top 10 genes in each set. 
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 FUMA gene function annotation 
Of the 183 gene names uploaded to FUMA GENE2FUNC, 15 were not recognised in 
the database, largely uncharacterised non-coding RNAs. FUMA reports enrichment 
for a range of gene sets, too many to easily summarise, but a few are noteworthy. 
The strongest enrichment for GO biological processes – one of the datasets included 
in DEPICT and used to generate reconstituted gene sets – is “Urate Metabolic 
Process” (adjusted p-value = 2.64x10-10, SLC16A9, SLC22A12, GCKR, SLC2A9, 
ABCG2, SLC17A1). This gene set was not even nominally significant in DEPICT (see 
Section 4.3.8) and the top ten genes assigned to it did not overlap with the set reported 
for this term in FUMA. The next most significant is “Lipid Metabolic Process”, 
containing 23 genes (Padj = 1.34x10-6). 
A heatmap (generated by FUMA directly) of gene expression across 53 tissue types 
from GTEx v6 is shown in Figure 36, and shows a group of genes highly expressed 
only in liver, as well as a smaller group expressed highly across a range of brain 
tissues. Differentially-expressed gene (DEG) analysis (Figure 37) in which pre-
calculated sets of DEGs were tested for enrichment in the set of genes identified in 
the GWAS showed significant enrichment for genes differentially expressed in Kidney 
Cortex, Liver and Subcutaneous Adipose Tissue, with significant up-regulation DEG 
sets in Kidney Cortex and Liver.  
These results support tissue enrichment analyses performed by Adrienne Tin and 
Yong Li in both DEPICT and stratified LD-score regression (not detailed here) for our 






Figure 36 – FUMA-generated heatmap of GTEx gene expression for the serum urate 
loci. 
Cell colour is average log2 transformed expression per tissue type. Cells are clustered 




Figure 37 – FUMA-generated plot of differentially-expressed genes by tissue type. 
Based on enrichment of input genes in pre-calculated sets of DEGs per tissue type. Red 
bars denote significant enrichment (Bonferroni-corrected P-value). 
 
 Genetic correlations 
Of the traits tested, 214 had significant genetic correlations with serum urate (P < 
0.05/832). The strongest positive genetic correlations were with serum urate itself (in 
previously published GWAS), with values around 1, and with gout. There were also 
positive strong correlations with metabolic syndrome components including 
triglycerides in small HDL (rg = 0.50), HOMA-IR (a measure of insulin resistance, rg = 
0.49) and fasting insulin levels (rg = 0.45), as well as CKD and cardiometabolic risk 
factors including obesity, waist circumference, body fat, and type 2 diabetes. Strong 
negative correlations were observed with a variety of HDL cholesterol-related 







Figure 38 – Genetic correlations between serum urate EA and LD-Hub traits 
All traits with absolute rg > 0.35 are shown. Brackets contain the PMID of the GWAS summary 
statistics used in cross-trait LD-score regression, or else UKB to indicate the UK Biobank. 
  
4.3.10.1 Sex-stratified genetic correlations 
4.3.10.1.1 Genetic correlation between sexes 
The genetic correlation between serum urate in females and serum urate in males 
was also calculated using LDSC. The correlation was high (rg = 0.875, SErg = 0.047, 
P = 2.7715 x 10-77) but as seen in Figure 38, for the overlap should be 1 or higher for 
173 
a trait correlated against itself. This is consistent with the existence of sex-specific 
genetic variants controlling serum urate levels.  
To test for additional undiscovered sex-specific loci, I excluded the two loci with known 
sex effects, SLC2A9 and ABCG2, by removing all SNPs within 1Mb of the gene 
boundaries (defined as taken as 4:9,772,777-10,056,560 and 4:89,011,416-
89,152,474 respectively). This resulted in a stronger genetic correlation, as expected 
(rg = 0.9094, SErg = 0.0301). However, this value is still smaller than 1, which may 
reflect additional unidentified heterogeneity between males and females that is below 
the genome-wide threshold for significance in GWAS. 
4.3.10.1.2 Genetic correlations with other phenotypes 
Fifty-three of the 128 traits tested showed significant genetic correlation with serum 
urate in males or females (Supplementary Table 7). Of these, none showed 
significant differences between sexes at an FDR-corrected threshold of Q < 0.05. Nine 
traits were nominally significant before multiple testing correction (P < 0.05, Table 30, 
Figure 39).  
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Table 30 – Traits with a nominally significant difference in genetic correlation between 
sexes. 
* denotes significant genetic correlations at Q < 0.05. Q-values for sex difference are 

































Smoking -0.050 -0.260 6.06E-01 1.95E-03* -2.225 0.026 
Years of 
schooling 

















Anthropometric 0.102 0.235 6.70E-02 2.71E-05* 1.973 0.049 




Cardiometabolic 0.106 0.220 4.01E-03* 1.01E-05* 2.068 0.039 
BMI Anthropometric 0.196 0.330 1.47E-05* 8.94E-10* 2.102 0.036 
Type 2 
Diabetes 
Glycaemic 0.141 0.329 2.57E-02* 4.16E-05* 2.102 0.036 
Waist to hip 
ratio 





Figure 39 - Comparison of 
genetic correlations with serum 
urate between males and 
females. 
Positive values indicate 
stronger genetic correlations in 
females, negative indicate 
stronger in males. Dashed lines 
indicate the threshold of 




This meta-analysis is the largest yet run on serum urate, and represents a four-fold 
increase on the discovery sample from Köttgen et al.74.  Of the 183 loci reported, 147 
were considered novel – not previously reported in GWAS of serum urate74,77. This is 
in part due to the increased density of the new HRC imputation panel, but also reflects 
the dramatic increase in power that comes from the increased sample size.  
However, it must be noted that the definition of novel locus is quite simplistic, being 
based purely on distance to previous loci, without taking LD structure into account – 
by necessity, since the transethnic nature of the dataset means LD structure is highly 
variable between cohorts. Some of the novel loci are clustered around known strong 
serum urate hits – in particular, the cluster around SLC22A12 on chromosome 11. If 
a full conditional analysis (performed at the study level across all ethnic groups and 
meta-analysed) were performed in this region, or the predefined region of 1Mb per 
locus was relaxed, it is likely that some of the associations would disappear. However, 
the majority of novel loci are spaced across the genome, with at least one hit on every 
autosome, so even a conditional analysis or wider locus window would still leave a 
very large number of novel associations.  
Step-wise conditional analysis on individual study genotype data would have a 
prohibitively high administrative burden in a meta-analysis such as this, but the UK 
Biobank – a single cohort with a sample size that exceeds even that of this combined 
meta-analysis – would be an ideal dataset for testing the independence and fine 
structure of these loci. It is, of course, a European ancestry cohort, and so might not 
reflect the variation in non-European populations, but as a single cohort, one analyst 
could perform a full step-wise conditional analysis – including SNPs one at a time as 
covariates in the regression model, and joint analyses of local variant effects 
(including testing for epistatic interactions) – without assumption of a pattern of LD as 
required in a consortium meta-analysis. Unfortunately, the release of the biochemistry 
data for the cohort has been delayed, and there is no linkage yet to NHS blood test 
results, meaning no measures of serum urate are available. 
Statistical fine mapping and gene-expression co-localisation analyses performed by 
the analysis group (not detailed here) were used to prioritise likely causal variants in 
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a number of loci, including prioritising the SLC17A4 gene in the 6p22.2 region, which 
contains four SLC17 family transporter genes.  
However, this fine mapping is not without potential flaws. In particular, the credible set 
generation, where statistical analysis is used to predict a set of SNPs that likely 
contains the causal SNP, is strongly dependent on the p-values as input. This means 
that the inclusion of a SNP is sensitive to the contribution and sample size of the 
combined populations that include it. Specifically, in the PDZK1 locus, a strong case 
for a causal variant had been made from experimental work at rs1967017, which 
modified an HNF4A binding site upstream of the gene251. However, this variant is not 
included in the credible set in our analysis, while a variant in strong LD with it, following 
1000G-UK reference samples, is. This could be explained by the fact that due to 
uneven genotyping arrays and imputation quality across cohorts meta-analysed the 
selected adjacent variant had a higher sample size, and thus a lower p-value.  
This discrepancy was identified by the group in the very late stages of preparation of 
the paper, and impact of equal contribution of cohorts to region analysed on the 
credible set results will be examined before final publication. Though unfortunate, this 
does highlight a limitation of consortium analysis – that decisions must be made as a 
group, and changes in direction are much more difficult to implement. The conclusions 
of an analysis are always partially dependent on the methods used to achieve them.  
The trend within the GWAS field is towards publishing full results in public repositories 
such as dbGaP143, and our meta-analysis will be no exception. This will allow our 
results to be used in future analyses by researchers across the world. Because of the 
increasing availability of GWAS summary statistics, the development of methods that 
can utilise these results without needing individual genotype and phenotype data is 
an area of active development. LDSC and MR-base are two noteworthy tools using 
summary statistics which have appeared just within my brief tenure as a PhD 
candidate, and doubtless more will be developed over time. By making our raw results 
available to other researchers, we allow them to be re-analysed and integrated into 
new tools, ensuring our findings will not remain static, instead leading to increasingly 
accurate insights into the biology of serum urate regulation in the future.  
Given the flaws highlighted above, an even better policy might be to publish individual 
cohort-level GWAS results, allowing future researchers the same level of flexibility 
and detail as we have had, and allowing others to test our choices of methods and 
parameters. Unfortunately, this is an unlikely prospect. The additional burden of 
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hosting the data notwithstanding, individual cohorts would have to consent, and many 
may have to withhold this to ensure compliance with their ethical agreements with 
their participants.  
 Trans-ethnic meta-regression in MR-MEGA 
4.4.2.1 Trans-ethnic index SNPs 
Fourteen of the transethnic index SNPs were identified as having significant ancestry-
associated heterogeneity. Rates of renal urate clearance are known to vary in different 
populations, specifically being reduced in Polynesian women252 and Maori men253, 
which has been suggested to be due to founder effects increasing the frequency of 
deleterious alleles in SLC2A9250. We detected both ancestry-associated and residual 
heterogeneity at this locus. This suggests that while mean allele frequency differences 
between populations explains some of the heterogeneity, either there are more 
granular differences in allele frequency between populations at this locus that are not 
captured by our three PCs, or that there is another factor driving the heterogeneity of 
effect – perhaps an environmental interaction that is not related to ancestry. 
Heterogeneity has been reported for gout at ABCG2, where the apparent causal SNP 
in Europeans has not been found to have an effect in Maori, but this may have been 
driven by the frequency of the causal allele being relatively low in this group254. 
SLC17A1 has been reported as consistently associated with gout despite varying 
allele frequencies across populations250, and this is reflected in our results – there is 
no significant heterogeneity detected at this locus in MR-MEGA or METAL.  
Of the remaining loci, DEFB131A and CLNK are clustered within a 1Mb region around 
SLC2A9 on chromosome 4. Seven more are within a 4.5Mb window containing 
SLC22A12, a region where heterogeneity between populations has not been 
previously reported. The remaining three are dispersed: INHBC and MYL2 on 
chromosome 12 and CPT1C on chromosome 19.  
Of the eight loci with the smallest association p-values using MR-MEGA, six had 
significant heterogeneity (SLC2A9, ABCG2, SLC22A12, CLNK, GCKR and 
HRASLS2). Similarly, five of the six loci with the largest absolute effects have 
significant heterogeneity (SLC2A9, HRASLS2, ABCG2, HAO2, SLC22A12 and 
CPT1C). This co-occurrence of strong GWAS effects and detectable ancestry-
associated heterogeneity suggests that our findings are at least partially affected by 
sample size, presumably due to the relatively small number of non-European cohorts. 
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While the Biobank Japan sample is large, it is one single cohort, and the MR-MEGA 
method is only able to account for heterogeneity between cohorts, not within them – 
this has to be accounted for at a study level. Additional and larger non-European 
cohorts would also allow us to utilise MR-MEGA’s fine-mapping capabilities. This 
takes advantage of LD structure variation between populations to narrow down the 
region containing the causal SNP.  
The bias towards Europeans in GWAS cohorts has been a characteristic of the field 
since the very beginning. This is because European ancestry cohorts were the first to 
be collected and genotyped – a consequence of the countries which have funded 
population genetics research having interest in their own populations first. Generation 
Scotland, for example, is funded in part by the Scottish Government as a research 
resource. While a cohort of 20,000 individuals from an African country might have 
been be a highly useful resource from a scientific perspective, it lacks the political 
relevance of a study of the local population, making it unlikely to secure government 
support. This state of affairs is rapidly changing as it becomes more apparent that 
diverse samples are needed, but as it can take years to gather the data for a cohort, 
progress is slow. 
4.4.2.2 Loci unique to MR-MEGA analysis 
Despite the predominantly European sample, MR-MEGA identified nine loci with small 
but significant association signals which did not overlap with the loci from the METAL 
analysis. These are reported in the CKDGen paper despite the comparatively low p-
values for the index SNPs as several of them remain of interest. 
4.4.2.2.1 SLC2A2 
The most significant of these loci is SLC2A2, with an index SNP P-value of 1.84 x  
10-9. The locus contains 18 significant SNPs and the effect of the index SNP, while 
modest, is estimated as over twice as large by MR-MEGA compared to METAL (0.050 
compared to 0.0207). Several SLC family proteins have been associated with serum 
urate levels in previous GWAS, making this a promising candidate. Variation in this 
gene has been associated with response to metformin in obese individuals, a 
medication used to treat type 2 diabetes. Like other SLC2A family genes, SLC2A2 
encodes a glucose transporter, GLUT2 – a high-capacity, low-affinity glucose 
transporter which plays a role in glucose uptake in the liver and in glucose 
reabsorption in the kidney proximal convoluted tubule255. It is also expressed in the 
intestine and the central nervous system. Knockouts of GLUT2 in mouse has shown 
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it to be essential for glucose reuptake in the kidney, but dispensable for uptake in the 
gut255. Xenopus oocytes injected with SLC2A2 cRNA were not found to have 
significant serum urate uptake, in contrast to those injected with SLC2A9 cRNA57. If 
GLUT2 has a true effect on serum urate levels, it is likely to be mediated through its 
effect on glucose regulation.  
Lookup of the SLC2A2 index SNP in the ancestry-specific meta-analyses shows that 
it has its strongest effect in AA but is only nominally significant due to the low sample 
size. It is actually genome-wide significant in EAS, but the index SNP identified in the 
EAS meta-analysis is in the nearby gene EIF5A2, encoding a protein related to 
translation elongation. While this could potentially be the causal gene, I believe 
SLC2A2 to be a stronger candidate for having a real effect due to its role in glucose 
transport and therefore energy metabolism, a process known to be coupled to urate 
levels. If this is the case, this locus is a clear example of the potential benefits of using 
the MR-MEGA approach over meta-analysing separately by self-reported ancestry. 
The greater power and ethnic diversity has facilitated detection of a promising gene 
that the transethnic meta-analysis failed to detect due to the lack of a signal in 
Europeans.  
4.4.2.2.2 ZMIZ1 
ZMIZ1 is the second-strongest MR-MEGA unique hit, with five SNPs in the locus 
around the index SNP rs697238, which is nominally significant in AA, EA and EAS. 
This SNP is reported in PhenoScanner as being associated with type II diabetes in 
the UK Biobank. The encoded protein ZMIZ1 is part of the protein inhibitor of activated 
STAT (PIAS) family, a group of proteins that bind and regulate DNA-binding 
transcription factors, with ZMIZ1 reported to interact with the androgen receptor256. It 
is downregulated in patients with multiple sclerosis257, a condition associated with 
reduced serum urate levels9, though it is unclear whether it is causal258. 
4.4.2.2.3 TAPT1-AS1 
TAPT1-AS1 is a non-coding RNA. PhenoScanner reports significant associations with 
acute renal failure in the UK Biobank, as well as a variety of ‘cause of death’ 
phenotypes related to gastrointestinal haemorrhage.  
4.4.2.2.4 ALDH5A1 
ALDH5A1 encodes an aldehyde dehydrogenase that catalyses the degradation of the 
neurotransmitter gamma-aminobutyric acid (GABA)259. GABA has multiple roles and 
is expressed highly in the insulin-producing β-cells of the pancreas, where it can 
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promote β-cell survival. PhenoScanner reports associations between SNPs in 
ALDH5A1 and death due to B-cell lymphoma in the UK Biobank140, and the index SNP 
rs73728140 has been associated with alkaline phosphatase levels180 . Expression of 
ALDH5A1 has been shown to be suppressed by hsa-miR-29a-3p (a highly abundant 
miRNA in human liver) in human hepatocytes. Interestingly, this miRNA also 
suppresses expression of SLC22A7, a novel serum urate locus identified in the 
transethnic meta-analysis260. 
 Sex-stratified analysis 
The sex-stratified analyses are perhaps most notable for their lack of significant 
results. Despite each sex having sample sizes in well excess of the Köttgen et al. 
(2013) GWAS, only four additional significant loci were detected, all in females, and 
all close to the threshold of significance. Two of these are uncharacterised lincRNAs. 
The index SNP in INPP5A is a hit for bone mineral density in UK Biobank, and the 
protein is involved in calcium release in mice – its deletion leads to cerebellar 
degeneration261.TRIM29 is an immune inhibitor that is co-opted by Epstein-Barr virus 
when infecting airway epithelial cells262, and has been implicated as a tumour 
suppressor gene. The link to female-specific serum urate levels is unclear in either 
case and may reflect that the target genes in associations is not necessarily the 
closest gene.  
The other noteworthy absence is in the difference in effect between sexes. SLC2A9 
and ABCG2 have both been known since the discovery of their association with serum 
urate levels to carry variants with different effects in each sex – the index SNP from 
Köttgen et al. 2012 in SLC2A9 has a stronger serum urate-increasing effect in women 
than in men, and the reverse is true for ABCG274. In our results, the lead SNP for 
SLC2A9, rs3775947, has nearly twice as large a serum urate-increasing effect in 
females as in males (βM = 0.1954, βF = 0.3556). In ABCG2, rs74904971 has a 1.38-
fold stronger effect in males than females (βM = 0.2338, βF = 0.1692). 
However, considering the significant differences in serum urate levels between males 
and females, it is surprising that no additional loci are detected as genome-wide 
significant. The fact that the genetic correlation between males and females is not 
equal to 1, even when SLC2A9 and ABCG2 were excluded, supports the conclusion 
that there are still additional loci with undiscovered sex-specific effects. Several loci 
were below the suggestive significance threshold (P < 10-5) in this analysis. These 
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may become significant when this analysis is repeated in, and likely meta-analysed 
with, the larger sample available in the UK Biobank. Future analyses could include 
age by sex interaction terms as an attempt to account for the effect of the menopause 
on urate levels in females. 
Of the 183 primary meta-analysis index SNPs, six showed significant effect 
differences between sexes: SLC2A9, ABCG2, CAPN1, GCKR, IDH2, and SLC22A12 
(Pdiff < 0.05/183). Sex-specific effects on uric acid at the GCKR locus were identified 
in Köttgen et al. 2013, but as here, not at the genome-wide significant level74.  
The rate of urate clearance in the kidney has been shown to be affected by varying 
levels of oestrogen61–63, leading to the suggestion that sex hormones are the primary 
drivers of sex differences in serum urate levels. This may account for the small 
number of loci with significant variation between sexes if hormonal effects on serum 
urate are not affected by the genetic variants uncovered.  
However, it seems likely that there would be genetic variants which modulate 
hormonal effect, and thus would appear differentially associated with women and 
men.  For example, rs2244608, a SNP close to the HNF1A gene which is one of the 
variants with a suggestively-significant sex-specific effect, is a potential candidate for 
such a modulating effect, as its predicted function is to modify the binding of the 
oestrogen receptor and transcription factor ESR2263–265. The question remains open. 
 Serum urate GRS and Gout 
The serum urate GRS score is clearly associated with gout in the independent UK 
Biobank cohort, with prevalence increasing steadily across risk score categories, and 
a 100-fold difference in risk between the highest and the lowest. 3.46% of the study 
population fell within the highest three GRS categories (≥ 5.87 mg/dL). Individuals in 
these categories had a greater than 3-fold increased risk for gout compared to the 
most common category. This is comparable to a modest effect size for monogenic 
disease (OR > 3)266, but the prevalence of high GRS within the population is much 
higher than most monogenic disorders.  
When split into a training and testing set, including the serum urate GRS showed 
significant improvements compared to age and sex alone in predicting gout status. It 
should be noted that this is not predicting future cases of gout, but rather current gout 
status. The GRS is still a smaller component of the risk compared to age and sex 
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together, but as GRS and age are fixed at birth, it may be possible to identify 
individuals who are at high risk of gout but have not yet developed it. In several years’ 
time, once the UK Biobank phenotype databases have been updated with new cases 
of disease, it will be possible to assess whether any of our ‘incorrect’ predictions of 
gout status are in fact accurate predictions of future gout status.  
Together, these finding highlight the clinical value of genetic risk scores for disease 
prevention – many GWAS loci have small effects but taken together they can confer 
a significant risk of disease on an individual. Because this risk is genetic, it remains 
constant throughout life, meaning an individual can be advised early in life if they have 
a genetic predisposition towards high serum urate levels, and thus an increased risk 
of gout. While this information must be explained carefully to ensure patients 
understand that a genetic risk does not mean they will inevitably develop the disease, 
there is evidence that it can lead to behavioural changes. The GeneRISK study in 
Finland provided patients with a web interface (“KardioKompassi”) which summarised 
their CVD risk, including genetic risk, and followed their behavioural changes over 
time267. In a presentation at the European Society of Human Genetics meeting in 
Milan in 2018, they presented unpublished results showing that the greatest risk-
reducing behavioural changes were seen in patients with high genetic risk. The serum 
urate GRS I have constructed could be used to provide patients with similar guidance 
on reducing their risk of gout. While not a fatal disease, gout causes considerable 
pain over prolonged periods, and could lead to improved quality of life for high-risk 
individuals if risk-reducing habits are formed early. 
 Genetic correlations between serum urate levels and published 
GWAS phenotypes 
The strongest genetic correlations were observed with previous GWAS of serum 
urate – (these are actually >1, as LD-score regression does not provide a bounded 
estimation, but this is acceptable provided that estimates are not greatly in excess of 
1). A strong correlation was seen with UK Biobank self-reported gout, which is also 
expected. Many positive correlations were seen with fat mass traits in UK Biobank, 
as well as obesity, BMI and hip circumference that are likely capturing the same 
effect – a genetic link between high BMI and high serum urate levels. Other strong 
positive correlations include traits related to triglycerides in HDL and LDL 
cholesterol, CKD and diabetes related traits including HOMA-IR, a measure of 
insulin resistance. This wide range of cardio-metabolic traits and diseases reflects 
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known observational correlates of serum urate. Strong negative correlations include 
many traits related to HDL-cholesterol, known to be negatively associated with 
serum urate, and, curiously, father’s age at death. This suggests a possible link 
between low serum urate and longevity, which is in contrast to historical 
observations that long-lived species tend to have higher serum urate 
concentrations268. However, the known correlation between high serum urate and 
risk factors for cardiometabolic disease may explain this apparent contradiction in 
humans. A link between family longevity and low serum urate independent of kidney 
function has similarly been previously reported in Ashkenazi Jews269. 
No significant sex differences in genetic correlations were detected after multiple 
testing correction, likely due to the relatively small sample sizes, but nine traits were 
nominally significant (P < 0.05). Larger GWAS sample sizes would lead to smaller 
SEs in the calculation of rg, which may lead to some of these suggestive signals 
becoming significant. 
Sex-differences in many of the phenotypes make intuitive sense – for example, 
these results suggest that variants associated with later menopause are associated 
with lower serum urate levels in women but show no association in men. This could 
be confounded by BMI and hormonal levels both positively correlating with serum 
urate levels but does lead to an interesting possibility – that the shared variants 
between serum urate and age of menopause are not affecting serum urate levels in 
men. This would support the intuitive notion that there are sex-specific serum urate 
loci beyond those that we have identified, perhaps regulating the interaction 
between sex hormones and serum urate levels. 
 Limitations of annotation 
The number of hits makes the downstream analysis of these results a complex 
prospect. The Köttgen et al. analysis identified eighteen novel loci, a small enough 
number for each to be manually investigated in detail by a team of analysts, but 
already a formidable task. Understanding individual roles of the 147 loci identified in 
this analysis is a far greater undertaking, and manual annotation and literature 
searching becomes an unrealistic prospect within the timescale of a single 
publication, or even a PhD thesis. Instead, large GWAS projects are increasingly 
turning to bioinformatics tools to interpret the highly polygenic associations. Tools 
such as DEPICT and FUMA aim to integrate some of the vast quantity of publicly-
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available information to link GWAS hits to known pathways, expression data and work 
on model organisms. They have proven to be versatile and useful methods, but there 
are problems with this approach.  
The first is that these frameworks are limited by their methodology – any approach to 
reducing the dimensionality of a dataset will inevitably result in the loss of information, 
and the mathematical and statistical methods used to do this will favour certain kinds 
of information over others, in a way that may not always be obvious to a user.  
The second is that an information aggregator can only ever be as good as the 
information it aggregates. Even during the process of writing this thesis I have found 
flawed information in the PhenoScanner database, where the GWAS results from the 
OLINK-IMPROVE study are clearly incorrect. Nonetheless these results have been 
integrated into the PhenoScanner database, and incorrect conclusions may have 
been drawn from a pQTL that simply did not exist. Databases have to be kept up to 
date, and tools have to be maintained. One can use multiple tools to compensate for 
each individual approach’s weaknesses, but the user quickly arrives back at the 
problem of having too much data to process manually. 
 The ‘omnigenic’ hypothesis 
GWAS signals are often spread across the genome, and the implicated genes are 
rarely obviously connected to the disease or trait in question. One interpretation of the 
complexity of GWAS results that has generated a lot of discussion in recent months 
is the ‘omnigenic’ hypothesis put forward by Boyle et al. in 2017270. They propose that 
instead of trying to understand each hit in isolation, gene regulatory networks can be 
used to identify ‘core’ genes, which have a direct effect on the complex trait. Because 
all the genes expressed within the relevant cell-type will have some small impact on 
the function of these core genes, and so explain the bulk of the heritability of the trait 
without having a direct impact on the trait itself. Under this framework, attempting to 
understand individual GWAS hits for non-core genes in isolation is a fruitless exercise, 
at least as far as drug discovery is concerned. 
The authors suggest that a more useful approach is to use Whole Exome Sequencing 
to search for rare variants of large effect which may tag core genes, and to focus on 
the construction of cell-type specific gene-regulatory networks. Several recent 
publications have adopted the omnigenic hypothesis to explain their findings271,272, but 
the paradigm has not gone unchallenged. In particular, Wray et al.273 believe it does 
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not reflect our current knowledge of the polygenicity of complex traits and diseases, 
although they agree that the prioritisation of gene-regulatory networks is valuable.  
Personally, I do not find the omnigenic hypothesis to be particularly compelling – partly 
because I believe the term is redundant when ‘polygenic’ already covers most of the 
key concepts, but primarily because the theory hinges on the assumption that a small 
number of core genes are driving variation in a trait, which, while compelling and 
undeniably neat, I do not believe we can state to be true.  
Interpreting uric acid under the omnigenic model might initially seem quite intuitive. 
As it is linked to so many metabolic processes, one might expect to see transcription 
factors that control the metabolic rate in the cell and the production of waste products 
as the core genes at the centre of a wide network. We have in fact identified some of 
these in our meta-analyses, for example HNF1A and HNF4A, major transcription 
factors in the liver and the kidney proximal tubules – the relevant tissues for urate – 
and they do indeed regulate a large number of other genes, many of which are 
unrelated to uric acid levels. However, while these genes definitely have an effect on 
serum urate levels, to consider these the core genes would be to dismiss the urate 
transporters as less important peripheral genes. This would miss their importance as 
key targets for pharmaceutical interventions.  
Consequently, some have suggested the omnigenic model is best viewed as a 
gradient from ‘core’ genes to peripheral genes, with varying influence on the traits – 
which, in my view, is indistinguishable from the polygenic model we are already using.  
In the case of serum urate, a more useful concept to understand the results of our 
meta-analysis may be that of pleiotropy – the same variant or gene having an effect 
on multiple different traits. Many of the loci identified in our results are highly 
pleiotropic, which may be indicative of co-regulation of related processes between 
serum urate and other traits. Understanding the mechanisms driving this pleiotropy 
may lead to new possibilities for urate-altering pharmaceutical interventions that avoid 
disrupting other processes in the cell. 
 The future of GWAS 
The UK Biobank has proven massively disruptive to the status quo in the GWAS field. 
In part because any individual can now run a large GWAS with minimal investment of 
time, money or manpower. More significantly, however, several groups have 
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automated pipelines for GWAS of almost all the phenotypes included in the UK 
Biobank catalogue and made these results available online in tools such as 
GeneAtlas274, the Global Biobank Engine275 and PhenoScanner140. In many cases, it 
is now unnecessary to run a straightforward GWAS on a trait if it has already been 
included in one of these databases.   
Consortia have monopolised the GWAS field for several years now, but almost 
overnight, their era may be coming to an end. A regrettable side effect of the wide 
availability of UK Biobank data may be a reduction of willingness to collaborate with 
others – instead of almost every scientist in the GWAS field working together by 
necessity in one consortium, each individual can now operate alone without sacrificing 
access to data. Instead of collaboration, labs must compete to be the first to publish 
an analysis. And the UK Biobank is merely the first ‘supercohort’ – others are close 
behind, including the ambitious Million Veteran Program, a self-proclaimed ‘mega-
biobank’ that aims to recruit one million US veterans, linking genotypes to rich data 
from healthcare providers276. Soon even the UK Biobank may be dwarfed.  
This is not to say that GWAS consortia will disappear. These groups represent much 
of the talent within the field, and each one brings together the collective knowledge of 
experts within their specialist area. A GWAS is just a statistical technique. Knowing 
how to prepare the phenotypes – who to exclude, how to transform the data, what 
covariates will be relevant – is more complex, and beyond the simple analyses 
performed by the UK Biobank GWAS databases currently available. The future of the 
field may lie in more sophisticated analyses that integrate data that is not publicly 
available, such as the kidney eQTL mapping and transethnic analyses included in our 
paper.  
The field is undoubtedly changing, but the end of GWAS has been predicted before. 
There has been a pattern in recent years of running bigger and bigger GWAS, and 
while this has led to the identification of increasingly large numbers of variants, it is 
unlikely to be sufficient to carry a project. Consortia will have to identify their unique 
strengths if they wish to remain competitive in the era of biobanks. 
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 Gout risk in the UK Biobank 
5.1 Background 
 The UK Biobank cohort 
The UK Biobank is a recent publicly-available prospective cohort with rich phenotypic 
data on over 500,000 participants of UK origin75,234. Genotypic data has been released 
for all 500,000 participants on a custom panel combining the HRC imputation panel 
with structural variants from the 1000 Genomes Project. 
The cohort is noteworthy for two aspects: its size, and its open availability. For a 
nominal access fee, and subject to approval of a proposed project, any researcher in 
the world can gain access to a population cohort of half a million individuals with rich 
phenotypic data. This allow statistical power previously only available to consortia 
meta-analysing dozens of smaller cohorts, which carries a significant administrative 
burden and has greater risk of heterogeneity due to varying techniques between 
groups. Any follow up analyses must either be performed only in whatever small 
cohorts the lead analysts have direct access to, or else must be sent back to all 
collaborators, a process which can take as long as the primary analysis to complete. 
In contrast, the UK Biobank is a single cohort, with consistent techniques applied for 
the measurement of all phenotypes. Complete data on all participants is available to 
the analyst – and often there is only one – making more complex downstream 
analyses such as conditional testing to identify distinct signals much more practical, 
and considerably faster.  
Unfortunately, the unprecedented scale of the UK Biobank project means that it is 
something of a trailblazer, inevitably leading to unforeseen delays and setbacks. Most 
regrettable of these is the delay in the release of the blood biochemistry data. 
Originally scheduled for release in mid-2017, this has been pushed back several times 
and at the time of writing remains unreleased with no anticipated schedule. The delay 
has been due to quality control problems that stem from scaling assays to half a 
million individuals, and the data is as yet unsuitable for analysis, though UK Biobank 
reports that it will still be released at some point. 
This data unfortunately includes measurements of serum urate, which formed a 
component of the original proposal for my PhD. I was intending to take advantage of 
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the size of the cohort to perform a series of stratified GWAS – dividing the cohort 
based on phenotypes known to be related to uric acid. This was to begin with a sex 
and BMI-stratified analysis, that would develop a smaller initial analysis published by 
our group in 201569, and would likely have also included stratification by alcohol 
consumption. I also considered imputing phenotypes into the UK Biobank for the 
proteins identified in Chapter 2 using the genetic variants identified in meta-analysis 
(Section 2.3.5).  
At the time of writing, the UK Biobank biochemistry data remains unreleased. The 
serum urate measurements would have been a valuable resource both for supporting 
the analyses described in this thesis and for performing standalone analyses, but the 
cohort has still been useful without it. Gout status is available from self-reported data, 
and additionally hospital admission records include ICD10 codes which can be used 
to identify gout cases (code M10). This information was used to test association 
between the CKDGen serum urate GRS and gout (Section 4.2.5). UK Biobank genetic 
data was also used as a reference population for estimating LD structure to allow 
approximate conditional analysis in Europeans.  
 Gout case/hypernormal control analysis 
Most people with hyperuricaemia do not develop gout. Consequently, there is 
considerable interest in identifying commonalities between high risk individuals who 
do not develop the disease that distinguish them from those who do. One approach 
to identify genetic factors affecting gout propensity is to use hyperuricaemic controls 
in a case-control GWAS. If both cases and controls are hyperuricaemic, differences 
between them may reflect other aspects of gout such as monosodium urate crystal 
deposition and inflammatory response to crystals. A project using this approach is 
currently being coordinated by Professor Tony Merriman (University of Otago).  
Serum urate is not the sole factor affecting gout risk, however, with diet as a major 
factor and sex, age and ethnicity all contributing. In a study on the National Health 
and Nutrition Examination Survey 2007-2008 (a survey assessing the health a 
nutrition of people in the USA ), of the 5,707 men and women over 20 with gout, 74% 
had hypertension, 71% CKD stage two or greater, 53% were obese, 26% had 
diabetes, 24% nephrolithiasis (kidney stones), 14% had suffered myocardial 
infarction, 11% had heart failure, and 10% had suffered a stroke. For all comorbidities, 
the proportions were significantly higher than in non-gouts277. 
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While the biochemistry data remains unavailable in the UK Biobank, many 
phenotypes are available that are (or co-occur with) comorbidities of gout. By using a 
linear combination of these phenotypes, I have constructed a predictive model that 
generates a gout risk score for an individual. In contrast to the serum urate GRS in 
Section 4.3.6, which assesses the utility of SNPs associated with serum urate for 
predicting gout, this phenotypic gout risk score is intended to identify high-risk non-
cases – so called ‘hypernormal’ controls – for use in a case-control GWAS. This 
analysis should detect genetic variants that confer increased resistance or 
susceptibility to gout independently of the environmental risks included in the model 
and has the additional benefit of being possible before the biochemistry data is 
released.  
This project is still under development in collaboration with Professor Tony Merriman 
and Dr Tanya Major (University of Otago). I have used the Generation Scotland cohort 
to construct a gout prediction model and applied this model in the UK Biobank to 
identify a list of individuals who could be used as high-risk controls. This information 
has been sent to our collaborators in Otago, who will run the GWAS. Final results are 
not yet available, but the development of the prediction model and its findings are 
presented below. 
5.2 Methods 
 Generation Scotland 
The Generation Scotland: Scottish Family Health Study is described in Section 
3.2.1.4. For the purposes of this analysis, only unrelated individuals were used. This 
was assessed by removing one of each pair of individuals with a kinship coefficient of 
greater than 0.015625 (1/64, corresponding to the average shared kinship between 
second-degree cousins) in an identity-by-state kinship matrix calculated using the ‘ibs’ 
function in the GenABEL R package132 
Gout status was obtained from a combination of self-report, prescription of serum 
urate-reducing medication from NHS prescription data (allopurinol, febuxostat, 
benzbromarone or probenecid) and SMR01 hospital admissions data (any instance 
of ICD10 code M10, corresponding to gout). 
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 Phenotypes  
The initial set of phenotypes to be tested was based on those available in both 
Generation Scotland and UK Biobank – this unfortunately ruled out eGFR, as 
creatinine is not yet publicly released in the latter.  
The initial input phenotypes were age, sex, BMI, height, weight, waist-to-hip ratio, 
body fat percentage, systolic and diastolic blood pressure (SBP and DBP 
respectively) (averaged across two readings and corrected for blood-pressure 
reducing medication by adding 15 and 10 mm Hg to SBP and DBP, respectively, for 
individuals reported to be taking BP-lowering medication, as per the protocols used 
by the International Consortium for Blood Pressure278), heart rate (averaged across 
two measurements), hypertension calculated from blood pressure measurements 
(SBP ≥140 mm Hg or DBP ≥90 mm Hg), self-reported high blood pressure and units 
of alcohol consumed per week.  
After preliminary testing, to reduce the number of combinations required for testing, 
this set of phenotypes was reduced to age, sex, BMI, waist-to-hip ratio, body fat 
percentage, self-reported high blood pressure, hypertension calculated from 
corrected blood pressure measurements and units of alcohol consumed per week. 
Only individuals with no missing phenotypes were retained in the analysis. 
 Linear regression 
The R package ‘bestglm’279 was used to regress gout status on all possible 
combinations of covariates in Generation Scotland using logistic regression models. 
The best model was selected based on lowest value of both the Akaike information 
criterion (AIC). The AIC is an estimator of the quality of a statistical model of a set of 
data and is intended to balance goodness-of-fit against overfitting. Bestglm calculates 
the AIC automatically and uses this to select the best model.  
 Gout risk score in UK Biobank 
The best model was then used to generate a gout risk score from phenotype data in 
the UK Biobank using the ‘predict’ function from the package stats. Accuracy of 
prediction was assessed with the AUC of a ROC curve using the model ‘gout ~ gout 
risk score’. This analysis was performed under UK Biobank projects 8304 and 12611. 
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Gout risk scores were given to the Merriman group to allow selection of the best 
threshold for classifying an individual as a hypernormal control, depending on the 
number required. Proposed thresholds included the median, mean and 3rd quartile of 
the risk score across the whole cohort. 
 Comparison to serum urate risk score  
Establishing whether the gout risk score merely identifies hyperuricaemic individuals 
would ideally be done by comparing serum urate levels to the score. In the absence 
of this data, I constructed a serum urate genetic risk score (GRS) as a proxy measure 
of serum urate levels in UK Biobank individuals. This score was constructed as 
described in 4.2.5, but as the results of the CKDGen meta-analysis are unpublished 
and this project is an independent effort, I instead used SNPs and effect sizes 
reported in Köttgen et al. (2013)74. 
5.3 Results 
 Generation Scotland phenotype summaries 
Phenotype preparation in Generation Scotland lead to a dataset containing 147 
unrelated gout cases and 6223 controls. Summaries of quantitative phenotypes are 
given in Table 31. The analysis dataset contained 2,772 males and 3,598 females, 
with 920 cases of self-reported high-blood pressure and 2,453 cases of hypertension 
calculated from blood pressure measurements. Body fat percentage included some 
unlikely extremely low values, possibly due to inaccurate readings from the 
bioimpedance machine. However, most values are biologically feasibly, so in the 
absence of a strong justification for a threshold to remove the low values, I have 
chosen to retain them. 
Table 31 – Summary of quantitative phenotypes tested for gout risk model in Generation 
Scotland. 
 Age BMI WHR Body Fat % Alcohol (units/week) 
Min 18 16.02 0.41 1 0 
Median 51 26.03 0.86 29.8 8 
Mean 49.35 26.78 0.87 30.06 10.79 
Max 92 56.6 2.23 57.6 215 
SD 13.72 5.03 0.09 9.39 12.50 
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 Gout risk model 
The best logistic regression model contained terms for age, sex, BMI, self-reported 
high blood pressure and alcohol consumption. The coefficients for this model are 
given in Table 32. 
Table 32 – Coefficients included in the gout risk score model 
Coefficients: Estimate Std. Error P-value 
(Intercept) -11.8634 0.7550 < 2 x10-16 
Age 0.0601 0.0084 9.99 x10-13 
Sex (Male) 1.6819 0.2275 1.44 x10-13 
BMI 0.1190 0.0154 1.30 x10-14 
S.R. High Blood Pressure 0.6439 0.1876 6.0 x10-4 
Alcohol (units/week) 0.0139 0.0051 6.28 x10-3 
 
 Correlation with serum urate in Generation Scotland 
Gout risk scores were calculated for Generation Scotland and compared to serum 
urate measurements obtained from EHRs (described in Section 3.2.1.4). Overlap 
between individuals with serum urate measurements and those with complete 
phenotypes for generating gout risk scores was low at only 126 individuals. No 
significant correlation was observed between serum urate levels and gout risk score 
(Spearman’s r = 0.0568, p = 0.528). Correlations were stronger when separated by 
sex, with Spearman’s r = 0.0933 for females and 0.153 for males (Figure 40), but the 
correlation was still not significant (p = 0.0436 and 0.270 respectively). 
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 UK Biobank phenotypes 
Gout status was provided by the Merriman group (UK BB project 12611), and was 
ascertained from self-report, hospital admissions and prescription of serum urate-
lowering medication. Individuals with no information available on gout status were 
removed, leaving 105,421 individuals with definite gout status. After filtering to retain 
only individuals with complete phenotypes for gout prediction, 73,015 remained. The 
majority of individuals removed at this stage were missing alcohol consumption data. 
Summaries of the quantitative phenotypes used to generate gout risk scores are given 
in Table 33. The analysis dataset comprised 33310 females to 39705 males, of whom 
19,245 self-reported high blood pressure. 
Compared to Generation Scotland, average age is similar although the range of ages 
represented is narrower. BMI is comparable, but alcohol consumption appears to be 
slightly higher in the UK Biobank. Both cohorts have a few extremely high-
consumption individuals. 
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Table 33 – Summary of quantitative phenotypes used to generate gout risk score in UK 
Biobank. 
 Age BMI Alcohol (units/week) 
Min 40.00 14.67 0.00 
Median 58.00 26.50 16.80 
Mean 56.88 27.04 22.72 
Max 73.00 61.00 239.40 
SD 7.84 4.33 19.11 
 
 UK Biobank risk scores 
Risk scores were generated using the model specified in Table 32. The distribution 
of risk scores is displayed in Figure 41, and it can be clearly observed that while gout 
cases have higher risk scores on average than controls, there are still large numbers 
of controls with high risk scores.  
The model was also used to predict gout status as a means of testing the model in an 
independent population sample. The ROC curve comparing predicted to actual gout 
status is given in Figure 42, with an AUC of 0.8441, suggesting the model predicts 




Figure 41 - Gout risk score distribution in UK Biobank. 
a Kernel density plot of gout risk score split by gout case (1) vs control (0) status.  
b Boxplot of gout risk score by gout case/control status. 
 
 
Figure 42 - ROC curve for gout status prediction in UK Biobank from gout risk score.  
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 Relationship to serum urate GRS 
The serum urate GRS was completely uncorrelated with the gout risk score across 
the whole sample (Spearman’s r = 0.00173, Figure 43). The correlation was stronger 
in gout cases only, but still relatively weak (Spearman’s r = 0.102). 
 
Figure 43 - Scatterplot of gout risk score against serum urate genetic risk score in 
the UK Biobank. 
 Defining hypernormals 
One possible example for defining hypernormality would be to take a threshold of the 
3rd quartile of the gout risk score (>0.0577). This give a ratio of 1,961 gout cases to 
16,761 hypernormal controls. One could also apply the risk score cut-off to gout cases 
as well, to exclude gout cases where the cause is not reflected in the comorbidities 
used to generate the score, and ensure the risks are comparable between groups, 
leaving 1,493 cases.  
A more stringent threshold could be the 90th percentile (>0.114, 879 cases, 6423 
controls) or a more biologically meaningful one the median risk score value of gout 
cases (>0.103, 980 cases, 7572 controls). Exploratory genetic analyses using these 
are to be made by the Merriman group. 
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5.4 Conclusions 
The use of ‘hypernormal  controls’ has been criticised in the field of psychiatric 
genetics, where it has been claimed to introduce bias280. In this example, a 
hypernormal control is a healthy individual with no history of psychiatric disorders at 
all, while the case can have any number of disorders as long as this includes the one 
of interest. Thus, it is impossible to distinguish between an association driven by the 
trait of interest and an association driven by another disorder – by selecting controls 
with no disorders at all, one increases the risk that many phenotypes differ between 
cases and controls. This concern has been noted more generally, as a caution that 
while a hypernormal control study can be more powerful, one must be aware of 
possible bias when selecting controls281. 
To avoid the problem of introducing bias, our analysis should apply the same score 
threshold to both cases and controls. Although this reduces the sample size, the risk 
of detecting loci associated with the phenotypes used to generate the score is also 
reduced. In this sense, our analysis will be closer to a risk-matched control analysis 
and caution should still applied when interpreting the results.  
When the Merriman group run this exploratory GWAS, it will be interesting to see 
whether the results identify loci not seen in a parallel case-hyperuricaemic-control 
analysis. While the overlap between individuals with complete phenotypes for 
calculating gout risk scores and individuals with serum urate measurements is small 
in Generation Scotland, there appears to be no correlation in this cohort. In UK 
Biobank, the comparison of the gout risk score with the serum urate genetic risk score 
suggests that the gout score is capturing an element of risk that is distinct from an 
individual’s genetic predisposition to hyperuricaemia. The GRS will of course not 
completely capture serum urate levels as environmental factors will also affect this, 
but as observed in Section 4.3.7.2, a serum urate GRS provided additional predictive 
power for gout over just age and sex.  
In the interim, the results of the gout phenotypic risk score are presented here. By 
using only non-genetic, non-urate risk factors, I have been able to construct a model 
that predicts gout status with an AUC of 0.84, comparable to the performance of the 
age + sex + GRS model used in Section 4.3.7.2. It is my belief that the ‘misclassified’ 
individuals, those predicted to have gout but who do not, may represent the best set 
of individuals to uncover novel genetic variants protective of gout.  
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 Conclusions and summary 
In this thesis, I have combined two complementary approaches to improve and extend 
our understanding of uric acid and the role it plays in health and disease – its 
relationship with other phenotypes, specifically endophenotypes related to disease, 
and its relationship with genotype. 
In Chapter 2, eleven protein biomarkers for cardiovascular disease were identified as 
being significantly correlated with serum urate levels independently of all the 
remaining 266 proteins tested, as well as age, sex, BMI, eGFR and alcohol 
consumption. Some of these expand on previously reported associations, including 
FGF-21 and FGF-23, demonstrating that the correlations are not explained by any of 
the wide range of covariates included in my models. In other cases, implicit 
associations have been reported, such as that between the uricosuric drug 
benzbromarone and FABP4, but no explicit correlation with serum urate has been 
identified. In many cases, my results represent, to the best of my knowledge, the first 
time that these associations have been identified.  
The protein biomarkers were selected for their association with cardiovascular 
disease or inflammation – and intriguingly, despite the pro-inflammatory role of uric 
acid, no proteins from the INF panel were identified in any of my analyses. Of course, 
CCL3 and IL-1RA are both proteins that play a role in inflammation, but both were on 
the CVD panels. This perhaps hints that the inflammatory role of serum urate is 
sufficiently closely associated with cardiovascular disease that the serum urate-
related inflammatory proteins are biomarkers for CVD.  
I have also investigated associations between serum urate and levels of specific lipid 
species, identifying a negative correlation with PC 38:6, a lipid associated with 
progression of Alzheimer’s disease and Huntington’s disease. Several other lipid 
associations were also identified.  
Despite the targeted set of proteins initially queried, a diverse range of biological 
processes are implicated in the results, including phosphate metabolism and bone 
development, glucose metabolism, adipocyte function, blood pressure regulation. In 
many cases the link with serum urate is known, but the mechanism is only partially 
understood. More targeted analyses, for example, in the case of FGF-21 and GCKR, 
could establish whether the connection with serum urate is driven by pleiotropy or 
whether the relationship is causal. The release of the SCALLOP consortium’s GWAS 
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results for CVD-II, CVD-III and INF proteins will facilitate greatly expanded querying 
of associated pQTLs.  
Chapter 3 began to explore the relationship between variation in the genome and 
serum levels of uric acid in our in-house cohorts, a sample of over 10,000. Though 
larger GWAS have been run in the past, I identified a number of loci that were 
unreported at the time of analysis, in part due to the increased density and accuracy 
of the HRC imputation panel, which allows SNPs closer to the true causal variant to 
be tested for association with the phenotype.   
In addition to this, this chapter showcases the capacity of electronic health record 
linkage in Generation Scotland to provide valid phenotypic data for use in analyses. 
Clinical measurements of uric acid from NHS blood tests for 2,077 individuals were 
used in a GWAS of serum urate which identified the known strong SLC2A9 signal and 
confirming its validity, and also identified novel signals in three additional genes. 
These results were published as part of Nagy et al. (2017)206, and the EHR linkage is 
described more fully in Kerr et al. (2017)282. We also identified an unusual signal in 
the ORCADES cohort on chromosome 11, which we hypothesise may be caused by 
a pericentric inversion containing the gene SLC22A12, encoding the known urate 
transporter URAT1. Though we cannot easily test this hypothesis, we will soon have 
access to whole genome sequencing data which might identify rare coding or 
structural variants in URAT1 in individuals who appear to drive this signal. 
In Chapter 4, I have expanded on this exploration of genotypic associations with 
serum urate, reporting my contributions to the large meta-analysis of over 450,000 
individuals run by the CKDGen consortium, which at the time of writing is about to be 
submitted for publication. This major collaboration is the work of many authors, but I 
have played a central role in the meta-analysis itself, as well as running many of the 
secondary analyses. We have identified 183 loci genome-wide, with 147 considered 
novel – a five-fold increase in the number of loci known to influence serum urate 
levels, and a major resource that will be made available to the broader scientific 
community.  
When the UK Biobank biochemistry data is released, it will likely not be long before 
GWAS of these new phenotypes are run, including urate – this will mean a sample 
size of up to half a million individuals, almost certainly exceeding the size we have 
achieved with our meta-analysis, and requiring much less analyst time. There is an 
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inevitable question which must be asked: was our analysis worth it? I believe that it 
was, for three reasons.  
Firstly, previous rounds of data release from the UK biobank have shown an early 
‘gold rush’, where groups race to be the first to publish GWAS results for new 
phenotypes. For example, a pre-publication manuscript of an analysis of the UK 
Biobank depression phenotypes was released on bioRχiv (www.biorxiv.org, a pre-
print server for biological sciences, where researchers can upload papers that have 
not yet been accepted for publication, both to share their results as early as possible, 
and to establish precedent and avoid competition with other groups) within a single 
week of the data being published283. In this case, the scope was limited to a small set 
of phenotypes and the analysis thorough, but in others, automated pipelines have 
been used to run a GWAS on every phenotype available, and the results released as 
a ‘resource’ without further comment140,274,275. While these easily-queried databases 
are undeniably a valuable resource – I have made use of them myself several times 
in this thesis – they provide no interpretation of the results. All the user gets is an 
association and a P-value for a SNP with a trait. In contrast, a paper such as ours 
develops the analysis further, using the combined experience of a large analyst group 
to interpret results, and performing downstream fine-mapping and annotation as well 
as expert knowledge of phenotypes studied.   
Secondly, while the UK Biobank is a powerful resource, it represents a primarily 
European-ancestry sample, with 94.6% of participants self-reporting their ethnicity as 
“White British”, a slightly higher proportion than the UK as a whole (91.3%)284. While 
representative of its country of origin, it covers only a limited part of the spectrum of 
genetic diversity worldwide – a criticism that can be aimed at the GWAS field in 
general. The political and scientific factors driving this have been debated285–287 but it 
is clear that there is a disadvantage to missing this diversity. For example, the PAGE 
study looked at variants identified in Europeans as being associated with BMI, lipid 
levels and type 2 diabetes in five non-European populations, and found that 25% of 
these had a different effect in at least of one population288. Differences in LD and 
haplotype frequency across populations can also be useful tools for fine-mapping. 
While our study is still predominantly European, it contains a significant non-European 
component, which we have been able to use to identify loci that would otherwise have 
been missed. Using my transethnic meta-regression analysis implemented in MR-
MEGA, I was even able to use data from multiple ethnicities to identify an association 
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with the SLC2A2 locus, a region that was identified in East Asians separately, but with 
a lead SNP in the less promising candidate EIF5A2. 
Finally, the fact we ran our GWAS on a separate sample to the UK Biobank allows it 
to be used as a resource for secondary analyses. Because the effects for the SNPs 
used to create the risk score were established in a separate population, we avoid 
having to choose between dividing our sample into a training and testing set, 
sacrificing power, or running the GRS regression in the same data set used to build 
the score, risking overfitting of the model, and failing to prove its generalisability.  
Additionally, when the UK Biobank data is released, as the overlap between our 
sample and the UK Biobank is minimal (though non-zero, as there are at the least a 
small number of individuals represented in both UK Biobank and Generation 
Scotland), it will be possible to meta-analyse the GWAS results from our project 
together with the new data. This combined sample will approach a million individuals 
and will likely bring a whole new wave of associated loci, which might help to address 
the question of whether urate follows the ‘omnigenic’ structure.  
This analysis has also fed back into the results from Chapter 2, with the meta-analysis 
used to look up SNPs associated with serum levels of the protein biomarkers 
significantly correlated with uric acid. A promising association was at the GCKR locus 
for FGF-21, but no colocalisation of signals was detected. However, since this locus 
was only suggestively associated with FGF-21, it will be informative to repeat using 
the results from the larger GWAS currently being run by SCALLOP. 
The field of statistical genetics is constantly evolving, with new tools and methods 
constantly being developed and refined. Even in the time since completing analysis 
on this thesis, a new method has been published by O’Connor and Price for 
distinguishing in genetic correlations genetic pleiotropy from causation289, avoiding 
the confounding that creates problems in MR from shared aetiology between traits. 
This method that could be applied to the tests for genetic correlation between protein 
biomarkers and serum urate, once the SCALLOP consortium has published GWAS 
of sufficient size to apply the method. Adrienne Tin is currently running this analysis 
on the CKDGen urate results, to supplement the publication.  The method currently 
lacks the straightforward and user-friendly implementation of LDSC or LD-hub, the 
other Price group methods, making it difficult to implement at this late stage, but it 
serves to illustrate that this field is under constant development. Our published results 
will hopefully be integrated into many projects to come. 
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Chapter 5 is a review of the progress on a collaborative project with the Merriman 
group at the University of Otago. This project began as an exploration of how to make 
use of the UK Biobank cohort before the release of the biochemistry data. While the 
data release has been pushed back multiple times over the last three years, with no 
release date yet confirmed, this project has developed into a thriving collaboration.  
The use of controls with a high phenotypic risk for gout should complement their 
ongoing analysis using hyperuricaemic control, as our preliminary work appears to 
show that these capture different elements of gout risk. That gout status can already 
be predicted quite accurately in the UK Biobank is also of interest. The comorbidities 
of gout are well known, but I to my knowledge no one has published their predictive 
ability in a general healthy population – although I have found an abstract from the 
2013 American College of Rheumatology meeting290 that predicted incident gout in 
hyperuricaemics. My model was able to predict gout status more accurately, but as I 
am predicting prevalent rather than incident gout, a true comparison will not be 
possible until more data is available on incident cases from the cohort. I look forward 
to seeing the development of this analysis. 
These separate chapters explore in detail different facets of two central questions – 
how is urate metabolism and homeostasis regulated, and how does its dysregulation 
lead to disease? Serum urate levels are a convenient proxy measure for a complex 
integration of physiological processes, including metabolism of urate, renal excretion 
and reabsorption, elimination in the intestine and dietary intake of purines. I have 
identified a large number of new regions of the genome associated with variation in 
serum urate levels, both independently and as part of a large GWAS consortium. 
Though we have interpreted these results as best we can, and our results support a 
strong role for the kidney in regulation of serum urate levels, it will likely take many 
years before the roles of the loci we have detected are fully understood. I have also 
identified multiple protein biomarkers for cardiovascular disease that appear to be 
linked to changes in serum urate levels, which, with further investigation of pleiotropy 
and causality, may help elucidate the mechanisms that connect hyperuricaemia with 
CVD.  
On the question of further work, in particular I would like to further understand the link 
between serum urate levels and the proteins I identified, starting by testing whether 
they persist when a different platform is used to quantify them. The INTERVAL cohort 
has offered to apply my technique to their SOMAscan data, which measures an order 
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of magnitude more proteins than the Olink data we have available. If associations 
were found to persist on a different platform and with the levels of a much wider range 
of proteins taken into account, their validity would be strongly confirmed. The release 
of more detailed pQTL data from SCALLOP will also testing of causality with MR and 
other techniques. And finally, when the UK Biobank serum urate data is finally 
released, genetic associations for these proteins could be used to impute their levels 
in this very large cohort, allowing stratification and interaction analyses with uric acid 
levels – an early aim for this project, before the delay made this unfeasible. As with 
many endeavours in science, I conclude this project with as many new questions as 
I have answers. 
In summary, this thesis has contributed to the study of uric acid homeostasis and its 
related disease through exploration of its relationship with both genotype and with 
endophenotypes related with disease.  
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XI. Supplementary Tables 
Supplementary Table 1 – List of all Olink proteins and non-Olink phenotypes included 
in correlation and lasso regression analyses. 
Figure Display Name Protein Name Symbol UniProt ID 
CVD2_101_BMP.6 Bone morphogenetic protein 6 BMP-6 P22004 
CVD2_102_ANG.1 Angiopoietin-1 ANG-1 Q15389 
CVD2_103_ADM ADM ADM P35318 
CVD2_105_CD40.L CD40 ligand CD40-L P29965 
CVD2_106_SLAMF7 SLAM family member 7 SLAMF7 Q9NQ25 
CVD2_107_PlGF Placenta growth factor PGF P49763 
CVD2_108_ADAM.TS13 
A disintegrin and metalloproteinase with 
thrombospondin motifs 13 
ADAM-TS13 Q76LX8 
CVD2_109_Protein.BOC Brother of CDO Protein BOC Q9BWV1 
CVD2_110_IL.4RA Interleukin-4 receptor subunit alpha IL-4RA P24394 
CVD2_111_SRC Proto-oncogene tyrosine-protein kinase Src SRC P12931 
CVD2_112_IL.1ra Interleukin-1 receptor antagonist protein IL-1ra P18510 
CVD2_113_IL.6 Interleukin-6 IL6 P05231 
CVD2_114_TNFRSF10A 
Tumour necrosis factor receptor superfamily member 
10A 
TNFRSF10A O00220 
CVD2_115_STK4 Serine/threonine-protein kinase 4 STK4 Q13043 
CVD2_116_IDUA Alpha-L-iduronidase IDUA P35475 
CVD2_117_TNFRSF11A 
Tumour necrosis factor receptor superfamily member 
11A 
TNFRSF11A Q9Y6Q6 
CVD2_118_PAR.1 Proteinase-activated receptor 1 PAR-1 P25116 
CVD2_120_TRAIL.R2 TNF-related apoptosis-inducing ligand receptor 2 TRAIL-R2 O14763 
CVD2_121_PRSS27 Serine protease 27 PRSS27 Q9BQR3 
CVD2_122_TIE2 Angiopoietin-1 receptor TIE2 Q02763 
CVD2_123_TF Tissue factor TF P13726 
CVD2_124_IL1RL2 Interleukin-1 receptor-like 2 IL1RL2 Q9HB29 
CVD2_125_PDGF.subunit.B Platelet-derived growth factor subunit B PDGF subunit B P01127 
CVD2_126_IL27 Interleukin-27 IL-27 Q8NEV9 
CVD2_127_IL.17D Interleukin-17D IL-17D Q8TAD2 
CVD2_128_CXCL1 C-X-C motif chemokine 1 CXCL1 P09341 
CVD2_129_LOX.1 Lectin-like oxidized LDL receptor 1 LOX-1 P78380 
CVD2_130_Gal.9 Galectin-9 Gal-9 O00182 
CVD2_131_GIF Gastric intrinsic factor GIF P27352 
CVD2_132_SCF Stem cell factor SCF P21583 
CVD2_133_IL.18 Interleukin-18 IL-18 Q14116 
CVD2_134_FGF.21 Fibroblast growth factor 21 FGF-21 Q9NSA1 
CVD2_135_PIgR Polymeric immunoglobulin receptor PIgR P01833 
CVD2_136_RAGE Receptor for advanced glycosylation end products RAGE Q15109 
CVD2_137_SOD2 Superoxide dismutase [Mn], mitochondrial SOD2 P04179 
CVD2_138_CTRC Chymotrypsin C CTRC Q99895 
CVD2_139_FGF.23 Fibroblast growth factor 23 FGF-23 Q9GZV9 
CVD2_140_SPON2 Spondin-2 SPON2 Q9BUD6 
CVD2_141_GH Growth hormone GH P01241 
CVD2_142_FS Follistatin FS P19883 
CVD2_143_GLO1 Lactoylglutathione lyase GLO1 Q04760 
CVD2_144_CD84 SLAM family member 5 CD84 Q9UIB8 
CVD2_145_PAPPA Pappalysin-1 PAPPA Q13219 
CVD2_148_SERPINA12 Serpin A12 SERPINA12 Q8IW75 
CVD2_149_REN Renin REN P00797 
CVD2_150_DECR1 2,4-dienoyl-CoA reductase, mitochondrial DECR1 Q16698 
CVD2_151_MERTK Tyrosine-protein kinase Mer MERTK Q12866 
CVD2_152_TIM Kidney Injury Molecule KIM1 Q96D42 
CVD2_153_THBS2 Thrombospondin-2 THBS2 P35442 
CVD2_154_TM Thrombomodulin TM P07204 
CVD2_155_VSIG2 V-set and immunoglobulin domain-containing protein 2 VSIG2 Q96IQ7 
CVD2_156_AMBP Protein AMBP AMBP P02760 
CVD2_157_PRELP Prolargin PRELP P51888 
CVD2_158_HO.1 Heme oxygenase 1 HO-1 P09601 
CVD2_159_XCL1 Lymphotactin XCL1 P47992 
CVD2_160_IL16 Pro-interleukin-16 IL16 Q14005 
CVD2_161_SORT1 Sortilin SORT1 Q99523 
CVD2_162_CEACAM8 
Carcinoembryonic antigenrelated cell adhesion 
molecule 8 
CEACAM8 P31997 
CVD2_163_PTX3 Pentraxin-related protein PTX3 PTX3 P26022 
CVD2_164_PSGL.1 P-selectin glycoprotein ligand 1 PSGL-1 Q14242 
CVD2_165_CCL17 C-C motif chemokine 17 CCL17 Q92583 
CVD2_166_CCL3 C-C motif chemokine 3 CCL3 P10147 
CVD2_167_MMP.7 Matrix metalloproteinase-7 MMP-7 P09237 
CVD2_168_IgG.Fc.receptor.II.b 
Low affinity immunoglobulin gamma Fc region receptor 
II-b 
IgG Fc receptor II-b P31994 
CVD2_169_ITGB1BP2 Melusin ITGB1BP2 Q9UKP3 
CVD2_170_DCN Decorin DCN P07585 
CVD2_171_Dkk.1 Dickkopf-related protein 1 Dkk-1 O94907 
CVD2_172_LPL Lipoprotein lipase LPL P06858 
CVD2_173_PRSS8 Prostasin PRSS8 Q16651 
CVD2_174_AGRP Agouti-related protein AGRP O00253 
CVD2_175_HB.EGF Proheparin-binding EGF-like growth factor HB-EGF Q99075 
CVD2_176_GDF.2 Growth/differentiation factor 2 GDF-2 Q9UK05 
CVD2_177_FABP2 Fatty acid-binding protein, intestinal FABP2 P12104 
CVD2_178_THPO Thrombopoietin THPO P40225 
CVD2_179_MARCO Macrophage receptor MARCO MARCO Q9UEW3 
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CVD2_180_GT Gastrotropin GT P51161 
CVD2_181_BNP Natriuretic peptides B BNP P16860 
CVD2_182_MMP.12 Matrix metalloproteinase-12 MMP-12 P39900 
CVD2_183_ACE2 Angiotensin-converting enzyme 2 ACE2 Q9BYF1 
CVD2_184_PD.L2 Programmed cell death 1 ligand 2 PD-L2 Q9BQ51 
CVD2_185_CTSL1 Cathepsin L1 CTSL1 P07711 
CVD2_186_hOSCAR Osteoclast-associated immunoglobulin-like receptor hOSCAR Q8IYS5 
CVD2_187_TNFRSF13B 
Tumour necrosis factor receptor superfamily member 
13B 
TNFRSF13B O14836 
CVD2_188_TGM2 Protein-glutamine gamma-glutamyltransferase 2 TGM2 P21980 
CVD2_189_LEP Leptin LEP P41159 
CVD2_190_CA5A Carbonic anhydrase 5A, mitochondrial CA5A P35218 
CVD2_191_HSP.27 Heat shock 27 kDa protein HSP 27 P04792 
CVD2_192_CD4 T-cell surface glycoprotein CD4 CD4 P01730 
CVD2_193_NEMO NF-kappa-B essential modulator NEMO Q9Y6K9 
CVD2_194_VEGF.D Vascular endothelial growth factor D VEGFD O43915 
CVD2_195_PARP.1 Poly [ADP-ribose] polymerase 1 PARP-1 P09874 
CVD2_196_HAOX1 Hydroxyacid oxidase 1 HAOX1 Q9UJM8 
CVD3_101_TNFRSF14 
Tumour necrosis factor receptor superfamily member 
14 
TNFRSF14 Q92956 
CVD3_102_LDL.receptor Low-density lipoprotein receptor LDL receptor P01130 
CVD3_103_ITGB2 Integrin beta-2 ITGB2 P05107 
CVD3_105_IL.17RA Interleukin-17 receptor A IL-17RA Q96F46 
CVD3_106_TNF.R2 Tumour necrosis factor receptor 2 TNF-R2 P20333 
CVD3_107_MMP.9 Matrix metalloproteinase-9 MMP-9 P14780 
CVD3_108_EPHB4 Ephrin type-B receptor 4 EPHB4 P54760 
CVD3_109_IL2.RA Interleukin-2 receptor subunit alpha IL2-RA P01589 
CVD3_110_OPG Osteoprotegerin OPG O00300 
CVD3_111_ALCAM CD166 antigen ALCAM Q13740 
CVD3_112_TFF3 Trefoil factor 3 TFF3 Q07654 
CVD3_113_SELP P-selectin SELP P16109 
CVD3_114_CSTB Cystatin-B CSTB P04080 
CVD3_115_MCP.1 Monocyte chemotactic protein 1 MCP-1 P13500 
CVD3_116_CD163 Scavenger receptor cysteine-rich type 1 protein M130 CD163 Q86VB7 
CVD3_117_Gal.3 Galectin-3 Gal-3 P17931 
CVD3_118_GRN Granulins GRN P28799 
CVD3_120_MEPE Matrix extracellular phosphoglycoprotein MEPE Q9NQ76 
CVD3_121_BLM.hydrolase Bleomycin hydrolase BLM hydrolase Q13867 
CVD3_122_PLC Perlecan PLC P98160 
CVD3_123_LTBR Lymphotoxin-beta receptor LTBR P36941 
CVD3_124_Notch.3 Neurogenic locus notch homolog protein 3 Notch 3 Q9UM47 
CVD3_125_TIMP4 Metalloproteinase inhibitor 4 TIMP4 Q99727 
CVD3_126_CNTN1 Contactin-1 CNTN1 Q12860 
CVD3_127_CDH5 Cadherin-5 CDH5 P33151 
CVD3_128_TLT.2 Trem-like transcript 2 protein TLT-2 Q5T2D2 
CVD3_129_FABP4 Fatty acid-binding protein, adipocyte FABP4 P15090 
CVD3_130_TFPI Tissue factor pathway inhibitor TFPI P10646 
CVD3_131_PAI Plasminogen activator inhibitor 1 PAI P05121 
CVD3_132_CCL24 C-C motif chemokine 24 CCL24 O00175 
CVD3_133_TR Transferrin receptor protein 1 TR P02786 
CVD3_134_TNFRSF10C 
Tumour necrosis factor receptor superfamily member 
10C 
TNFRSF10C O14798 
CVD3_135_GDF.15 Growth/differentiation factor 15 GDF-15 Q99988 
CVD3_136_SELE E-selectin SELE P16581 
CVD3_137_AZU1 Azurocidin AZU1 P20160 
CVD3_138_DLK.1 Protein delta homolog 1 DLK-1 P80370 
CVD3_139_SPON1 Spondin-1 SPON1 Q9HCB6 
CVD3_140_MPO Myeloperoxidase MPO P05164 
CVD3_141_CXCL16 C-X-C motif chemokine 16 CXCL16 Q9H2A7 
CVD3_142_IL.6RA Interleukin-6 receptor subunit alpha IL-6RA P08887 
CVD3_143_RETN Resistin RETN Q9HD89 
CVD3_144_IGFBP.1 Insulin-like growth factor-binding protein 1 IGFBP-1 P08833 
CVD3_145_CHIT1 Chitotriosidase-1 CHIT1 Q13231 
CVD3_148_TR.AP Tartrate-resistant acid phosphatase type 5 TR-AP P13686 
CVD3_150_PSP.D Pulmonary surfactant-associated protein D PSP-D P35247 
CVD3_151_PI3 Elafin PI3 P19957 
CVD3_152_Ep.CAM Epithelial cell adhesion molecule Ep-CAM P16422 
CVD3_153_AP.N Aminopeptidase N AP-N P15144 
CVD3_154_AXL Tyrosine-protein kinase receptor UFO AXL P30530 
CVD3_155_IL.1RT1 Interleukin-1 receptor type 1 IL-1RT1 P14778 
CVD3_156_MMP.2 Matrix metalloproteinase-2 MMP-2 P08253 
CVD3_157_FAS Tumour necrosis factor receptor superfamily member 6 FAS P25445 
CVD3_158_MB Myoglobin MB P02144 
CVD3_159_TNFSF13B Tumour necrosis factor ligand superfamily member 13B TNFSF13B Q9Y275 
CVD3_160_PRTN3 Myeloblastin PRTN3 P24158 
CVD3_161_PCSK9 Proprotein convertase subtilisin/kexin type 9 PCSK9 Q8NBP7 
CVD3_162_U.PAR Urokinase plasminogen activator surface receptor U-PAR Q03405 
CVD3_163_OPN Osteopontin OPN P10451 
CVD3_164_CTSD Cathepsin D CTSD P07339 
CVD3_165_PGLYRP1 Peptidoglycan recognition protein 1 PGLYRP1 O75594 
CVD3_166_CPA1 Carboxypeptidase A1 CPA1 P15085 
CVD3_167_JAM.A Junctional adhesion molecule A JAM-A Q9Y624 
CVD3_168_Gal.4 Galectin-4 Gal-4 P56470 
CVD3_169_IL.1RT2 Interleukin-1 receptor type 2 IL-1RT2 P27930 
CVD3_170_SHPS.1 
Tyrosine-protein phosphatase non-receptor type 
substrate 1 
SHPS-1 P78324 
CVD3_171_CCL15 C-C motif chemokine 15 CCL15 Q16663 
CVD3_172_CASP.3 Caspase-3 CASP-3 P42574 
CVD3_173_uPA Urokinase-type plasminogen activator uPA P00749 
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CVD3_174_CPB1 Carboxypeptidase B CPB1 P15086 
CVD3_175_CHI3L1 Chitinase-3-like protein 1 CHI3L1 P36222 
CVD3_176_ST2 ST2 protein ST2 Q01638 
CVD3_177_t.PA Tissue-type plasminogen activator t-PA P00750 
CVD3_178_SCGB3A2 Secretoglobin family 3A member 2 SCGB3A2 Q96PL1 
CVD3_179_EGFR Epidermal growth factor receptor EGFR P00533 
CVD3_180_IGFBP.7 Insulin-like growth factor-binding protein 7 IGFBP-7 Q16270 
CVD3_181_CD93 Complement component C1q receptor CD93 Q9NPY3 
CVD3_182_IL.18BP Interleukin-18-binding protein IL-18BP O95998 
CVD3_183_COL1A1 Collagen alpha-1(I) chain COL1A1 P02452 
CVD3_184_PON3 Paraoxonase PON3 Q15166 
CVD3_185_CTSZ Cathepsin Z CTSZ Q9UBR2 
CVD3_186_MMP.3 Matrix metalloproteinase-3 MMP-3 P08254 
CVD3_187_RARRES2 Retinoic acid receptor responder protein 2 RARRES2 Q99969 
CVD3_188_ICAM.2 Intercellular adhesion molecule 2 ICAM-2 P13598 
CVD3_189_KLK6 Kallikrein-6 KLK6 Q92876 
CVD3_190_PDGF.subunit.A Platelet-derived growth factor subunit A PDGF subunit A P04085 
CVD3_191_TNF.R1 Tumour necrosis factor receptor 1 TNF-R1 P19438 
CVD3_192_IGFBP.2 Insulin-like growth factor-binding protein 2 IGFBP-2 P18065 
CVD3_193_vWF von Willebrand factor vWF P04275 
CVD3_194_PECAM.1 Platelet endothelial cell adhesion molecule PECAM-1 P16284 
CVD3_195_NT.pro.BNP N-terminal prohormone brain natriuretic peptide NT-proBNP NA 
CVD3_196_CCL16 C-C motif chemokine 16 CCL16 O15467 
INF_101_IL.8 Interleukin-8 IL-8 P10145 
INF_102_VEGF.A Vascular endothelial growth factor A VEGF-A P15692 
INF_105_MCP.3 Monocyte chemotactic protein 3 MCP-3 P80098 
INF_106_hGDNF Glial cell line-derived neurotrophic factor GDNF P39905 
INF_107_CDCP1 CUB domain-containing protein 1 CDCP1 Q9H5V8 
INF_108_CD244 Natural killer cell receptor 2B4 CD244 Q9BZW8 
INF_109_IL.7 Interleukin-7 IL-7 P13232 
INF_111_LAP.TGF.beta.1 
Latency-associated peptide transforming growth factor 
beta-1 
Lap TGF beta 1 P01137 
INF_114_IL.17C Interleukin-17C IL-17C Q9P0M4 
INF_116_IL.17A Interleukin-17A IL-17A Q16552 
INF_117_CXCL11 C-X-C motif chemokine 11 CXCL11 O14625 
INF_118_AXIN1 Axin-1 AXIN1 O15169 
INF_120_TRAIL TNF-related apoptosis-inducing ligand TRAIL P50591 
INF_121_IL.20RA Interleukin-20 receptor subunit alpha IL-20RA Q9UHF4 
INF_122_CXCL9 C-X-C motif chemokine 9 CXCL9 Q07325 
INF_123_CST5 Cystatin D CST5 P28325 
INF_124_IL.2RB Interleukin-2 receptor subunit alpha IL2-RA P01589 
INF_125_IL.1.alpha Interleukin-2 receptor subunit beta IL-2RB P14784 
INF_126_OSM Oncostatin-M OSM P13725 
INF_127_IL.2 N-terminal prohormone brain natriuretic peptide NT-proBNP NA 
INF_129_TSLP Thymic stromal lymphopoietin TSLP Q969D9 
INF_130_CCL4 C-C motif chemokine 4 CCL4 P13236 
INF_131_CD6 T cell surface glycoprotein CD6 isoform CD6 Q8WWJ7 
INF_134_SLAMF1 Signaling lymphocytic activation molecule SLAMF1 Q13291 
INF_135_TGFA Transforming growth factor alpha TGF-alpha P01135 
INF_136_MCP.4 Monocyte chemotactic protein 4 MCP-4 Q99616 
INF_137_CCL11 Eotaxin CCL11 P51671 
INF_138_TNFSF14 Tumour necrosis factor ligand superfamily member 14 TNFSF14 O43557 
INF_140_IL.10RA Interleukin-10 receptor subunit alpha IL-10RA Q13651 
INF_141_FGF.5 Fibroblast growth factor 5 FGF-5 Q8NF90 
INF_142_MMP.1 Matrix metalloproteinase-1 MMP-1 P03956 
INF_143_LIF.R Leukemia inhibitory factor receptor LIF-R P42702 
INF_145_CCL19 C-C motif chemokine 19 CCL19 Q99731 
INF_148_IL.15RA Interleukin-15 receptor subunit alpha IL-15RA Q13261 
INF_149_IL.10RB Interleukin-10 receptor subunit beta IL-10RB Q08334 
INF_150_IL.22.RA1 Interleukin-22 receptor subunit alpha-1 IL-22 RA1 Q8N6P7 
INF_151_IL.18R1 Interleukin-18 receptor 1 IL-18R1 Q13478 
INF_152_PD.L1 Programmed cell death 1 ligand 1 PD-L1 Q9NZQ7 
INF_153_Beta.NGF Beta-nerve growth factor Beta-NGF P01138 
INF_154_CXCL5 C-X-C motif chemokine 5 CXCL5 P42830 
INF_155_TRANCE TNF-related activation-induced cytokine TRANCE O14788 
INF_156_HGF Hepatocyte growth factor HGF P14210 
INF_157_IL.12B Interleukin-12 subunit beta IL-12B P29460 
INF_158_IL.24 Interleukin-24 IL-24 Q13007 
INF_159_IL.13 Interleukin-13 IL-13 P35225 
INF_160_ARTN Artemin ARTN Q5T4W7 
INF_161_MMP.10 Matrix metalloproteinase-10 MMP-10 P09238 
INF_162_IL.10 Interleukin-10 IL10 P22301 
INF_163_TNF Tumour necrosis factor TNF P01375 
INF_164_CCL23 C-C motif chemokine 23 CCL23 P55773 
INF_165_CD5 T-cell surface glycoprotein CD5 CD5 P06127 
INF_167_Flt3L Fms-related tyrosine kinase 3 ligand Flt3L P49771 
INF_168_CXCL6 C-X-C motif chemokine 6 CXCL6 P80162 
INF_169_CXCL10 C-X-C motif chemokine 10 CXCL10 P02778 
INF_170_4E.BP1 
Eukaryotic translation initiation factor 4E-binding 
protein 1 
4E-BP1 Q13541 
INF_171_IL.20 Interleukin-20 IL-20 Q9NYY1 
INF_172_SIRT2 SIR2-like protein 2 SIRT2 Q8IXJ6 
INF_173_CCL28 C-C motif chemokine 28 CCL28 Q9NRJ3 
INF_174_DNER 
Delta and Notch-like epidermal growth factor-related 
receptor 
DNER Q8NFT8 
INF_175_EN.RAGE Protein S100-A12 EN-RAGE P80511 
INF_176_CD40 CD40L receptor CD40 P25942 
INF_177_IL.33 Interleukin-33 IL-33 O95760 
INF_178_IFN.gamma Interferon gamma IFN-gamma P01579 
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INF_179_FGF.19 Fibroblast growth factor 19 FGF-19 O95750 
INF_180_IL.4 Interleukin-4 IL-4 P05112 
INF_181_LIF Leukemia inhibitory factor LIF P15018 
INF_182_NRTN Neurturin NRTN Q99748 
INF_183_MCP.2 Monocyte chemotactic protein 2 MCP-2 P80075 
INF_184_CASP.8 Caspase-8 CASP-8 Q14790 
INF_185_CCL25 C-C motif chemokine 25 CCL25 O15444 
INF_186_CX3CL1 Fractalkine CX3CL1 P78423 
INF_187_TNFRSF9 Tumour necrosis factor receptor superfamily member 9 TNFRSF9 Q07011 
INF_188_NT.3 Neurotrophin-3 NT-3 P20783 
INF_189_TWEAK 
Tumour necrosis factor (Ligand) superfamily, member 
12 
TWEAK O43508 
INF_190_CCL20 C-C motif chemokine 20 CCL20 P78556 
INF_191_ST1A1 Sulfotransferase 1A1 ST1A1 P50225 
INF_192_STAMPB STAM-binding protein STAMBP O95630 
INF_193_IL.5 Interleukin-5 IL5 P05113 
INF_194_ADA Adenosine Deaminase ADA P00813 
INF_195_TNFB TNF-beta TNFB P01374 
INF_196_CSF.1 Macrophage colony-stimulating factor 1 CSF-1 P09603 
CVD1_AM Adrenomedullin AM NA 
CVD1_CA125 Ovarian cancer-related tumour marker 125 CA125 NA 
CVD1_ECP Eosinophil cationic protein ECP NA 
CVD1_EGF Epidermal growth factor EGF NA 
CVD1_ESM1 Endothelial cell-specific molecule 1 ESM1 NA 
CVD1_GAL Galanin peptides GAL NA 
CVD1_hK11 Kallikrein-11 hK11 NA 
CVD1_PRL Prolactin PRL NA 
Non-Olink Phenotypes    
Display Name Phenotype   
alc_gpW Alcohol consumption - - 
bmi Body Mass Index - - 
eGFR Estimated Glomerular Filtration Rate - - 
 
Supplementary Table 2 – Serum urate-Olink lasso regression mean coefficients 
Phenotype Cohort Count Coef. Mean Coef. SD 
BMI 
Vis & ORCADES 1000 0.073 0.002 
EGCUT 1000 0.100 0.002 
INTERVAL 7 0.000 0.000 
Lifelines DEEP 1000 0.090 0.001 
FGF-21 
Vis & ORCADES 1000 0.077 0.002 
EGCUT 1000 0.041 0.007 
INTERVAL 600 0.010 0.010 
Lifelines DEEP NA NA NA 
CCL3 
Vis & ORCADES 1000 0.010 0.000 
EGCUT 1000 0.017 0.002 
INTERVAL 0 - - 
Lifelines DEEP NA NA NA 
LDL-receptor 
Vis & ORCADES 999 0.020 0.005 
EGCUT 0 - - 
INTERVAL 0 - - 
Lifelines DEEP 1000 0.058 0.009 
PLC  
Vis & ORCADES 1000 0.049 0.013 
EGCUT 1000 0.029 0.005 
INTERVAL 0 - - 
Lifelines DEEP 0 - - 
FABP4 
Vis & ORCADES 1000 0.101 0.005 
EGCUT 1000 0.085 0.010 
INTERVAL 1000 0.048 0.006 
Lifelines DEEP 1000 0.020 0.004 
MMP-2 
Vis & ORCADES 1000 -      0.042 0.011 
EGCUT 138 -      0.001 0.002 
INTERVAL 0 - - 
Lifelines DEEP 892 -      0.012 0.011 
CHI3L1 
Vis & ORCADES 1000 0.030 0.002 
EGCUT 598 0.007 0.008 
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INTERVAL 0 - - 
Lifelines DEEP 0 - - 
PON3 
Vis & ORCADES 1000 -      0.070 0.001 
EGCUT 1000 -      0.026 0.004 
INTERVAL 0 - - 
Lifelines DEEP 1000 -      0.025 0.004 
IGFBP-2 
Vis & ORCADES 1000 -      0.137 0.005 
EGCUT 851 -      0.015 0.010 
INTERVAL 7 -      0.000 0.000 
Lifelines DEEP 1000 -      0.074 0.005 
eGFR 
Vis & ORCADES 1000 -      0.106 0.001 
EGCUT 1000 -      0.126 0.016 
INTERVAL 1000 -      0.107 0.019 
Lifelines DEEP 1000 -      0.073 0.015 
 
Supplementary Table 3 - Serum urate-lipidomic lasso regression mean coefficients. 
For all phenotypes appearing in 95% of models in one or more analyses. 
Phenotype Subset Count Coef. Mean Coef. SD 
alc_gpW All 581 0.006 0.007 
alc_gpW CKD excluded 984 0.015 0.004 
alc_gpW Female 2 0.000 0.000 
alc_gpW Male 0 0.000 0.000 
bmi All 1000 0.195 0.003 
bmi CKD excluded 1000 0.197 0.003 
bmi Female 1000 0.197 0.006 
bmi Male 1000 0.128 0.009 
C_18__0 All 986 0.027 0.009 
C_18__0 CKD excluded 1000 0.026 0.004 
C_18__0 Female 938 0.008 0.003 
C_18__0 Male 0 0.000 0.000 
eGFR All 1000 -0.157 0.023 
eGFR CKD excluded 1000 -0.118 0.014 
eGFR Female 1000 -0.113 0.017 
eGFR Male 753 -0.014 0.015 
LPC_15__0 All 80 0.000 0.001 
LPC_15__0 CKD excluded 0 0.000 0.000 
LPC_15__0 Female 974 -0.014 0.007 
LPC_15__0 Male 0 0.000 0.000 
LPC_20__0 All 1000 -0.063 0.002 
LPC_20__0 CKD excluded 1000 -0.055 0.001 
LPC_20__0 Female 1000 -0.038 0.005 
LPC_20__0 Male 884 -0.031 0.019 
LPC_22__4 All 958 -0.034 0.022 
LPC_22__4 CKD excluded 999 -0.053 0.014 
LPC_22__4 Female 790 -0.021 0.019 
LPC_22__4 Male 2 0.000 0.000 
PC_30__1 All 801 -0.011 0.009 
PC_30__1 CKD excluded 984 -0.019 0.006 
PC_30__1 Female 945 -0.023 0.011 
PC_30__1 Male 0 0.000 0.000 
PC_38__3 All 801 0.011 0.009 
PC_38__3 CKD excluded 1000 0.027 0.004 
PC_38__3 Female 783 0.004 0.002 
PC_38__3 Male 0 0.000 0.000 
PC_O_34__2 All 986 -0.017 0.009 
PC_O_34__2 CKD excluded 960 -0.011 0.004 
PC_O_34__2 Female 0 0.000 0.000 
PC_O_34__2 Male 84 -0.001 0.003 
PC_O_36__2 All 1000 -0.060 0.008 
PC_O_36__2 CKD excluded 1000 -0.055 0.008 
PC_O_36__2 Female 1000 -0.060 0.003 
PC_O_36__2 Male 0 0.000 0.000 
PC_O_40__6 All 404 -0.007 0.010 
PC_O_40__6 CKD excluded 936 -0.030 0.012 
PC_O_40__6 Female 994 -0.021 0.005 
PC_O_40__6 Male 0 0.000 0.000 
PE_32__1 All 1000 0.033 0.008 
PE_32__1 CKD excluded 1000 0.029 0.006 
PE_32__1 Female 1000 0.047 0.008 
PE_32__1 Male 0 0.000 0.000 
PE_40__6 All 1000 0.183 0.014 
PE_40__6 CKD excluded 1000 0.218 0.020 
PE_40__6 Female 1000 0.121 0.010 
PE_40__6 Male 1000 0.183 0.017 
PLPE_16__0_20__5 All 581 0.011 0.012 
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PLPE_16__0_20__5 CKD excluded 960 0.014 0.005 
PLPE_16__0_20__5 Female 0 0.000 0.000 
PLPE_16__0_20__5 Male 2 0.000 0.000 
sbp All 998 0.030 0.008 
sbp CKD excluded 999 0.022 0.003 
sbp Female 994 0.031 0.011 
sbp Male 0 0.000 0.000 
SPM_15__0 All 494 -0.007 0.009 
SPM_15__0 CKD excluded 984 -0.024 0.007 
SPM_15__0 Female 994 -0.028 0.009 
SPM_15__0 Male 0 0.000 0.000 
SPM_dih_18__0 All 494 0.005 0.006 
SPM_dih_18__0 CKD excluded 997 0.029 0.007 
SPM_dih_18__0 Female 90 0.001 0.002 
SPM_dih_18__0 Male 0 0.000 0.000 
223 
 
Supplementary Table 4 – 183 index SNPs identified in the CKDGen trans-ethnic meta-analysis 
RSID Chr. position (b37) A1/A2 EAF Function Gene Name Effect (mg/dL) SE p-value I2 (%) Phet Panc-het Gout OR Gout OR 95% CI Gout OR 95% CI 
rs10803394 1 15,909,480 C/G 0.373 intron AGMAT -0.020 0.0032 5.83E-10 0 6.92E-01 3.50E-01 0.96 0.93 0.98 
rs79598313 1 27,284,913 T/C 0.026 intron KDF1 0.102 0.0127 1.16E-15 10.7 2.43E-01 8.00E-02 1.39 1.28 1.50 
rs10890263 1 44,061,032 T/C 0.737 intron PTPRF -0.020 0.0037 4.83E-08 17.9 1.01E-01 7.50E-01 0.99 0.96 1.02 
rs584425 1 48,536,798 A/G 0.333 unknown SKINT1L -0.021 0.0033 1.36E-10 0.9 4.56E-01 6.20E-01 0.98 0.95 1.00 
rs2356864 1 50,839,740 A/G 0.568 unknown DMRTA2 0.020 0.0034 1.69E-09 0 8.96E-01 5.30E-01 1.02 1.00 1.05 
rs662026 1 91,531,022 A/G 0.800 unknown ZNF644 0.021 0.0038 3.26E-08 0 7.25E-01 8.30E-01 1.04 1.00 1.07 
rs7417952 1 93,854,186 C/G 0.396 unknown DR1 -0.023 0.0037 2.75E-10 0 5.51E-01 9.00E-01 0.95 0.90 1.00 
rs141990161 1 119,943,525 T/C 0.985 unknown HAO2 0.133 0.0235 1.59E-08 26.4 7.11E-02 8.40E-02 1.19 1.04 1.36 
rs10910845 1 145,723,120 A/C 0.539 unknown NBPF20 0.060 0.0034 1.10E-69 0 6.63E-01 4.40E-01 1.12 1.09 1.15 
rs11204682 1 150,595,537 T/G 0.193 intron, near-gene-3’ ENSA 0.032 0.0043 6.00E-14 0.9 4.55E-01 4.00E-02 1.03 1.00 1.06 
rs2070803 1 155,157,715 A/G 0.497 near-gene-3’ TRIM46 0.054 0.0033 2.12E-60 14 1.61E-01 8.20E-01 1.08 1.05 1.11 
rs12134456 1 155,722,506 C/G 0.635 intron GON4L -0.044 0.0048 6.33E-20 4.4 3.76E-01 7.10E-01 0.94 0.92 0.97 
rs2760215 1 163,675,883 T/C 0.451 unknown LOC100422212 -0.022 0.0033 7.55E-12 0 7.41E-01 4.60E-01 0.97 0.95 1.00 
rs56129505 1 186,718,261 T/C 0.288 unknown PACERR 0.021 0.0037 2.61E-08 0 5.65E-01 8.40E-01 1.03 1.00 1.06 
rs2970581 1 212,083,512 A/G 0.036 unknown INTS7 0.059 0.0100 3.78E-09 0 6.15E-01 3.60E-03 1.12 1.04 1.19 
rs6746275 2 635,857 A/C 0.847 unknown TMEM18 0.035 0.0043 5.50E-16 14.8 1.47E-01 6.50E-01 1.04 1.00 1.07 
rs10177191 2 9,246,721 T/C 0.400 unknown ASAP2 -0.018 0.0032 3.05E-08 0 8.85E-01 7.50E-01 0.98 0.95 1.00 
rs72782806 2 15,788,511 A/G 0.230 unknown DDX1 0.023 0.0038 1.02E-09 0 5.32E-01 6.70E-01 1.02 0.99 1.05 
rs72804857 2 27,161,476 C/G 0.150 intron DPYSL5 0.028 0.0044 2.53E-10 16.3 1.24E-01 4.50E-01 1.06 1.02 1.10 
rs1260326 2 27,730,940 T/C 0.436 missense GCKR 0.066 0.0032 2.97E-95 44.3 6.22E-05 1.70E-03 1.21 1.18 1.24 
rs62140395 2 28,244,926 C/G 0.117 intron BABAM2 0.050 0.0064 8.68E-15 6.4 3.28E-01 4.70E-01 1.11 1.07 1.16 
rs10084334 2 37,250,891 C/G 0.617 intron HEATR5B 0.019 0.0034 4.33E-08 0 7.31E-01 1.70E-01 1.00 0.97 1.03 
rs142874192 2 54,900,899 C/G 0.957 unknown SPTBN1 -0.059 0.0103 1.08E-08 0 9.52E-01 8.90E-01 0.94 0.83 1.06 
rs6730325 2 59,315,828 A/G 0.667 unknown LINC01122 -0.019 0.0034 2.58E-08 0 5.79E-01 4.60E-01 0.97 0.95 1.00 
rs7572603 2 61,552,145 C/G 0.639 intron USP34 -0.023 0.0033 3.62E-12 0 8.43E-01 4.00E-01 0.95 0.92 0.97 
rs12987661 2 69,813,458 T/C 0.879 intron AAK1 0.043 0.0052 4.32E-16 0 8.61E-01 8.30E-01 1.05 1.01 1.09 
rs759219 2 71,163,225 T/C 0.413 intron ATP6V1B1 -0.018 0.0032 9.23E-09 0 6.77E-01 3.80E-02 0.99 0.96 1.01 
rs6707386 2 113,981,022 A/G 0.354 intron PAX8 0.018 0.0032 3.93E-08 0 9.93E-01 5.70E-01 1.02 1.00 1.05 
rs17050272 2 121,306,440 A/G 0.430 unknown LINC01101 0.028 0.0032 1.01E-17 22.4 5.13E-02 9.00E-02 1.02 0.99 1.05 
rs2304667 2 121,989,489 A/G 0.421 coding-syn. intron TFCP2L1 0.023 0.0038 1.02E-09 0 8.89E-01 6.60E-01 1.02 0.97 1.08 
rs11683692 2 145,509,615 T/C 0.946 intron TEX41 -0.047 0.0083 1.55E-08 10.5 2.37E-01 8.50E-01 1.00 0.95 1.06 
rs2307394 2 148,716,428 T/C 0.632 missense, untranslated-5’ ORC4 -0.020 0.0032 1.05E-09 6.9 3.15E-01 4.20E-01 0.97 0.94 1.00 
rs113704612 2 158,294,018 T/G 0.035 intron CYTIP -0.080 0.0118 1.14E-11 0 5.93E-01 1.90E-01 0.91 0.83 1.00 
rs1457231 2 161,101,562 T/C 0.705 intron LINC02478 0.019 0.0035 3.17E-08 0 9.34E-01 3.10E-01 1.02 0.99 1.05 
rs2075251 2 170,011,458 A/T 0.657 intron LRP2 -0.037 0.0035 7.01E-27 1.5 4.42E-01 1.80E-01 0.92 0.89 0.95 
rs10198459 2 177,273,272 T/C 0.253 unknown MTX2 0.027 0.0036 1.27E-13 0 6.90E-01 3.20E-01 1.06 1.03 1.09 
rs3769810 2 183,037,246 A/G 0.757 intron PDE1A 0.022 0.0037 2.81E-09 0 8.67E-01 1.70E-01 1.05 1.02 1.09 
rs1047891 2 211,540,507 A/C 0.287 missense CPS1 -0.024 0.0036 1.91E-11 1.4 4.44E-01 1.90E-02 0.97 0.94 1.00 
rs1949651 2 213,117,629 T/C 0.519 intron ERBB4 0.021 0.0032 2.64E-11 7.4 2.99E-01 7.60E-01 1.04 1.01 1.07 
rs73058028 3 31,528,128 C/G 0.644 unknown STT3B 0.018 0.0032 1.54E-08 0 5.69E-01 4.60E-01 1.00 0.97 1.02 
rs699465 3 52,310,442 A/G 0.148 intron WDR82 0.033 0.0046 4.60E-13 0 6.30E-01 2.80E-03 1.08 1.04 1.12 
rs2244552 3 53,055,522 A/G 0.547 intron SFMBT1 -0.043 0.0031 1.06E-43 10.2 2.37E-01 2.10E-02 0.91 0.89 0.94 
rs7039 3 69,154,343 C/G 0.446 untranslated-3’ ARL6IP5 -0.021 0.0031 5.24E-11 6.1 3.32E-01 6.00E-01 0.97 0.94 0.99 
rs9859616 3 125,149,488 A/G 0.219 unknown SNX4 -0.024 0.0038 4.17E-10 0 8.88E-01 3.80E-01 0.98 0.95 1.01 
224 
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rs11718633 3 126,012,421 T/C 0.194 unknown KLF15 -0.027 0.0046 7.64E-09 0 6.15E-01 5.80E-01 0.96 0.93 0.99 
rs78946096 3 132,188,163 A/G 0.947 intron DNAJC13 -0.060 0.0099 1.48E-09 8 3.08E-01 9.70E-01 0.91 0.86 0.96 
rs12496412 3 141,741,823 A/G 0.668 intron TFDP2 0.021 0.0033 5.30E-10 0 9.93E-01 4.60E-01 1.01 0.99 1.04 
rs6805417 3 142,762,487 T/C 0.343 intron U2SURP 0.019 0.0033 1.10E-08 0 9.21E-01 3.80E-01 1.03 1.01 1.06 
rs60388273 3 149,214,543 A/G 0.228 intron TM4SF4 0.030 0.0044 3.15E-11 3.7 3.88E-01 3.00E-01 1.03 0.98 1.08 
rs62294340 3 169,155,476 A/G 0.354 intron MECOM -0.021 0.0032 7.62E-11 0 6.93E-01 5.90E-01 0.96 0.93 0.99 
rs1533096 4 4,784,139 C/G 0.595 intron LOC101928279 0.020 0.0036 3.16E-08 0 5.43E-01 6.40E-01 0.99 0.96 1.01 
rs6820627 4 9,491,205 A/G 0.071 unknown DEFB131A -0.100 0.0107 4.66E-21 28.6 2.54E-02 3.20E-05 0.89 0.84 0.95 
rs3775947 4 9,995,240 T/C 0.691 intron SLC2A9 0.277 0.0033 0.00E+00 90 1.10E-109 1.50E-127 1.51 1.47 1.56 
rs12504795 4 10,499,344 T/C 0.741 intron CLNK 0.075 0.0035 4.25E-101 51.4 2.74E-07 1.70E-18 1.15 1.11 1.18 
rs11940694 4 39,414,993 A/G 0.464 intron KLB -0.017 0.0031 2.37E-08 0 8.75E-01 9.90E-02 0.95 0.93 0.98 
rs10857147 4 81,181,072 A/T 0.712 unknown FGF5 0.028 0.0035 1.67E-15 0 9.73E-01 3.00E-01 1.04 1.01 1.07 
rs116183010 4 88,468,158 A/G 0.024 unknown SPARCL1 0.096 0.0138 3.66E-12 22.7 6.67E-02 2.10E-01 1.29 1.19 1.41 
rs74904971 4 89,050,026 A/C 0.196 intron ABCG2 0.217 0.0043 0.00E+00 73.7 1.58E-25 3.90E-25 2.04 1.96 2.12 
rs35232147 4 89,916,224 T/C 0.373 intron FAM13A 0.018 0.0032 3.37E-08 0 4.85E-01 1.70E-01 1.05 1.03 1.08 
rs11097693 4 101,121,391 A/G 0.584 intron LOC101929353 -0.019 0.0031 9.03E-10 0 7.48E-01 7.70E-01 0.96 0.93 0.98 
rs12644329 4 143,634,746 A/G 0.643 intron INPP4B -0.019 0.0034 8.47E-09 0 5.89E-01 2.90E-01 0.98 0.95 1.00 
rs1440411 4 144,158,285 T/C 0.605 unknown USP38 -0.027 0.0033 1.18E-15 0 6.58E-01 6.90E-01 0.98 0.96 1.01 
rs455213 5 34,660,235 T/C 0.596 intron RAI14 -0.023 0.0033 2.07E-12 22.3 5.13E-02 2.10E-01 0.96 0.93 0.98 
rs116379131 5 39,961,618 A/T 0.034 unknown LINC00603 -0.058 0.0105 3.15E-08 10.4 2.40E-01 2.70E-01 1.01 0.94 1.08 
rs10942549 5 72,426,137 C/G 0.301 intron TMEM171 -0.040 0.0035 1.09E-30 26.9 2.22E-02 3.00E-02 0.92 0.90 0.95 
rs28362590 5 176,731,452 T/G 0.656 intron, near-gene-5’ PRELID1 0.021 0.0034 1.05E-09 0 8.29E-01 1.80E-01 1.05 1.02 1.08 
rs7757144 6 1,997,865 A/G 0.626 intron GMDS -0.022 0.0033 2.31E-11 0 8.14E-01 3.00E-01 0.96 0.94 0.99 
rs3904600 6 7,109,665 C/G 0.405 intron RREB1 0.057 0.0038 5.23E-51 0 8.52E-01 2.20E-01 1.08 1.05 1.11 
rs77951490 6 25,236,645 A/G 0.053 unknown LOC101928663 0.060 0.0086 2.59E-12 24.1 4.30E-02 5.70E-01 1.08 1.03 1.15 
rs1359232 6 25,809,716 A/C 0.401 intron SLC17A1 -0.089 0.0033 5.59E-159 0 9.40E-01 2.20E-01 0.85 0.83 0.87 
rs35942569 6 26,339,131 A/G 0.905 unknown BTN3A2 -0.061 0.0068 1.19E-19 16.6 1.26E-01 9.50E-02 0.88 0.84 0.92 
rs57440165 6 26,843,517 A/C 0.921 intron GUSBP2 -0.060 0.0077 4.25E-15 13.3 1.92E-01 8.50E-01 0.89 0.85 0.93 
rs35501037 6 27,739,566 A/T 0.088 unknown LOC100131289 0.052 0.0069 3.36E-14 0 6.93E-01 9.30E-01 1.11 1.06 1.16 
rs7752448 6 28,301,099 A/G 0.881 intron ZSCAN31 -0.040 0.0052 7.44E-15 23.1 4.45E-02 1.80E-02 0.91 0.87 0.94 
rs3118365 6 28,839,908 A/G 0.092 unknown LINC01623 0.046 0.0067 5.81E-12 4.7 3.68E-01 6.90E-01 1.11 1.06 1.16 
rs429479 6 29,372,323 A/G 0.904 unknown OR12D2 -0.047 0.0067 2.02E-12 0 7.08E-01 1.30E-01 0.90 0.86 0.94 
rs753725 6 30,890,871 T/C 0.406 intron VARS2 0.021 0.0034 1.05E-09 3.3 4.04E-01 3.90E-01 1.02 0.99 1.05 
rs9271585 6 32,590,879 A/C 0.333 unknown HLA-DQA1 -0.025 0.0036 6.94E-12 15 1.65E-01 3.20E-02 0.98 0.95 1.01 
rs742493 6 40,998,167 T/C 0.894 missense UNC5CL 0.035 0.0054 8.26E-11 5.6 3.44E-01 4.00E-01 1.03 0.98 1.07 
rs56401710 6 43,269,180 A/C 0.587 intron SLC22A7 -0.042 0.0037 5.00E-30 23.2 1.01E-01 5.50E-01 0.98 0.92 1.04 
rs10223666 6 43,805,502 C/G 0.733 unknown VEGFA 0.044 0.0037 1.27E-32 0 9.60E-01 1.30E-01 1.05 1.02 1.08 
rs9373896 6 107,169,822 A/T 0.147 intron LOC100422737 0.030 0.0052 9.09E-09 3.5 3.93E-01 3.40E-01 1.01 0.96 1.06 
rs4897160 6 126,223,944 A/G 0.470 intron NCOA7 0.024 0.0031 2.04E-14 19.1 8.87E-02 9.70E-02 1.03 1.00 1.05 
rs62435145 7 1,286,567 T/G 0.532 unknown UNCX 0.040 0.0038 3.80E-26 11.7 2.39E-01 8.90E-01 1.06 1.03 1.10 
rs12669187 7 30,915,478 A/G 0.135 intron INMT-MINDY4 0.032 0.0057 1.25E-08 0 6.08E-01 6.10E-01 1.08 1.01 1.15 
rs1051921 7 73,007,943 A/G 0.168 ncRNA, untranslated-3’ MLXIPL -0.051 0.0042 2.86E-34 10.2 2.39E-01 6.50E-01 0.89 0.87 0.92 
rs11551890 7 97,845,713 A/G 0.488 untranslated-3’ TECPR1 0.024 0.0040 2.05E-09 9.7 2.51E-01 4.50E-01 1.03 1.00 1.05 
rs73728279 7 151,411,494 T/G 0.273 intron PRKAG2 0.033 0.0043 1.15E-14 0.8 4.58E-01 4.50E-02 1.08 1.05 1.11 
rs11781985 8 8,589,783 T/C 0.803 unknown CLDN23 -0.025 0.0041 7.38E-10 12.3 1.97E-01 4.10E-01 0.99 0.96 1.02 
rs34861762 8 23,748,420 T/C 0.366 unknown STC1 0.034 0.0033 1.62E-25 24.5 3.31E-02 8.60E-02 1.02 1.00 1.05 
rs7005606 8 32,401,501 T/G 0.597 intron NRG1 -0.021 0.0032 9.56E-11 0 6.08E-01 9.90E-01 0.97 0.95 1.00 
rs2941487 8 76,480,350 T/C 0.529 unknown HNF4G -0.043 0.0031 5.68E-44 13.6 1.68E-01 9.00E-01 0.95 0.92 0.97 
rs62517932 8 77,031,593 A/G 0.079 unknown LINC01111 0.041 0.0069 3.04E-09 8.4 2.78E-01 1.90E-01 1.01 0.96 1.06 
rs12548367 8 95,929,202 T/C 0.679 unknown TP53INP1 0.024 0.0033 4.39E-13 21 6.17E-02 2.60E-01 1.03 1.00 1.05 
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rs2436962 8 103,645,813 A/G 0.180 unknown KLF10 0.026 0.0042 2.51E-10 0 9.43E-01 8.80E-01 1.03 0.99 1.07 
rs3850445 9 16,703,381 A/G 0.384 intron BNC2 0.021 0.0037 1.69E-08 0 9.94E-01 7.80E-01 1.03 0.99 1.06 
rs7868781 9 33,141,320 A/G 0.609 intron B4GALT1 0.030 0.0032 5.34E-20 20.3 6.94E-02 3.90E-01 1.05 1.02 1.08 
rs3174352 9 95,219,248 A/G 0.464 intron, untranslated-3’ CENPP -0.019 0.0032 3.41E-09 30.2 9.40E-03 7.00E-01 0.98 0.96 1.01 
rs1800977 9 107,690,450 A/G 0.318 near-gene-5’, untranslated-5’ ABCA1 -0.019 0.0034 7.95E-09 3.7 3.90E-01 7.10E-01 0.97 0.95 1.00 
rs62585312 9 130,723,419 C/G 0.935 intron FAM102A 0.053 0.0068 4.11E-15 0 8.41E-01 5.00E-01 1.07 1.01 1.14 
rs10901057 9 134,245,698 C/G 0.258 unknown PRRC2B -0.026 0.0047 2.71E-08 0 9.12E-01 1.10E-01 0.92 0.88 0.96 
rs74440730 10 16,920,892 A/C 0.894 intron CUBN -0.039 0.0059 5.50E-11 0 6.72E-01 6.70E-01 0.92 0.88 0.95 
rs10994860 10 52,645,424 T/C 0.168 near-gene-5’, untranslated-5’ A1CF 0.061 0.0045 7.44E-42 23.8 3.87E-02 2.80E-02 1.11 1.07 1.14 
rs1649078 10 60,293,320 A/C 0.513 intron BICC1 -0.045 0.0034 2.68E-39 25.1 4.37E-02 9.90E-02 0.94 0.92 0.97 
rs1171617 10 61,467,182 T/G 0.770 intron SLC16A9 0.081 0.0044 2.14E-77 0 9.04E-01 5.10E-01 1.15 1.12 1.19 
rs9415676 10 65,010,626 A/G 0.650 intron JMJD1C -0.019 0.0033 4.53E-09 0 9.85E-01 9.30E-01 0.96 0.93 0.98 
rs9420446 10 88,880,689 T/C 0.314 intron FAM35A -0.041 0.0044 1.37E-20 1.4 4.45E-01 8.20E-01 0.96 0.92 0.99 
rs35198068 10 114,754,784 T/C 0.721 intron TCF7L2 0.028 0.0038 2.57E-13 4.5 3.69E-01 1.90E-01 1.00 0.98 1.03 
rs10886117 10 119,480,578 A/G 0.262 unknown EMX2 0.028 0.0040 2.42E-12 14.8 1.49E-01 4.80E-01 1.03 1.00 1.07 
rs4962699 10 126,477,209 A/G 0.250 intron EEF1AKMT2 0.020 0.0036 1.65E-08 0 6.71E-01 5.40E-01 1.06 1.03 1.09 
rs3741210 11 2,169,540 A/G 0.658 intron, ncRNA IGF2 0.019 0.0034 1.17E-08 0 8.72E-01 1.50E-01 1.01 0.99 1.04 
rs35229181 11 30,241,698 A/G 0.792 unknown FSHB 0.022 0.0038 5.56E-09 10.7 2.26E-01 6.30E-01 1.02 0.99 1.05 
rs963837 11 30,749,090 T/C 0.592 unknown DCDC1 0.034 0.0033 4.75E-25 0 5.35E-01 5.00E-02 1.05 1.02 1.08 
rs174594 11 61,619,829 A/C 0.606 intron FADS2 -0.018 0.0033 4.88E-08 15.8 1.32E-01 9.50E-04 0.97 0.95 1.00 
rs148838714 11 62,732,352 A/G 0.066 unknown SLC22A6 -0.074 0.0091 2.14E-16 46.6 8.48E-05 1.40E-09 0.98 0.89 1.06 
rs143825439 11 63,319,993 T/G 0.054 near-gene-3’ HRASLS2 -0.224 0.0121 1.23E-76 76.4 1.69E-17 4.80E-27 1.02 0.88 1.18 
rs1006207 11 63,849,812 T/C 0.563 intron MACROD1 -0.047 0.0035 3.54E-41 64.7 4.72E-14 3.20E-26 0.99 0.96 1.02 
rs531763 11 64,352,063 A/G 0.565 unknown SLC22A12 -0.116 0.0035 1.58E-246 83.7 2.30E-55 1.50E-67 0.86 0.84 0.89 
rs34888828 11 64,968,104 A/G 0.110 intron CAPN1 -0.057 0.0056 1.45E-23 75 6.91E-27 1.10E-49 1.02 0.97 1.07 
rs4014195 11 65,506,822 C/G 0.688 unknown RNASEH2C -0.051 0.0034 6.87E-52 7.2 3.04E-01 2.90E-02 0.89 0.87 0.91 
rs4073582 11 66,050,712 A/G 0.310 intron CNIH2 -0.041 0.0037 5.41E-28 79.2 4.14E-37 1.00E-66 0.97 0.94 0.99 
rs7110302 11 66,690,454 T/C 0.377 intron PC -0.018 0.0033 4.56E-08 5.3 3.51E-01 4.90E-01 0.97 0.94 0.99 
rs11227805 11 67,246,757 T/C 0.180 unknown AIP -0.027 0.0046 8.72E-09 49.4 4.61E-06 4.00E-15 1.03 1.00 1.06 
rs11217257 11 119,238,455 A/G 0.668 intron USP2 -0.027 0.0035 2.81E-15 0 7.62E-01 4.60E-01 0.96 0.93 0.98 
rs2058787 12 15,208,908 A/G 0.316 unknown LINC01489 -0.020 0.0033 5.75E-09 0 5.05E-01 4.30E-01 0.97 0.94 0.99 
rs4149056 12 21,331,549 T/C 0.847 missense SLCO1B1 0.024 0.0043 2.22E-08 0 5.01E-01 2.00E-01 1.03 0.99 1.06 
rs836968 12 50,267,335 T/C 0.371 intron FAIM2 -0.020 0.0034 4.56E-09 0 8.07E-01 5.90E-01 0.99 0.96 1.02 
rs11169926 12 52,248,787 A/C 0.344 intron LOC105369971 0.030 0.0034 4.43E-18 0 4.90E-01 5.20E-01 1.05 1.02 1.08 
rs73119306 12 57,826,982 A/G 0.786 near-gene-5’ INHBC 0.071 0.0042 7.45E-65 33.5 3.69E-03 6.80E-06 1.17 1.13 1.20 
rs12368865 12 58,422,642 A/G 0.907 unknown LINC02403 0.045 0.0067 1.31E-11 0 5.80E-01 7.70E-01 1.14 1.09 1.19 
rs17550549 12 111,357,471 T/C 0.144 intron MYL2 -0.035 0.0053 5.18E-11 33.9 3.29E-03 4.60E-09 1.05 1.00 1.11 
rs10774625 12 111,910,219 A/G 0.467 intron ATXN2 0.032 0.0038 1.29E-17 0 6.69E-01 8.40E-01 1.07 1.04 1.10 
rs17696736 12 112,486,818 A/G 0.582 intron NAA25 -0.028 0.0039 2.43E-13 0 5.21E-01 4.10E-01 0.95 0.92 0.97 
rs11066390 12 113,163,766 A/G 0.268 unknown RPH3A 0.025 0.0038 2.97E-11 6.6 3.19E-01 1.80E-01 1.05 1.02 1.08 
rs1800574 12 121,416,864 T/C 0.033 missense, untranslated-5’ HNF1A -0.085 0.0111 2.57E-14 20.8 7.24E-02 1.60E-01 0.92 0.85 0.99 
rs148015593 12 122,523,668 T/G 0.495 unknown MLXIP 0.029 0.0031 3.42E-21 14.8 1.49E-01 1.90E-01 1.06 1.04 1.09 
rs74397112 12 133,094,111 T/C 0.148 intron FBRSL1 0.043 0.0055 1.34E-14 14.3 1.73E-01 2.00E-03 1.07 1.03 1.11 
rs9579574 13 31,025,634 A/G 0.293 unknown HMGB1 -0.020 0.0036 2.03E-08 0 8.10E-01 1.50E-01 0.93 0.90 0.96 
rs626277 13 72,347,696 A/C 0.499 intron DACH1 0.025 0.0033 3.78E-14 1.6 4.39E-01 4.00E-01 1.02 1.00 1.05 
rs8022225 14 55,767,069 A/G 0.556 intron FBXO34 -0.018 0.0031 1.81E-08 2 4.29E-01 6.50E-01 0.97 0.95 1.00 
rs861536 14 104,167,564 A/G 0.665 intron, near-gene-3’, untranslated-3’ KLC1 0.021 0.0036 2.81E-09 13.1 1.79E-01 2.70E-01 1.05 1.02 1.08 
rs11070231 15 40,021,576 A/C 0.570 intron FSIP1 -0.028 0.0033 2.07E-17 0 5.54E-01 7.20E-01 0.97 0.95 1.00 
rs2957740 15 72,307,691 A/G 0.412 intron MYO9A -0.024 0.0036 3.38E-11 9.7 2.52E-01 3.40E-01 0.98 0.96 1.01 
rs8039418 15 73,441,432 T/C 0.471 intron NEO1 -0.018 0.0032 2.39E-08 1 4.53E-01 1.40E-01 0.97 0.95 1.00 
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RSID Chr. position (b37) A1/A2 EAF Function Gene Name Effect (mg/dL) SE p-value I2 (%) Phet Panc-het Gout OR Gout OR 95% CI Gout OR 95% CI 
rs2472297 15 75,027,880 T/C 0.242 unknown CYP1A1 -0.028 0.0048 8.49E-09 0 7.87E-01 9.70E-01 0.96 0.93 0.99 
rs73436803 15 75,619,201 T/C 0.244 unknown COMMD4 -0.027 0.0039 2.58E-12 0 4.77E-01 1.70E-02 0.96 0.93 0.98 
rs11072567 15 76,298,744 A/G 0.500 intron NRG4 -0.042 0.0032 2.52E-39 25 3.08E-02 9.60E-02 0.93 0.90 0.95 
rs494268 15 76,815,713 T/C 0.908 intron SCAPER 0.032 0.0054 3.96E-09 0 9.87E-01 3.00E-01 1.09 1.04 1.14 
rs8024386 15 90,670,526 A/C 0.774 unknown IDH2 -0.022 0.0039 2.12E-08 12.3 1.97E-01 3.30E-02 0.92 0.89 0.95 
rs12908437 15 99,287,375 T/C 0.433 intron IGF1R 0.045 0.0031 3.77E-46 0 6.90E-01 1.90E-01 1.05 1.03 1.08 
rs77924615 16 20,392,332 A/G 0.203 intron PDILT -0.027 0.0040 1.27E-11 23 4.60E-02 9.60E-01 0.98 0.95 1.01 
rs2219647 16 51,733,405 A/G 0.266 unknown LINC01571 0.021 0.0035 5.38E-09 12.8 1.83E-01 9.40E-01 1.04 1.01 1.07 
rs62033406 16 53,824,226 A/G 0.553 intron FTO -0.019 0.0032 3.23E-09 9.5 2.52E-01 1.30E-02 0.96 0.93 0.98 
rs56230350 16 68,166,971 A/C 0.873 intron NFATC3 0.026 0.0046 3.08E-08 0 4.99E-01 2.30E-01 1.02 0.98 1.06 
rs62052820 16 69,575,238 A/G 0.194 unknown MIR1538 0.043 0.0040 1.17E-26 2 4.29E-01 7.10E-01 1.08 1.05 1.12 
rs4788815 16 71,634,811 A/T 0.343 unknown TAT -0.024 0.0033 2.93E-13 0 6.73E-01 6.80E-01 0.98 0.95 1.00 
rs9302635 16 72,144,174 T/C 0.763 intron DHX38 -0.028 0.0046 2.24E-09 0 8.88E-01 5.40E-01 0.97 0.94 1.00 
rs57652769 16 79,753,976 T/C 0.295 unknown MAFTRR -0.037 0.0034 2.32E-27 0 5.74E-01 9.40E-01 0.96 0.93 0.98 
rs11644696 16 81,572,093 A/G 0.408 intron CMIP 0.019 0.0033 6.42E-09 0 6.97E-01 5.10E-01 1.01 0.99 1.04 
rs7212936 17 1,646,651 A/C 0.452 intron, near-gene-5’ SERPINF2 -0.018 0.0032 1.75E-08 8.2 2.87E-01 2.80E-01 0.97 0.95 1.00 
rs2453580 17 19,438,321 T/C 0.639 intron SLC47A1 0.022 0.0035 3.49E-10 0 4.84E-01 2.50E-02 1.04 1.01 1.06 
rs7209801 17 42,323,376 A/G 0.403 unknown SLC4A1 0.019 0.0033 5.19E-09 0 9.24E-01 2.00E-01 1.03 1.00 1.06 
rs3794748 17 53,365,172 A/G 0.352 intron HLF 0.033 0.0034 8.68E-23 15.3 1.42E-01 7.50E-02 1.05 1.03 1.08 
rs2645477 17 57,845,624 A/C 0.521 intron VMP1 0.018 0.0031 7.66E-09 12.6 1.89E-01 7.20E-02 1.02 1.00 1.05 
rs9895661 17 59,456,589 T/C 0.674 intron BCAS3 0.053 0.0038 7.63E-45 28.5 1.54E-02 2.80E-02 1.09 1.06 1.13 
rs164011 17 74,273,165 A/G 0.411 intron QRICH2 -0.021 0.0033 1.05E-10 0 7.91E-01 9.10E-01 0.96 0.93 0.98 
rs10438961 18 42,779,107 T/G 0.730 unknown SLC14A2 -0.021 0.0037 2.01E-08 0 9.80E-01 9.40E-02 0.97 0.94 0.99 
rs11663816 18 57,876,227 T/C 0.754 unknown MC4R -0.026 0.0036 1.25E-12 6 3.34E-01 7.30E-02 0.93 0.91 0.96 
rs7259484 19 1,813,207 A/G 0.653 near-gene-5’ ATP8B3 0.021 0.0036 3.60E-09 0 8.55E-01 1.50E-01 1.01 0.98 1.05 
rs4807003 19 4,957,133 A/G 0.316 intron UHRF1 -0.028 0.0041 8.85E-12 6.5 3.23E-01 5.00E-01 0.97 0.95 1.00 
rs10405423 19 7,211,311 A/C 0.700 intron INSR 0.033 0.0037 1.11E-18 0 6.35E-01 1.20E-02 1.06 1.03 1.09 
rs56338130 19 18,235,871 T/C 0.224 intron MAST3 0.023 0.0038 4.15E-09 13.1 1.79E-01 6.70E-01 1.03 1.00 1.06 
rs10418164 19 33,411,139 T/G 0.455 intron CEP89 0.025 0.0032 3.14E-15 3.6 3.91E-01 7.50E-01 1.04 1.02 1.07 
rs62128132 19 50,217,955 T/C 0.967 unknown CPT1C -0.115 0.0144 1.99E-15 72.7 7.42E-16 3.00E-07 0.78 0.72 0.84 
rs12625256 20 10,638,386 A/T 0.594 intron JAG1 0.019 0.0032 1.93E-09 0 7.01E-01 3.90E-01 1.03 1.00 1.05 
rs6138584 20 25,463,148 A/T 0.236 intron NINL 0.023 0.0038 2.50E-09 0 9.91E-01 9.40E-01 1.02 0.99 1.06 
rs6119524 20 33,373,813 T/C 0.343 intron NCOA6 0.020 0.0033 3.50E-09 19.9 7.43E-02 4.00E-01 1.00 0.97 1.03 
rs73611258 20 39,742,284 A/G 0.648 intron TOP1 0.024 0.0039 4.03E-10 7.3 3.01E-01 3.70E-01 1.01 0.97 1.04 
rs6031598 20 43,056,149 T/G 0.535 intron HNF4A -0.022 0.0032 1.73E-12 9.4 2.58E-01 9.60E-01 0.95 0.92 0.97 
rs1407040 20 57,472,174 T/C 0.685 intron GNAS -0.025 0.0033 5.70E-14 23 4.37E-02 4.40E-02 0.98 0.95 1.00 
rs2834319 21 35,357,025 T/C 0.851 unknown LOC101928126 -0.026 0.0045 8.90E-09 0 8.37E-01 7.60E-01 0.98 0.94 1.01 
rs219781 21 37,832,621 T/G 0.247 near-gene-3’ CLDN14 -0.027 0.0042 2.22E-10 0 8.64E-01 5.30E-01 0.95 0.93 0.98 
rs12484809 22 44,325,631 T/C 0.284 intron PNPLA3 -0.035 0.0037 1.73E-20 0 5.84E-01 9.20E-01 0.91 0.88 0.94 
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Supplementary Table 5 – MR-MEGA SNPs not identified as METAL index SNPs with the filter on number of cohorts > 37 relaxed.  
** denotes a P-value significant at P < 5E-8 and the * symbol significant at P < 0.05/22. 
rsID Chr. Position Gene Function EA/NEA EAF N N cohorts N SNPs N Eth Effect SE P Panc-het Pres-het METAL P 
rs508926 1 28,578,825 RP5-1092A3.5 Downstream G/A 0.280 447,631 73 1 5 0.034 0.034 4.69E-08 2.03E-05* 1.91E-01 2.68E-04* 
rs186147970 1 120,484,718 NOTCH2 Intron C/T 0.006 66,139 8 1 1 1.586 2.645 4.13E-14 9.22E-01 6.94E-01 1.46E-16** 
rs188991775 1 147,336,171 RP11-314N2.2 Intergenic T/C 0.995 66,369 6 2 1 -1.282 4.208 9.16E-12 1.12E-03* 4.79E-01 8.93E-11** 
rs3774046 3 170,737,003 SLC2A2 Intron G/A 0.160 457,616 74 18 5 0.050 0.048 1.84E-09 4.40E-04* 1.61E-01 8.72E-07* 
rs17325213 4 11,955,802 TAPT1-AS1 Intergenic T/C 0.056 239,512 48 4 4 1.481 0.258 3.59E-09 5.51E-08* 3.78E-01 3.49E-03 
rs550638591 4 36,873,382 RP11-500G9.1 Intergenic C/T 0.003 24,997 6 2 1 28.806 5.659 1.45E-10 4.88E-11** 9.79E-01 5.35E-01 
rs1346144 4 79,625,361 RP11-576N17.4 Intergenic A/G 0.631 422,278 72 1 5 -0.186 0.052 2.24E-08 7.53E-03 8.94E-01 2.65E-07* 
rs73728140 6 24,507,003 ALDH5A1 Intron G/A 0.046 445,653 69 1 5 0.064 0.056 1.03E-08 2.88E-09** 5.14E-01 3.68E-01 
rs570169004 9 70,930,514 RP11-561O23.5 Intron G/A 0.010 60,114 6 1 1 -12.620 81.275 7.66E-10 3.83E-10** 2.17E-03* 2.01E-01 
rs697238 10 80,947,668 ZMIZ1 Intron G/T 0.614 456,290 73 5 5 0.026 0.034 2.46E-09 1.37E-03* 2.91E-02 3.11E-07* 
rs60808706 11 2,857,233 KCNQ1 Intron A/G 0.160 446,270 72 1 5 -0.013 0.055 1.67E-08 5.86E-02 7.53E-01 8.56E-08* 
rs334 11 5,248,232 Hb Missense A/T 0.060 34,279 8 3 2 0.057 0.726 3.01E-13 4.65E-01 4.24E-01 5.28E-15** 
rs11601310 11 48,085,189 PTPRJ Intron A/G 0.236 443,108 69 1 5 -0.011 0.039 8.60E-09 3.40E-05* 4.12E-01 5.04E-06* 
rs118077950 11 67,902,411 CTD-2655K5.1 Downstream A/G 0.105 143,037 9 10 4 -0.697 0.661 5.89E-12 1.37E-01 3.73E-02 3.14E-11** 
rs186255333 11 72,766,638 FCHSD2 Intron C/T 0.003 23,901 6 1 1 54.652 50.188 2.27E-08 2.42E-06* 2.77E-01 4.96E-03 
rs75198898 11 116,649,806 ZPR1 Intron A/G 0.058 166,398 9 2 3 1.434 0.245 2.89E-09 1.99E-06* 6.75E-01 8.51E-05* 
rs144074240 12 67,657,757 GGTA2P Downstream T/C 0.061 330,887 70 3 4 0.121 0.127 1.60E-08 1.33E-03* 9.68E-01 3.48E-07* 
rs145995319 14 98,100,885 RP11-76E12.1 Intron A/G 0.995 126,986 32 1 3 -7.805 2.311 3.18E-08 2.95E-08** 3.41E-05* 9.58E-02 
rs73051934 19 48,582,916 PLA2G4C Intron G/A 0.015 227,758 33 1 2 -5.485 0.833 2.76E-11 1.28E-11** 2.13E-01 1.70E-01 
rs200771360 19 49,129,618 SPHK2 Splice region T/G 0.009 69,248 7 5 1 -13.192 3.692 6.64E-23 6.97E-05* 2.38E-01 2.44E-17** 
rs563655432 19 49,634,571 PPFIA3 Intron T/G 0.009 63,227 6 8 1 -17.704 0.398 1.09E-44 1.11E-03 9.96E-01 1.93E-44 
rs562175867 19 51,044,313 LRRC4B Intron C/T 0.012 64,313 6 6 1 -21.339 6.681 1.77E-28 1.96E-05 1.75E-01 1.78E-21 
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Supplementary Table 6 – Spearman correlations between DEPICT exemplar gene sets 
(r > 0.2) 
Source Node Target Node 
Correlation 
Coefficient 
HEBP1 PPI HEBP1 PPI 1 
ABCC9 PPI ABCC9 PPI 1 
FLT1 PPI FLT1 PPI 1 
UBE2I PPI UBE2I PPI 1 
CRTC1 PPI CRTC1 PPI 1 
SERPINE1 PPI SERPINE1 PPI 1 
Response to Hypoxia SERPINE1 PPI 0.265213 
YWHAE PPI YWHAE PPI 1 
NR3C1 PPI NR3C1 PPI 1 
FHL2 PPI FHL2 PPI 1 
PLG PPI PLG PPI 1 
NCOA3 PPI NCOA3 PPI 1 
ACVR1B PPI ACVR1B PPI 1 
Transforming Growth Factor Beta Receptor  Cytoplasmic 
Mediator Activity 
ACVR1B PPI 0.20153 
PDGFC PPI PDGFC PPI 1 
ITGA5 PPI ITGA5 PPI 1 
ENSG00000215320 PPI ENSG00000215320 PPI 1 
Abnormal Long Bone Epiphyseal Plate Morphology ENSG00000215320 PPI 0.242783 
Abnormal Bone Ossification ENSG00000215320 PPI 0.339356 
SERPINE1 PPI Response to Hypoxia 0.265213 
Response to Hypoxia Response to Hypoxia 1 
Glucose Catabolic Process Response to Hypoxia 0.240306 
Kidney Development Kidney Development 1 
Regulation of Organ Morphogenesis Kidney Development 0.361279 
Enlarged Kidney Kidney Development 0.227648 
Thoracic Vertebral Transformation Kidney Development 0.220185 
Increased Glomerular Capsule Space Kidney Development 0.292251 
Liver Development Liver Development 1 
Steroid Hormone Receptor Activity Liver Development 0.218233 
Increased Glomerular Capsule Space Liver Development 0.207807 
Liver Development Steroid Hormone Receptor Activity 0.218233 
Steroid Hormone Receptor Activity Steroid Hormone Receptor Activity 1 
Decreased Circulating Cholesterol Level Steroid Hormone Receptor Activity 0.217517 
ACVR1B PPI 
Transforming Growth Factor Beta Receptor Cytoplasmic 
Mediator Activity 
0.20153 
Transforming Growth Factor Beta Receptor Cytoplasmic 
Mediator Activity 
Transforming Growth Factor Beta Receptor Cytoplasmic 
Mediator Activity 
1 
Microsome Microsome 1 
Electron Carrier Activity Microsome 0.223806 
Ppara Activates Gene Expression Microsome 0.608128 
Response to Hypoxia Glucose Catabolic Process 0.240306 
Glucose Catabolic Process Glucose Catabolic Process 1 
Hexose Metabolic Process Glucose Catabolic Process 0.376677 
Regulation of Carbohydrate Metabolic Process Regulation of Carbohydrate Metabolic Process 1 
Microsome Electron Carrier Activity 0.223806 
Electron Carrier Activity Electron Carrier Activity 1 
Glucose Catabolic Process Hexose Metabolic Process 0.376677 
Hexose Metabolic Process Hexose Metabolic Process 1 
Cell-Substrate Junction Cell-Substrate Junction 1 
Respiratory Tube Development Respiratory Tube Development 1 
Tube Development Respiratory Tube Development 0.301647 
Mesangial Cell Hyperplasia Respiratory Tube Development 0.212057 
Response to Nutrient Levels Response to Nutrient Levels 1 
Decreased Circulating Cholesterol Level Response to Nutrient Levels 0.20028 
Nuclear Hormone Receptor Binding Nuclear Hormone Receptor Binding 1 
Respiratory Tube Development Tube Development 0.301647 
Tube Development Tube Development 1 
Wnt-Activated Receptor Activity Wnt-Activated Receptor Activity 1 
Abnormal Long Bone Epiphyseal Plate Morphology Wnt-Activated Receptor Activity 0.463033 
Response to Peptide Hormone Stimulus Response to Peptide Hormone Stimulus 1 
Abnormal Glucose Homeostasis Response to Peptide Hormone Stimulus 0.426309 
Small Molecule Catabolic Process Small Molecule Catabolic Process 1 
Apical Part of Cell Apical Part of Cell 1 
Hydronephrosis Apical Part of Cell 0.278573 
Abnormal Kidney Physiology Apical Part of Cell 0.508863 
Decreased Urine Osmolality Apical Part of Cell 0.485054 
Enlarged Kidney Apical Part of Cell 0.297566 
Increased Urine Calcium Level Apical Part of Cell 0.74445 
Increased Circulating Potassium Level Apical Part of Cell 0.245951 
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Source Node Target Node 
Correlation 
Coefficient 
Increased Urine Sodium Level Apical Part of Cell 0.465027 
Kidney Cortex Atrophy Apical Part of Cell 0.361807 
Slc-Mediated Transmembrane Transport Apical Part of Cell 0.759477 
Negative Regulation of Growth Negative Regulation of Growth 1 
Embryonic Morphogenesis Embryonic Morphogenesis 1 
Thoracic Vertebral Transformation Embryonic Morphogenesis 0.892143 
Kidney Development Regulation of Organ Morphogenesis 0.361279 
Regulation of Organ Morphogenesis Regulation of Organ Morphogenesis 1 
Thoracic Vertebral Transformation Regulation of Organ Morphogenesis 0.231187 
Apical Part of Cell Hydronephrosis 0.278573 
Hydronephrosis Hydronephrosis 1 
Abnormal Kidney Physiology Hydronephrosis 0.51184 
Increased Circulating Aldosterone Level Hydronephrosis 0.337437 
Decreased Urine Osmolality Hydronephrosis 0.464381 
Enlarged Kidney Hydronephrosis 0.330851 
Increased Urine Calcium Level Hydronephrosis 0.400911 
Increased Circulating Potassium Level Hydronephrosis 0.469428 
Increased Urine Sodium Level Hydronephrosis 0.616328 
Kidney Cortex Atrophy Hydronephrosis 0.388661 
Mesangial Cell Hyperplasia Hydronephrosis 0.288615 
Decreased Embryo Size Decreased Embryo Size 1 
Response to Peptide Hormone Stimulus Abnormal Glucose Homeostasis 0.426309 
Abnormal Glucose Homeostasis Abnormal Glucose Homeostasis 1 
Apical Part of Cell Abnormal Kidney Physiology 0.508863 
Hydronephrosis Abnormal Kidney Physiology 0.51184 
Abnormal Kidney Physiology Abnormal Kidney Physiology 1 
Increased Circulating Aldosterone Level Abnormal Kidney Physiology 0.213069 
Decreased Urine Osmolality Abnormal Kidney Physiology 0.758218 
Enlarged Kidney Abnormal Kidney Physiology 0.457083 
Increased Urine Calcium Level Abnormal Kidney Physiology 0.709209 
Increased Circulating Potassium Level Abnormal Kidney Physiology 0.43471 
Increased Urine Sodium Level Abnormal Kidney Physiology 0.797942 
Kidney Cortex Atrophy Abnormal Kidney Physiology 0.414245 
Slc-Mediated Transmembrane Transport Abnormal Kidney Physiology 0.408202 
Hydronephrosis Increased Circulating Aldosterone Level 0.337437 
Abnormal Kidney Physiology Increased Circulating Aldosterone Level 0.213069 
Increased Circulating Aldosterone Level Increased Circulating Aldosterone Level 1 
Increased Circulating Potassium Level Increased Circulating Aldosterone Level 0.55589 
Increased Urine Sodium Level Increased Circulating Aldosterone Level 0.395197 
Apical Part of Cell Decreased Urine Osmolality 0.485054 
Hydronephrosis Decreased Urine Osmolality 0.464381 
Abnormal Kidney Physiology Decreased Urine Osmolality 0.758218 
Decreased Urine Osmolality Decreased Urine Osmolality 1 
Enlarged Kidney Decreased Urine Osmolality 0.571831 
Increased Urine Calcium Level Decreased Urine Osmolality 0.818558 
Increased Circulating Potassium Level Decreased Urine Osmolality 0.330216 
Increased Urine Sodium Level Decreased Urine Osmolality 0.70046 
Kidney Cortex Atrophy Decreased Urine Osmolality 0.323056 
Mesangial Cell Hyperplasia Decreased Urine Osmolality 0.208061 
Slc-Mediated Transmembrane Transport Decreased Urine Osmolality 0.456386 
ENSG00000215320 PPI Abnormal Long Bone Epiphyseal Plate Morphology 0.242783 
Wnt-Activated Receptor Activity Abnormal Long Bone Epiphyseal Plate Morphology 0.463033 
Abnormal Long Bone Epiphyseal Plate Morphology Abnormal Long Bone Epiphyseal Plate Morphology 1 
Abnormal Bone Ossification Abnormal Long Bone Epiphyseal Plate Morphology 0.662422 
Kidney Development Enlarged Kidney 0.227648 
Apical Part of Cell Enlarged Kidney 0.297566 
Hydronephrosis Enlarged Kidney 0.330851 
Abnormal Kidney Physiology Enlarged Kidney 0.457083 
Decreased Urine Osmolality Enlarged Kidney 0.571831 
Enlarged Kidney Enlarged Kidney 1 
Increased Urine Calcium Level Enlarged Kidney 0.555349 
Increased Urine Sodium Level Enlarged Kidney 0.521318 
Kidney Cortex Atrophy Enlarged Kidney 0.309675 
Mesangial Cell Hyperplasia Enlarged Kidney 0.23306 
Slc-Mediated Transmembrane Transport Enlarged Kidney 0.393148 
Kidney Development Thoracic Vertebral Transformation 0.220185 
Embryonic Morphogenesis Thoracic Vertebral Transformation 0.892143 
Regulation of Organ Morphogenesis Thoracic Vertebral Transformation 0.231187 
Thoracic Vertebral Transformation Thoracic Vertebral Transformation 1 
Steroid Hormone Receptor Activity Decreased Circulating Cholesterol Level 0.217517 
Response to Nutrient Levels Decreased Circulating Cholesterol Level 0.20028 
Decreased Circulating Cholesterol Level Decreased Circulating Cholesterol Level 1 
Apical Part of Cell Increased Urine Calcium Level 0.74445 
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Source Node Target Node 
Correlation 
Coefficient 
Hydronephrosis Increased Urine Calcium Level 0.400911 
Abnormal Kidney Physiology Increased Urine Calcium Level 0.709209 
Decreased Urine Osmolality Increased Urine Calcium Level 0.818558 
Enlarged Kidney Increased Urine Calcium Level 0.555349 
Increased Urine Calcium Level Increased Urine Calcium Level 1 
Increased Circulating Potassium Level Increased Urine Calcium Level 0.220863 
Increased Urine Sodium Level Increased Urine Calcium Level 0.661588 
Kidney Cortex Atrophy Increased Urine Calcium Level 0.414838 
Slc-Mediated Transmembrane Transport Increased Urine Calcium Level 0.682957 
Apical Part of Cell Increased Circulating Potassium Level 0.245951 
Hydronephrosis Increased Circulating Potassium Level 0.469428 
Abnormal Kidney Physiology Increased Circulating Potassium Level 0.43471 
Increased Circulating Aldosterone Level Increased Circulating Potassium Level 0.55589 
Decreased Urine Osmolality Increased Circulating Potassium Level 0.330216 
Increased Urine Calcium Level Increased Circulating Potassium Level 0.220863 
Increased Circulating Potassium Level Increased Circulating Potassium Level 1 
Increased Urine Sodium Level Increased Circulating Potassium Level 0.504154 
Apical Part of Cell Increased Urine Sodium Level 0.465027 
Hydronephrosis Increased Urine Sodium Level 0.616328 
Abnormal Kidney Physiology Increased Urine Sodium Level 0.797942 
Increased Circulating Aldosterone Level Increased Urine Sodium Level 0.395197 
Decreased Urine Osmolality Increased Urine Sodium Level 0.70046 
Enlarged Kidney Increased Urine Sodium Level 0.521318 
Increased Urine Calcium Level Increased Urine Sodium Level 0.661588 
Increased Circulating Potassium Level Increased Urine Sodium Level 0.504154 
Increased Urine Sodium Level Increased Urine Sodium Level 1 
Kidney Cortex Atrophy Increased Urine Sodium Level 0.281527 
Slc-Mediated Transmembrane Transport Increased Urine Sodium Level 0.298183 
ENSG00000215320 PPI Abnormal Bone Ossification 0.339356 
Abnormal Long Bone Epiphyseal Plate Morphology Abnormal Bone Ossification 0.662422 
Abnormal Bone Ossification Abnormal Bone Ossification 1 
Partial Prenatal Lethality Partial Prenatal Lethality 1 
Apical Part of Cell Kidney Cortex Atrophy 0.361807 
Hydronephrosis Kidney Cortex Atrophy 0.388661 
Abnormal Kidney Physiology Kidney Cortex Atrophy 0.414245 
Decreased Urine Osmolality Kidney Cortex Atrophy 0.323056 
Enlarged Kidney Kidney Cortex Atrophy 0.309675 
Increased Urine Calcium Level Kidney Cortex Atrophy 0.414838 
Increased Urine Sodium Level Kidney Cortex Atrophy 0.281527 
Kidney Cortex Atrophy Kidney Cortex Atrophy 1 
Mesangial Cell Hyperplasia Kidney Cortex Atrophy 0.23662 
Slc-Mediated Transmembrane Transport Kidney Cortex Atrophy 0.383702 
Respiratory Tube Development Mesangial Cell Hyperplasia 0.212057 
Hydronephrosis Mesangial Cell Hyperplasia 0.288615 
Decreased Urine Osmolality Mesangial Cell Hyperplasia 0.208061 
Enlarged Kidney Mesangial Cell Hyperplasia 0.23306 
Kidney Cortex Atrophy Mesangial Cell Hyperplasia 0.23662 
Mesangial Cell Hyperplasia Mesangial Cell Hyperplasia 1 
Increased Glomerular Capsule Space Mesangial Cell Hyperplasia 0.278367 
Kidney Development Increased Glomerular Capsule Space 0.292251 
Liver Development Increased Glomerular Capsule Space 0.207807 
Mesangial Cell Hyperplasia Increased Glomerular Capsule Space 0.278367 
Increased Glomerular Capsule Space Increased Glomerular Capsule Space 1 
Microsome Ppara Activates Gene Expression 0.608128 
Ppara Activates Gene Expression Ppara Activates Gene Expression 1 
Apical Part of Cell Slc-Mediated Transmembrane Transport 0.759477 
Abnormal Kidney Physiology Slc-Mediated Transmembrane Transport 0.408202 
Decreased Urine Osmolality Slc-Mediated Transmembrane Transport 0.456386 
Enlarged Kidney Slc-Mediated Transmembrane Transport 0.393148 
Increased Urine Calcium Level Slc-Mediated Transmembrane Transport 0.682957 
Increased Urine Sodium Level Slc-Mediated Transmembrane Transport 0.298183 
Kidney Cortex Atrophy Slc-Mediated Transmembrane Transport 0.383702 
Slc-Mediated Transmembrane Transport Slc-Mediated Transmembrane Transport 1 
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Supplementary Table 7 – All sex-separate genetic correlations significant in males or females. 
Highlighted cells are significant (Q < 0.05) or suggestive in the case of Psex-diff (P< 0.05). 




















Parents age at death 27015805 aging -0.225 -0.151 0.076 0.069 3.00E-03 2.88E-02 1.19E-02 7.81E-02 0.713752 0.475 0.669 
Fathers age at death 27015805 aging -0.271 -0.278 0.066 0.073 3.63E-05 1.00E-04 2.43E-04 5.52E-04 -0.07319 0.942 0.973 
Child birth weight 23202124 anthropometric -0.048 -0.125 0.054 0.051 3.68E-01 1.36E-02 5.74E-01 4.16E-02 -1.03506 0.301 0.498 
Body mass index 20935630 anthropometric 0.196 0.330 0.041 0.049 1.51E-06 2.11E-11 1.47E-05 8.94E-10 2.102316 0.036 0.258 
Body fat 26833246 anthropometric 0.235 0.323 0.052 0.051 6.18E-06 1.81E-10 4.62E-05 5.74E-09 1.210316 0.226 0.433 
Childhood obesity 22484627 anthropometric 0.102 0.235 0.045 0.050 2.40E-02 2.99E-06 6.70E-02 2.71E-05 1.972799 0.049 0.286 
Extreme bmi 23563607 anthropometric 0.251 0.313 0.062 0.064 5.48E-05 1.16E-06 3.24E-04 1.22E-05 0.698065 0.485 0.669 
Obesity class 1 23563607 anthropometric 0.192 0.318 0.042 0.062 4.13E-06 2.49E-07 3.39E-05 3.35E-06 1.687119 0.092 0.404 
Obesity class 2 23563607 anthropometric 0.225 0.345 0.055 0.067 4.34E-05 2.51E-07 2.81E-04 3.35E-06 1.388964 0.165 0.428 
Obesity class 3 23563607 anthropometric 0.181 0.310 0.078 0.083 2.09E-02 2.00E-04 6.10E-02 1.04E-03 1.129012 0.259 0.448 
rOverweight 23563607 anthropometric 0.193 0.311 0.044 0.048 1.39E-05 7.17E-11 9.79E-05 2.60E-09 1.821347 0.069 0.363 
Hip circumference 25673412 anthropometric 0.215 0.313 0.042 0.054 2.78E-07 8.45E-09 3.53E-06 1.79E-07 1.427208 0.154 0.428 
Waist circumference 25673412 anthropometric 0.243 0.382 0.048 0.071 2.98E-07 8.23E-08 3.61E-06 1.31E-06 1.62168 0.105 0.409 
Waist-to-hip ratio 25673412 anthropometric 0.186 0.329 0.040 0.052 3.10E-06 2.40E-10 2.71E-05 6.78E-09 2.192931 0.028 0.258 
Birth weight 27680694 anthropometric -0.029 -0.090 0.034 0.030 3.91E-01 2.50E-03 5.94E-01 1.04E-02 -1.35373 0.176 0.428 
Ulcerative colitis 26192919 autoimmune -0.139 -0.068 0.044 0.040 1.70E-03 8.70E-02 7.32E-03 1.81E-01 1.203485 0.229 0.433 
Femoral Neck bone mineral density 26367794 bone 0.042 0.120 0.046 0.036 3.57E-01 8.00E-04 5.66E-01 3.69E-03 1.332378 0.183 0.428 
Lumbar Spine bone mineral density 26367794 bone 0.020 0.095 0.045 0.036 6.47E-01 8.50E-03 7.94E-01 2.88E-02 1.303631 0.192 0.428 
Coronary artery disease 26343387 cardiometabolic 0.106 0.220 0.032 0.045 9.00E-04 9.14E-07 4.01E-03 1.01E-05 2.067604 0.039 0.258 
Intelligence 28530673 cognitive -0.042 -0.081 0.035 0.030 2.27E-01 6.60E-03 4.05E-01 2.36E-02 -0.8473 0.397 0.601 
Years of schooling 2016 27225129 education -0.062 -0.146 0.024 0.031 9.90E-03 3.29E-06 3.26E-02 2.78E-05 -2.13298 0.033 0.258 
College completion 23722424 education -0.079 -0.129 0.031 0.032 9.60E-03 4.98E-05 3.21E-02 3.08E-04 -1.12121 0.262 0.448 
Years of schooling  
(proxy cognitive performance) 
25201988 education -0.089 -0.152 0.033 0.035 7.40E-03 1.51E-05 2.57E-02 1.04E-04 -1.31006 0.190 0.428 
Years of schooling 2013 23722424 education -0.069 -0.156 0.033 0.039 3.82E-02 5.31E-05 9.42E-02 3.21E-04 -1.71967 0.085 0.404 
Type 2 Diabetes 22885922 glycemic 0.141 0.329 0.053 0.072 7.30E-03 5.24E-06 2.57E-02 4.16E-05 2.10235 0.036 0.258 
Fasting glucose main effect 22581228 glycemic 0.146 0.208 0.057 0.062 1.00E-02 9.00E-04 3.26E-02 4.01E-03 0.725926 0.468 0.669 
Fasting insulin main effect 22581228 glycemic 0.282 0.397 0.057 0.082 8.43E-07 1.27E-06 9.73E-06 1.29E-05 1.15224 0.249 0.448 
HbA1C 20858683 glycemic -0.005 0.168 0.057 0.062 9.24E-01 6.60E-03 9.54E-01 2.36E-02 2.065205 0.039 0.258 
HOMA-B 20081858 glycemic 0.186 0.302 0.055 0.057 8.00E-04 1.32E-07 3.69E-03 1.97E-06 1.455417 0.146 0.428 
HOMA-IR 20081858 glycemic 0.319 0.474 0.067 0.085 2.14E-06 2.58E-08 2.01E-05 5.04E-07 1.422285 0.155 0.428 
Leptin_adjBMI 26833098 hormone 0.138 0.137 0.070 0.056 4.85E-02 1.46E-02 1.15E-01 4.36E-02 -0.01342 0.989 0.989 
Leptin_not_adjBMI 26833098 hormone 0.273 0.367 0.076 0.067 3.00E-04 4.37E-08 1.49E-03 7.40E-07 0.93145 0.352 0.565 
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Chronic Kidney Disease 26831199 kidney 0.234 0.318 0.093 0.086 1.18E-02 2.00E-04 3.75E-02 1.04E-03 0.666792 0.505 0.669 
Serum creatinine (non-diabetes) 26831199 kidney -0.187 -0.208 0.047 0.046 7.29E-05 5.47E-06 4.11E-04 4.21E-05 -0.32386 0.746 0.920 
Serum creatinine 26831199 kidney -0.185 -0.200 0.049 0.046 2.00E-04 1.14E-05 1.04E-03 8.27E-05 -0.22931 0.819 0.933 
Serum cystatin c 26831199 kidney -0.287 -0.321 0.101 0.106 4.60E-03 2.40E-03 1.69E-02 1.02E-02 -0.22598 0.821 0.933 
HDL cholesterol 20686565 lipids -0.320 -0.324 0.047 0.054 5.99E-12 1.46E-09 3.34E-10 3.71E-08 -0.05919 0.953 0.973 
Triglycerides 20686565 lipids 0.341 0.288 0.057 0.053 2.73E-09 4.32E-08 6.30E-08 7.40E-07 -0.68648 0.492 0.669 
Forced expiratory volume  
in 1 second (FEV1) 
28166213 lung_function -0.080 -0.073 0.032 0.032 1.20E-02 2.13E-02 3.76E-02 6.15E-02 0.171754 0.864 0.934 
Forced Vital  
capacity(FVC) 
28166213 lung_function -0.093 -0.102 0.031 0.030 2.90E-03 8.00E-04 1.17E-02 3.69E-03 -0.20496 0.838 0.933 
Forced expiratory volume 
 in 1 second (FEV1) 
21946350 lung_function -0.127 -0.112 0.050 0.046 1.14E-02 1.44E-02 3.67E-02 4.35E-02 0.208986 0.834 0.933 
Anorexia Nervosa 24514567 psychiatric -0.036 -0.099 0.033 0.034 2.74E-01 3.80E-03 4.71E-01 1.44E-02 -1.32561 0.185 0.428 
Schizophrenia 25056061 psychiatric -0.052 -0.087 0.027 0.028 5.19E-02 1.70E-03 1.22E-01 7.32E-03 -0.90127 0.367 0.573 
Age at Menarche 25231870 reproductive -0.097 -0.124 0.032 0.030 2.90E-03 4.42E-05 1.17E-02 2.81E-04 -0.62347 0.533 0.689 
Age at Menopause 26414677 reproductive 0.015 -0.115 0.038 0.041 7.00E-01 4.50E-03 8.04E-01 1.68E-02 -2.3311 0.020 0.258 
Age of first birth 27798627 reproductive -0.107 -0.180 0.036 0.045 3.20E-03 6.13E-05 1.25E-02 3.54E-04 -1.26917 0.204 0.432 
Insomnia 28604731 sleeping 0.063 0.151 0.043 0.052 1.41E-01 3.80E-03 2.72E-01 1.44E-02 1.299458 0.194 0.428 
Insomnia 27992416 sleeping 0.077 0.174 0.037 0.048 3.62E-02 3.00E-04 9.10E-02 1.49E-03 1.607508 0.108 0.409 
Cigarettes smoked per day 20418890 smoking_behaviour 0.053 0.169 0.068 0.064 4.38E-01 8.00E-03 6.21E-01 2.75E-02 1.248338 0.212 0.432 
Former vs Current smoker 20418890 smoking_behaviour -0.050 -0.260 0.060 0.073 4.11E-01 4.00E-04 6.06E-01 1.95E-03 -2.22544 0.026 0.258 
Ever vs never smoked 20418890 smoking_behaviour 0.155 0.108 0.063 0.058 1.36E-02 6.16E-02 4.16E-02 1.38E-01 -0.54251 0.587 0.741 
Serumurate overweight 25811787 uric_acid 0.961 0.950 0.122 0.132 2.85E-15 5.49E-13 3.62E-13 4.65E-11 -0.05688 0.955 0.973 
Urate 23263486 uric_acid 1.027 1.067 0.150 0.135 6.57E-12 2.69E-15 3.34E-10 3.62E-13 0.195095 0.845 0.933 
 
